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Chapter 1      Introduction   
 
 
1.1 History 
Tuberculosis  (TB),  a  chronic  bacterial  infection  caused  by  Mycobacterium 
tuberculosis  (MTB)  is  one  of  the  oldest  recorded  human  diseases  and  one 
causing one of the world’s greatest public health problems (Smith, 2003; WHO, 
2010). The disease was recognised many centuries ago and is traced back to 
the  work  of  Robert  Koch  (Schluger,  2005).  Before  then,  a  French  physician 
Rene Theophile Hyacinthe Laennec (1781-1826) known for his invention of the 
stethoscope  also  pioneered  the  clinical-pathological  correlations  of TB  which 
marked a better understanding of the pathology and pathogenesis of TB. His 
landmark work ‘A Treatise on Diseases of the Chest’,  translated and published 
in  London  by  John  Forbes  in  1821,  provided  figures  illustrating  tuberculous 
cavities as well as descriptions of the pathologic changes now referred to as 
caseous necrosis (Laennec, 1821). 
Another  forerunner  of  Koch,  Jean-Antoine  Villemin  a  French  physician 
published  a  study  in  1868  titled  ‘Etudes  sur  la  tuberculosis’  (Studies  on 
Tuberculosis)  where  he  clearly  established  the  infectious  nature  of  TB. 
However,  he  was  unable  to  identify  the  causative  agent.  Robert  Koch 
announced his achievement at a meeting of the Physiological Society of Berlin 
in 1882 (Villemin, 1868). Koch contributed enormously to the study of TB.  Page | 2  
 
He  developed  staining  techniques  and  culture  media  for  MTB  as  well  as 
demonstrating  the  transmission  mode.  Based  on  his  understanding  of  the 
spread of disease, the isolation of patients with TB was recommended which 
remains the standard today.   
Koch’s postulate states that; “To prove that TB is caused by the invasion of 
bacilli…and multiplication of bacilli, it is necessary to grow them in pure culture 
... and by introducing isolated bacilli into animals, to reproduce the same morbid 
condition that is known to follow from inoculation with spontaneously developed 
tuberculous material” (Koch, 1882). 
Several years after identifying the bacteria responsible for TB, he reported the 
presence of tuberculin which did not cure the disease but which demonstrated 
the understanding of cell-mediated immune responses now recognised as the 
driving  forces  behind  the  clinical  manifestations  of  TB.  A  refinement  of  the 
preparation  remains a  key  component of TB  diagnostics  today  (Koch, 1882; 
Koch, 1890). 
Mycobacterium tuberculosis (MTB) genus Mycobacterium the causative agent 
of TB, like other actinomycetes were initially found in soil (Stead, 1997; Smith, 
2003). It is believed that some species evolved to live in mammals through the 
domestication of cattle. “Specifically, it has been hypothesized that M.  bovis, 
which  causes  a  TB-like  disease  in  cattle,  was  the  hypothetical  evolutionary 
precursor of MTB “. 
Data generated from characterisation of the genomes of the MTB complex by 
deoxyribonucleic acid (DNA) sequencing and related methods shows a greater 
than 99.9% similarity of DNA sequence among the members. The existence of 
synonymous  single-nucleotide  polymorphisms  (sSNP)  allows  discrimination 
between these closely related bacteria and the results suggest that  M. bovis 
evolved at the same time as MTB (Brosch et al., 2002; Sreevatsan et al., 1997; 
Smith, 2005). 
Consequently,  MTB  and  M.  bovis  are  thought  to  have  possibly  evolved 
independently  from  a  species  closely  related  to  M.  canetti  based  on  strong 
evidence  from  a  study  of  the  distribution  of  deletions  and  insertions  in  the 
genomes of the MTB complex (Brosch et al., 2002; Smith, 2005). Page | 3  
 
1.2 General Description of Mycobacterium tuberculosis genus  
The  term  tubercle  bacillus  designates  two  species  of  the  family 
Mycobacteriaceae,  order-  Actinomycetales:  M.  tuberculosis  and  M.  bovis 
((Murray et al., 2005; Todar, 2009). 
 
Fig.1.0  MTB  acid  fast  bacilli  (Reproduced  from  CDC,  Centres  for  Disease 
Control and Prevention, 2005). 
They  differ  from  other  mycobacterial  species  that  share  the  staining 
characteristic referred to as acid fastness (Figure 1.0). Three other  species    
M. ulcerans; M. microti, a pathogen for rodents and M. africanum an organism 
thought to be intermediate between M. tuberculosis and M. bovis  are said  to 
be a rare cause of human tuberculosis in Africa (Murray et al., 2005). They are 
closely related and represent other members of the M. tuberculosis complex. 
Disease due to M. bovis is relatively rare and the terms tubercle bacillus and M. 
tuberculosis  are  synonymous.  Humans  are  the  only  known  reservoir  of  M. 
tuberculosis.  Many  non-pathogenic  mycobacteria  frequently  form  part  of  the 
normal flora (Todar, 2005). 
 
1.2.1  Physiology and Morphology of Mycobacteria 
Bacteria are classified in the genus Mycobacterium on the basis of their acid-
fastness,  the  presence  of  mycolic  acids  (containing  60-90  carbons  that  are 
cleaved by pyrolysis to C22-C26 fatty acid methyl esters) and a high (61-71%) 
guanine  plus  cytosine  content  in  their  deoxyribonucleic  acid  (Murray  et  al, 
2005).  Page | 4  
 
 
 
 
Fig.1.1 Schematic diagram of mycobacterial cell wall (adapted from Niederweis, 
2011). 
   
Species such as Nocardia, Rhodococcus, and Gordonia are partially acid-fast 
but have their mycolic acid chains shorter than mycobacterium. The structure of 
the  cell  wall  is  typical  of  gram  positive  bacteria  having  an  inner  plasma 
membrane overlaid with a peptidoglycan layer and no outer membrane (Fig. 
1.1).  The  rigid  core  of  the  cell  wall  is  composed  of  three  macromolecules; 
peptidoglycan,  arabinogalactan  and  mycolic  acids.  Anchored  in  the  plasma 
membrane  are  proteins,  phosphatidylinositol  mannosides  (PIM)  and 
lipoarabinomannan (LAM).  
The peptidoglycan layer forms the foundation upon which arabinogalactans (a 
branched  polysaccharide  consisting  of  D-arabinose  and  D-galactose)  are 
attached.  Lipids,  glycolipids  and  peptidogycolipids  are  also  present  and 
altogether  comprise  60%  of  the  cell  wall  weight.  15%  of  this  weight  is 
constituted  by  transport  proteins  and  porins  (pore-forming  proteins)  which 
intersperse the cell layers. The purified protein derivatives (PPDs) are used as 
skin test reagents to measure exposure to MTB (Marwick, 1992; Daniel, 1991; 
Murray et al., 2005). Page | 5  
 
 
1.2.2 Growth and cultural characteristics 
Characteristic properties exhibited by MTB such as acid-fastness, slow growth, 
resistance to detergents, to common antibacterial antibiotics, antigenicity and 
clumping is attributed to the complex lipid cell wall they possess (Murray et al., 
2005). 
 
Fig.1.2 Colonies of Mycobacterium tuberculosis on Lowenstein-Jensen medium 
CDC (Todar, 2009). 
  
M. tuberculosis grows slowly, lacks pigment, produces niacin, reduces nitrates, 
produces heat-sensitive catalase (inactivated by heating to 68˚C at pH 7.0) in 
small quantity and is usually sensitive to Isoniazid (INH). These characteristics 
have been used to differentiate MTB from other mycobacteria (Mandell et al., 
2000).  
INH-resistant  strains  are  not  known  to  produce  catalase  while  M.  bovis  is 
usually niacin-negative and does not reduce nitrates. Stained smears prepared 
from  BACTEC  bottles  demonstrate  serpentine  ‘cording’  which  serves  as  a 
sensitive and specific marker for M. tuberculosis whereas mycobacteria other 
than tuberculosis orient randomly (Yagupsky et al., 1990). M. tuberculosis is a 
fairly  large  non-motile  rod-shaped  bacterium  distantly  related  to  the 
Actinomycetes with a high cell wall content of high molecular weight lipids.  Page | 6  
 
The rods are 2 - 4 µm in length and 0.2 - 0.5 µm in width (Mandell et al., 2000; 
Todar, 2009). M. tuberculosis is an obligate aerobe and it is generally accepted 
that MTB complexes are always found in the well-aerated upper lobes of the 
lungs.  It  is  a  facultative  intracellular  parasite  normally  found  living  in 
macrophages with a slow generation time of fifteen - twenty hours, compared 
with much less than one hour for most bacterial pathogens. Growth is slow with 
the generation time being between fifteen to twenty hours. Visible growth takes 
place from four to six weeks on solid media (Figure 1.2).  
The slow generation time is a physiological characteristic that may contribute to 
its virulence (Todar, 2009). Two media are used to grow MTB, Middlebrook's 
medium which is an agar based medium and Lowenstein-Jensen medium which 
is  an  egg  based  medium.  MTB  colonies  are  small  and  buff  coloured  when 
grown  on  either  medium.  Both  types  of  media  contain  inhibitors  to  keep 
contaminants from out-growing MTB (Brooks and Carroll, 2007; Todar, 2009).  
 
1.2.3  Antigenic structure 
Mycobacteria  being  complex  unicellular  organisms  contain  many  antigenic 
proteins and sugars. The antigens are divided into cytoplasmic (soluble) and 
cell wall lipid bound (insoluble) antigens. These features have been used to 
classify species and type strains (Table 1.1).   
 
Table 1.1. Description of antigenic proteins 
 
Group 
 
Description 
 i         Those common to all mycobacteria 
 ii         Those restricted to slowly growing species 
 iii       Those occurring in rapidly growing species 
 iv       Those unique to each individual species 
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The  soluble  antigens  are  divisible  into  those  that  remain  within  the  cell 
cytoplasm until released by autolysis or mechanical disruption and those that 
are  actively  secreted  by  living  whole  cells  (Grange,  1996).  MTB  epitopes 
(antigenic determinants) are divisible according to their distribution within the 
genus. Stanford and Grange (1974) described four groups of soluble antigens 
as shown in Table 1.1 and Figure 1.3. 
 
 
 
   
 
 
 
 
 
 
 
Fig.1.3  The  distribution  of  soluble  antigens  in  the  genus  Mycobacterium 
(adapted from Grange, 1996). 
 
Several  workers  have  attempted  to  isolate  the  species  specific  (group  iv) 
antigens for use in diagnostic  tests but that proved difficult in that they found 
that  specific  epitopes  often  occur  on  the  same  protein  as  shared  epitopes 
(Grange, 1996).  Another phenomenon reported was that a given determinant 
may  be  present  on  a  range  of  molecules  of  differing  physical  and  chemical 
properties.    Nevertheless,  A60  antigen,  the  major  heat  stable  component  of 
PPD,  which  forms  the  basis  of  the  sero-diagnostic  test  for  TB  has  been 
characterised by gel filtration and ion exchange chromatography (Charpin et al., 
1990).  
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Serotypes have been identified in several other species but not in MTB which is 
rough  and  readily  auto  -  agglutinates.  The  responsible  antigens  have  been 
identified as the sugar moieties on a group of peptidoglycolipids and phenolic 
glycolipids collectively termed mycosides (Grange, 1996). 
 
1.2.4  Pathogenicity and virulence determinants 
According  to  Vera-Cabrera  et  al.,  2007,  the  basis  for  MTB  virulence  is  not 
completely understood. Although genetic changes in MTB was considered to 
occur very rarely, micro hybridisation assays in conjunction with the complete 
genomic sequence of MTB show that large sequences of DNA can be deleted 
more  frequently  than  expected.    A  group  of  MTB  isolates  devoid  of  the 
phospholipase  C-type  enzymes  plcA-plcB-plcC  were  characterised  by 
polymerase  chain  reaction,  sequencing  and  micro  array  techniques 
(Frothingham et al., 1994; Cole at al., 1998, Fleischmann et al., 2002). 
Phospholipases  C  are  well  recognised  virulence  factors  of  several 
microorganisms,  including  Clostridium  spp,  Listeria  monocytogenes,  and 
Pseudomonas aeruginosa etc. They act by either destroying cellular tissues as 
in Clostridium spp or by lysing the phagolysosomal membranes and releasing 
intracellular  microorganisms  in  the  cytoplasm  as  in  the  case  of  L. 
Monocytogenes (Williamson and Titball, 1993; Tilney, 1989; Vera- Cabrera et 
al.,  2007).  Several  genes  encoding  phospholipase  C  –  type  enzymes;  plcA-
plcB-plcC and plcD have been found in MTB. Types A, B and C are similar 
unlike plcD. This was found to be missing, or interrupted in many MTB isolates 
including  H37Rv  (a  virulent  strain)  (Cole  et  al.,  1998;  Vera-  Cabrera  et  al., 
2007).  
Studies on phospholipases by Raynaud et al. (2002) showed the deficiency in 
the ability of triple or quadruple mutants to multiply in the lungs and spleen of 
infected  animals,  with  possible  relevance  to  the  survival  of  MTB  in  tissues.  
Investigations by other workers demonstrated less cavitary disease in humans 
with the more the genomic deletions in a clinical isolate of MTB (Kato-Maeda et 
al., 2001).  
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A study by Glickman, Cox and Jacobs  (2000) on the genetic basis for cording 
(the formation  of  strand-like  clumps  of mycobacteria  in  culture) a  phenotype 
associated  with  virulence;  found  that  cording  behaviour  was  dependent  on 
normal functioning of the pca A gene (a novel member of a family of MTB S- 
adenosyl methionine- dependent methyl transferases). It has been shown to be 
required for ʱ-mycolic acid cyclopropanation which is an important component 
of the MTB cell wall synthesis.  When the gene was mutated and used to infect 
mice in a model which is usually lethal, the organisms did not persist or kill the 
animals,  suggesting  that  the  pca  (pyruvate  carboxylase)  gene  is  indeed  a 
virulence factor. Protein tyrosine phosphatase (MptpB) has also been implicated 
in  MTB  virulence  (Singh  et  al.,  2003;  Soeller  et  al.,  2007).  Based  on  their 
studies,  MptpB  is  considered  to  deactivate  human  proteins  involved  in  γ-
interferon signalling pathway which in turn would prevent the immune system 
from acting against the bacteria. 
 
1.2.5  Genetics of M. tuberculosis 
The  complete  sequencing  of  MTB  DNA  was  accomplished  in  1998  by 
investigators at the Pasteur Institute. The sequencing of the virulent laboratory 
strain H37Rv revealed the genome to contain 4,411,529 base pairs encoding 
over 4,000 genes.  A high percentage of guanine-cytosine rich sequences and 
large numbers of genes devoted to fatty acid synthesis were observed (Cole et 
al., 1998; Behr et al., 1999; Fleischmann et al., 2002; Schluger, 2007).  
Certain  populations  appear  to  have  a  high  degree  of  vulnerability  to  TB. 
Extreme susceptibility to the disease has been observed in Eskimo populations 
in North America, in Yanomami Indians in the Brazilian Amazon and in black 
populations in the United States (Hoeppner and Marciniuk, 2000; Sousa et al., 
1997; Stead et al., 1990). 
It has been recognised that a substantial percentage of individuals will recover 
from TB  without  drug  treatment.  Historically,  a  tragic experience  occurred  in 
Lubeck, Germany in the year 1929 where 249 infants were accidentally injected 
with a stock of live, virulent MTB. This led to the death of 76 infants with 173 
survivors  thereby  lending  support  to the  notion  of  some  capability  for innate Page | 10  
 
resistance  (Schluger,  2005).  A  clue  to  the  genetic  basis  of  resistance  was 
provided by Gros and colleagues (1981), who identified a strain of mice with 
rare  vulnerability  to  overwhelming  infection  with  leishmania,  salmonella  and 
certain mycobacteria particularly M. bovis.  
Genetic mapping of murine chromosome by some scientists identified a gene 
initially  called  Bcg  but  later  re-named  nramp1  to  be  responsible  for  the 
production  of  a  so-called  natural  resistance-associated  macrophage  protein. 
(Supek et al., 1996 ; Blackwell et al., 1995, 1996). Bellamy et al. (1998) have 
identified several polymorphisms in the human nramp1 gene and from studies 
conducted; there is increased relative risk for moving from latent infection to 
active  disease  associated  with  certain  polymorphisms.  However,  the  risk 
attributable to these polymorphisms is believed to be relatively small and it was 
shown by their investigation that resistance or susceptibility to TB is a complex 
genetic trait (Dorman et al., 2004, 1998). 
 
1.2.6  Clinical findings and diagnosis 
MTB is transmitted primarily via the respiratory route. The organism expelled 
during coughing, sneezing or talking in the droplet form or as the desiccated 
airborne bacilli enters the respiratory tract and a person only need  inhale a 
small number of these to be infected (WHO, 2010). Early symptoms of active 
TB can include weight loss, fever, night sweats, and loss of appetite.  
Symptoms may be vague, however, and go unnoticed by the affected person. 
For some, the disease either goes into remission (halts) or becomes chronic 
and more debilitating with cough, chest pain, and bloody sputum. Symptoms of 
TB involving areas other than the lungs vary, depending upon the organ or area 
affected (NIAID, 2007). 
To identify those who may have been exposed to M. tuberculosis, health-care 
providers typically inject the purified protein derivative called tuberculin under 
the skin of the forearm.  If a red welt forms around the injection site within 72 
hours, the person may have been infected however, this doesn't necessarily 
mean he or she has active disease.  
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People who may test positive on the tuberculin/mantoux test include  
  Most people with previous exposure to M. tuberculosis  
  Some people exposed to bacteria related to M. tuberculosis  
  Some people born outside the United States who were vaccinated with the 
TB vaccine used in other countries  
If people have an obvious reaction to the skin test, other tests can help to show 
if they have active TB. In making a diagnosis, doctors rely on symptoms and 
other physical signs, the person's history of exposure to TB and X-rays that may 
show evidence of M. tuberculosis infection. The chest X-ray may show lower 
zone infiltrates and unilateral or diffuse bilateral shadowing. In some cases the 
chest  X-ray  may  be  normal  in  spite  of  being  sputum  culture-positive 
(Woodhouse, 2003; NIAID, 2007).  
The health care provider would take sputum and other samples to see if the TB 
bacteria  will  grow  in  the  laboratory.  If  bacteria  grow,  this  positive  culture 
confirms the diagnosis of TB. Due to the fact that M. tuberculosis grows very 
slowly, it can take up to four weeks to confirm the diagnosis. An additional two 
to three weeks usually are needed to determine which antibiotics can be used 
to treat the disease. 
 
1.2.7  Immunity and vaccination 
One study in 1978, prior to the Acquired Immune Deficiency Syndrome (AIDS) 
epidemic showed that 85% of new TB cases were pulmonary but  MTB can 
spread through the blood stream and the lymphatic system to the brain, bones, 
eyes, and skin (extra pulmonary TB) ( Hopewell, 1994; Smith, 2003; Williams et 
al.,1995). 
According to Wallgren (1948), the progression and resolution of the disease can 
be divided into four stages. The first stage involves inhaled aerosols becoming 
implanted in alveoli after three to eight weeks leading to dissemination by the 
lymphatic system to regional lymph nodes in the lung forming the primary or 
Ghon complex. Conversion to tuberculin reactivity occurs at this stage.   Page | 12  
 
The second stage is characterised by the haematogenous spread of bacteria 
into many organs and in some individuals, this disseminated (miliary) TB can be 
acute and fatal. This lasts for about three months. The third stage lasting three 
to seven months may involve inflammation of the pleural surfaces causing chest 
pain but this stage can be delayed for up to two years. Then free bacteria or 
their components are thought to interact with sensitised CD4 T lymphocytes that 
are  attracted  leading  to  proliferation  and  release  of  inflammatory  cytokines 
(Wallgren,  1948;  Kamholz,  1996;  Smith,  2003).The  last  stage  where  the 
disease does not progress may take up to three years.  
Murray  et  al.  (2005)  describes  the  histological  signs  as  being  due  to 
components of the host response to the infection rather than specific virulence 
factors elaborated by the bacteria.   The helper (CD4+) T cells and cytotoxic  
(CD8+)  T  cells  are  stimulated  as  the  bacteria  grows  leading  to  antibody 
production by the CD4+ cells. However the response elicited has been shown 
to be ineffective in controlling the disease because the bacteria are protected in 
their  intracellular  location.  Interferon-γ  and  other  cytokines  released  activate 
macrophages which can engulf and kill the bacteria as well as cytotoxic T cells 
which can also lyse phagocytic cells with replicating bacteria. 
Mycobacteria  are  destroyed  with  minimal  tissue  damage  to  the  host  if  the 
bacterial load is small but when the bacteria are  many, the cellular immune 
response  results  in  tissue  necrosis.  Host  factors  such  as  cytokine  toxicity, 
ischaemia,  local  activation  of  the  complement  cascade  are  involved  in  the 
process (Murray et al., 2005). 
The  size  of  the  locus  of  infection  determines  how  easily  the  bacteria  are 
eliminated while localised collections of activated macrophages (granulomas) 
prevent  the  further  spread  of  the  bacteria.  Small  granulomas  are  killed  by 
macrophages while larger necrotic granulomas become encapsulated with fibrin 
which  protects  it.  The  bacteria  can  remain  dormant  in  this  state  or  be 
reactivated years later when the patient’s immune system is compromised. This 
accounts for the reason why disease may not develop in those exposed to MTB 
until late in life (Murray et al., 2005) 
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1.3  Epidemiology (Global Incidence) 
According to WHO report on TB; 
  Someone in the world is newly infected with TB bacilli every second 
  Overall, one - third of the world’s population is currently infected with the TB 
bacillus 
  5 -10% of people who are infected with TB bacilli but not with HIV become 
sick or infectious at some time during their life. People with HIV and TB 
infection are much more likely to develop TB (WHO Fact sheet No. 104). 
The World Health Organisation (WHO) report estimated that the largest number 
of new TB cases in 2005 occurred in the South- East Asia Region accounting 
for 34% of incident cases globally. However, the rate in sub - Saharan Africa is 
almost double that of South – East Asia at an estimated 350 cases per 100 000 
population (Table 1.2, Figures 1.4.1- 3). WHO 2007 report estimated that 1.6 
million deaths resulted from TB in 2005 equal to an estimated 4400 deaths a 
day.  
In  2009,  the  report  estimated  1.7  million  deaths  with  most  of  the  deaths 
occurring in Africa.  The 2010 report estimated 8.8 million new cases with 1.4 
million deaths including 0.35 million people with HIV.  
Globally, TB is pandemic but the highest rates per capita are in Africa where the 
scourge has been fuelled by the partnership with HIV/AIDS (Table 1.2).  Among 
people living  with HIV/AIDS, TB has been found to be the leading cause of 
death and about 200 000 people living with HIV/AIDS die from TB every year 
(Maher and Raviglione, 1999; WHO, 2010).  
Multi-drug  resistance  (MDR)  has  occurred  in  virtually  all  countries  recently 
surveyed  by  WHO  and  partners.  About  450  000  MDR-  TB  new  cases  are 
estimated to occur each  year with  countries  in  the former Soviet  Union and 
China  having  the  highest  rates. The World  Health  Organization Global Task 
force on XDR-TB in October 2006 defined resistance to the two first line drugs, 
isoniazid and rifampicin as multi-drug resistant TB (MDR-TB) while resistance to 
at least two first line drugs plus resistance to any fluoroquinolones and any one 
of  the  second  line  anti  -TB  injectable  drugs  (amikacin,  kanamycin  or Page | 14  
 
capreomycin)  i.e.  three  of  six  of  the  second  line  drugs  is  referred  to  as 
extensively drug-resistant TB (XDR-TB) [Figure 1.5]. 
XDR-TB  which  is  extremely  difficult  to  treat  has  also  been  confirmed  in  all 
regions of the world. This situation was highlighted as a global threat to public 
health by WHO in 2006, especially in high HIV-prevalent countries. 
 
 
 
 
 
Fig.1.4.1 Chart illustrating estimated incidence of TB globally in 2008 
(www.who.int/topics/tuberculosis/en) 
 Page | 15  
 
    
  Fig.1.4.2 Chart illustrating estimated prevalence of TB in 2008 
(www.who.int/topics/tuberculosis/en) 
 
    
 
Fig. 1.4.3 Chart illustrating estimated mortality of TB in 2008 
(www.who.int/topics/tuberculosis/en).Page | 16  
 
Table 1.2. Estimated TB incidence, prevalence and mortality, 2008 
 
  Incidence
1  Prevalence 
2  Mortality 
WHO region  no. in 
thousands 
% of 
global total 
rate per  
100 000 
pop
3 
no. in 
thousands 
rate per  
100 000  
pop 
no. in 
thousands 
rate per 
100000  
pop 
Africa  2 828  30%  351  3 809  473  385  48 
The Americas  282  3%  31  221  24  29  3 
Eastern Mediterranean  675  7%  115  929  159  115  20 
Europe  425  5%  48  322  36  55  6 
South-East Asia  3 213  34%  183  3 805  216  477  27 
Western Pacific  1 946  21%  109  2 007  112  261  15 
Global total  9 369  100%  139  11 093  164  1 322  20 
1 Incidence is the number of new cases arising during a defined period.  
2 Prevalence is the number of cases (new and previously occurring) that exists at a given point in time. 
3 Pop indicates population. 
 
 Reproduced from www.who.int/mediacentre/factsheets/ 
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1.3.1 TB and HIV 
TB and HIV form a deadly partnership each speeding up the other’s progress. 
Someone who is HIV- positive and infected with TB bacilli is many times more 
likely to become sick with TB than a HIV negative person. HIV weakens the 
immune system and studies have shown that the natural history of HIV infection 
is altered by TB.  
Antigen-specific type 1 CD4+ T-helper cells provide stimulatory signals such as 
cytokine  gamma-interferon  which  activates  TB-infected  macrophages  to  limit 
intracellular replication of MTB (Woodhouse, 2003; WHO, 2010).  These cells 
are  also  targeted  by  HIV  virus  and  ultimately  destroyed.  HIV  viral  load  is 
observed to rise in TB disease and this has been demonstrated in vitro (Goletti 
et al., 1996). 
 
 1.3.2  Principles of therapy 
The goals of anti-TB therapy are to ensure a cure without relapse, to prevent 
death,  to  stop  transmission  of  MTB  and  to  prevent  the  emergence  of  drug-
resistant  disease  (Blumberg  and  Leonard,  2002).  Therapy  is  initiated  with  a 
multi-drug regimen to kill the bacteria rapidly in order to minimise or prevent the 
development of resistant strains as well as eliminate persistent organisms to 
prevent relapse (Blumberg and Leonard, 2002).   
The treatment of TB has two phases; initiation also known as the bactericidal or 
intensive  phase  and  continuation  (subsequent  sterilising  phase).  The  two 
phases reflect the understanding of the patho-physiology of TB. Based on this 
premise, three sub-populations of MTB are thought to exist in the host with TB 
(Blumberg  and  Leonard,  2002).    MTB  is  an  obligate  aerobe  so  the  rapidly 
growing  extra-cellular  organisms  constitute  the  largest  sub-population  which 
resides in well-oxygenated cavities containing 10
7 - 10
8 organisms. The second 
sub-population  resides  within  poorly  oxygenated  caseous  lesions  containing 
10
4-10
5  organisms.  These  are  considered  semi-dormant  and  undergo 
intermittent bursts of metabolic activity (Inderlied and Nash, 1996; Pfyffer, 2000; 
Blumberg and Leonard, 2002). 
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Fig. 1.5  Chemical structures of first line drugs used in therapy 
 
The third sub-population consists of a small number of organisms fewer than 
10
4-10
5  in  number.  They  are  believed  to  be  semi-dormant  within  acidic 
environments  whether  intra-cellular  (in  macrophages)  or  extra-cellular  within 
areas  of  active  inflammation  and  recent  necrosis  (Blumberg  and  Leonard, 
2002).  
Isoniazid and rifampicin are two drugs which form the cornerstone of anti-TB 
therapy (Figure 1.5). Isoniazid has early bactericidal activity while pyrazinamide Page | 19  
 
(PZA) has weak early bactericidal activity within the first few weeks of therapy. 
The rapidly dividing cells are eliminated early in effective therapy and after two 
months of treatment, about 80% of patients are culture negative (WHO, 2010; 
Blumberg  and  Leonard,  2002).  The  second  and  third  sub-populations  are 
responsible  for  treatment  failures  and  relapses  so  prolonged  treatment  is 
required.  The  sterilising  properties  of  rifampicin  and  PZA  are  utilised  in  the 
continuation phase. The activity of rifampicin persists throughout therapy while 
that  of  PZA  is mainly  seen  in  the  first  two  months  (Blumberg  and  Leonard, 
2002). Treatment of MDR-TB requires 18 - 24 months of treatment with second 
line drugs which are less active, more toxic and expensive (WHO, 2010). 
 
1.3.3  Drugs used in TB treatment and mechanisms of action 
The initial therapy for TB consists of a four drug regimen; isoniazid, rifampicin, 
pyrazinamide and ethambutol. The minimum duration for the treatment of TB 
with  a  rifampicin  based  regimen  takes  six  to  nine  months  (short-course 
therapy). Longer courses are required for drug resistant TB such as MDR or 
XDR-TB (WHO, 2010; Blumberg and Leonard, 2002; NIAID, 2007). Table 1.4 
and Figures 1.6a -1.6c illustrate the drugs used and their mechanisms of action 
while  Table  1.5  summarises  the  actions.  Isoniazid  and  ethambutol  act  by 
inhibiting cell wall synthesis while rifampicin acts by inhibiting DNA dependent 
RNA polymerase.  
The mechanism by which pyrazinamide acted was unclear but recent studies 
(Shi et al., 2011) show that when the drug converts to its active form, pyrazinoic 
acid it then binds to an essential protein named ribosomal protein S1 (RpsA) 
which in turn prevents the production of other proteins needed by the bacteria 
for  physiological  functioning  (Figure  1.6b).  Ethambutol  is  believed  to  act  by 
inhibiting cell wall synthesis at the arabinogalactan layer. The proposed sites of 
drug activity for other drugs are shown in Figures 1.6a to 1.6d. Where drug 
resistance occurs to first-line drugs isoniazid and rifampicin, second–line drugs 
such  as  aminoglycosides  and  fluoroquinolones  are  added  as  combination 
therapy. With XDR-TB, treatment options are limited. However, other second 
line drugs which are more toxic are used and for a longer duration of therapy Page | 20  
 
(Table  1.3).  Table  1.4  describes  the  different  modes  of  general  antibacterial 
actions. 
 
Table 1.3. Drugs used in treating drug sensitive TB, options for treating MDR-
TB and XDR-TB as well as new drugs under development 
   Drug sensitive TB  MDR-TB  XDR-TB  New TB drugs  
Isoniazid (1952)  thioamides  ethambutol  pyrroles 
Rifampicin (1966)  cycloserine  pyrazinamide  macrolides 
Ethambutol (1961)  cyclic peptides  thioamides  oxazolidinones 
Pyrazinamide (1952)  aminoglycosides  cycloserine  nitroimidazole 
e.g.PA-824,OPC 
67683 
  fluoroquinolones  PAS  diarylquinoline 
e.g. TMC 207 
  p-aminosalicylic 
acid (PAS) 
streptomycin   
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Fig.1.6a Scheme showing first-line treatment of TB for drug-sensitive TB, with proposed sites of action (NIAID, 2007). Page | 22  
 
 
 
Fig.1.6b Scheme showing drugs inhibited in MDR-TB (isoniazid and rifampicin), and possible effective treatments using other 
drugs in combination (NIAID, 2007). Page | 23  
 
 
 
 
Fig.1.6c  Scheme illustrates drugs inhibited in XDR-TB (isoniazid, rifampicin, fluoroquinolones and at least one of three second 
line injectable)  with  possible effective treatments using other drugs in combination though treatment options become limited 
(NIAID, 2007). Page | 24  
 
 
 
Fig.1.6d New TB drugs under development with their proposed mechanisms of action (NIAID, 2007). 
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Table  1.4.    Summary  of  antimicrobial  action  of  some  clinically  important 
antibiotics (adapted from http://www.pathmicro.med.sc.edu and Rastogi and  
David,1993)
SITE OF  
ACTION 
ANTIBIOTIC  PROCESS INTERRUPTED  TYPE OF  
ACTIVITY 
cell wall  penicillin  cell wall crosslinking  bactericidal 
  cephalosporins  cell wall crosslinking  bactericidal 
  cycloserine  synthesis of cell wall peptides  bactericidal 
  vancomycin  mucopeptide synthesis  bactericidal 
  isoniazid  mycolic acid synthesis  bactericidal 
 
 
ethambutol  arabinogalactan synthesis  bacteriostatic 
cell membrane  amphotericin B  membrane function  fungicidal 
  nystatin  membrane function  fungicidal 
  polymixins  membrane integrity  bactericidal 
  pyrazinamide  Target unclear  bactericidal 
ribosomes       
50-S subunit  erythromycin  protein synthesis  bacteriostatic 
  chloramphenicol  protein synthesis  bacteriostatic 
  lincomycins  protein synthesis  bacteriostatic 
30-S subunit  aminoglycosides  protein synthesis  
and fidelity 
bactericidal 
  tetracyclines  protein synthesis  bacteriostatic 
nucleic acids  griseofulvin  cell division, microtubule assembly  fungistatic 
DNA/or RNA  rifampicin  RNA synthesis   bactericidal 
  quinolones  DNA gyrase (topoisomerase)  bactericidal Page | 26  
 
1.3.4  Antibiotic and molecular basis of resistance 
Globally,  the  emergence  of  MDR  and  XDR-TB  is  of  great  concern  as  the 
treatment options are restricted.  A strain of TB in KwaZulu-Natal in South Africa 
was  found  to  be  resistant  to  seven  of  the  nine  drugs  tested  (Wise,  2006). 
Inadequate drug regimens, poor patient adherence to therapy, use of immuno-
suppressive  drugs,  homelessness,  and mediocre  drug  quality  amongst  other 
factors have been implicated in acquired resistance (WHO, 2010; Youmans et 
al., 1946).  
In contrast to other bacteria, resistance of MTB is exclusively associated with 
chromosomal mutations i.e. they do not involve mobile genetic elements such 
as plasmids seen in other bacteria and mycobacteria (Pfyffer, 2000).  According 
to  Rüsch-Gerdes  (1992),  resistance  to  drugs  is  the  result  of  a  spontaneous 
genetic  event  and  an  amplification  of  a  natural  phenomenon  .Spontaneous 
mutations  occur  at  a  frequency  of  approximately  10
-5  -  10
-8  and  cavities  in 
pulmonary  TB  contain  as  many  as  10
7  -  10
9  organisms  leading  to  dual 
mutations being seen with a certain frequency (Inderlied and Nash, 1996).  
Rifampicin,  the  most  important  component  of  current  treatment  regimens, 
specifically interacts with prokaryotic RNA polymerase to inhibit transcription, 
which leads to cell death. Specific mutations in the rpoB gene, which encodes 
the β-subunit of the RNA polymerase, produce drug resistance by diminishing 
rifampicin binding affinity for the polymerase (Telenti et al., 1993). More than 
97% of all rifampicin- resistant TB isolates carry a mutation in the specific core 
region,  where  a  total of  15  distinct  mutations  has  been  identified.  Molecular 
research  reports  show that  more  than  a  single  gene  is responsible  for drug 
resistance and in isoniazid it is a complex result of single or multiple mutations 
such as deletions, mis-sense mutations in the katG, inhA, oxyR, ahpC and/or 
kasA gene (Kapur et al., 1994; Brennan, 1997; Telenti et al., 1997; Alcaide et 
al.,  1997;  Cole,  1995;  Ramaswamy  et  al.,  1998;  Pfyffer,  2000;  Chan  et  al., 
2007). 
 
1.4  Need for new drugs 
There is a need for the introduction of new effective TB control programmes and Page | 27  
 
novel, affordable anti-TB agents with little toxicity to replace those currently in 
use to which resistance has occurred (Newton et al., 2002).  Furthermore, drugs 
with broader ranges of activity are also required to target emerging pathogens 
such as those of the mycobacterium avium-intracellulare complex (MAC) which 
can result in opportunistic infectious diseases (Newton et al., 2002; Williams et 
al., 1995). As has already been discussed, the need for new drugs has been 
further intensified by the global TB problem due to the rising infection rates with 
HIV,  increased  travel  and  the  use  of  immunosuppressive  drugs.  New  drugs 
which show no interactions on concomitant administration with HIV drugs would 
be  of  great  advantage  over  existing  drugs  (Tomioka  and  Namba,  2006;  TB 
alliance, 2007).   
The last class of TB drugs was developed and approved in the 1960’s and the 
long duration of treatment is hindering global TB treatment. New anti-TB drugs 
are needed for three main reasons; to shorten or otherwise simplify treatment of 
TB caused by drug-susceptible organisms and MDR-TB, improve treatment of 
latent TB infection and have a new site of action (Pepper et al., 2007).  New 
categories of drugs that have shown promise for use in treating TB include the 
nitroimidazopyrans and the oxazolidinones.  Experimental data has shown that, 
a drug that can inhibit the enzyme isocitrate lyase thought to be necessary for 
maintaining the latent state would be useful for treatment of latent TB infection 
(Tomioka et al., 2008).  
A number of other interventions that might lead to improved treatment outcomes 
have been suggested. However, the drugs are still at different stages of clinical 
testing.  These  include  various  drug  delivery  systems,  cytokine  inhibitors; 
administration of “protective” cytokines such as interferon-gamma, interleukin 2 
and  nutritional  supplements  especially  vitamin  A  and  Zinc  (Tomioka  et  al., 
2008).  
Overall,  it  was  suggested  that  commercial  companies  involved  in  drug 
development perceive a lack of returns from investment in TB drug research 
seeing  that  a  large  percentage  of  the  disease  is  prevalent  in  developing 
countries  which  are  unable  to  meet  the  healthcare  needs  of  their  populace 
(Tomioka and Namba, 2006). 
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1.4.1 Natural products in drug discovery 
Natural  products  in  the  form  of  decoctions,  teas,  etc.,  have  been  used  for 
millennia for the  treatment  of disease. The  isolation  of  bioactive  compounds 
from natural sources remains a major source of new medicinals especially in 
the  area  of anti-infectives  and  cancer  (Newman and  Cragg,  2007;  Kingston, 
2011). 
Historically, plant natural products have served as one of the most significant 
source of new leads for pharmaceutical development. The success of natural 
products  in  drug  discovery  has  been  attributed  by  scientists  to  their  high 
chemical  diversity,  the  effects  of  evolutionary  pressure  to  create  biologically 
active  molecules  and  the  structural  similarity  of  protein  targets  across  many 
species (McChesney et al., 2007). The structural diversity seen lends support to 
the  belief  that  collections  of  natural  products  are  not  only  more  varied  than 
those  made  up  of  synthetic  compounds,  particularly  those  produced  by 
combinatorial chemistry, but are also more similar than synthetic compounds to 
the ‘chemical space’ occupied by drug molecules (Henkel  et al.,1999; Feher 
and Schmidt, 2003; Harvey 2007). 
It has been generally estimated that there are approximately 300,000 species of 
higher  plants  and  of  this  number  only  about  1%  or  roughly  3000  has  been 
utilised for food. Out of this 3000, about 150 have been commercially cultivated. 
On  the  other  hand,  approximately  10,000  of  the  world’s  plants  have 
documented medicinal properties (McChesney et al., 2007).  McChesney et al. 
(2007)  found  that  roughly  150-200  of  plant  materials  are  utilised  in  western 
medicine (the US, Western Europe etc).  
In more recent times, natural products have continued to be significant sources 
of  drugs  and  leads  (Newman  et  al.,  2003;  Cragg  et  al.,  2005;  McChesney, 
2007).  Approximately 80% of medicinal products up to 1996 were either directly 
derived from naturally occurring compounds or inspired by a natural product 
(Sneader, 1996; Harvey, 2007).   
Newman et al., (2003) in an extensive review of new drugs introduced between 
1981 and 2002 found that 28% of the 868 new chemical entities were natural 
products or derived from natural products, with another 24% created around a Page | 29  
 
pharmacophore from a natural product. In Butler’s review (2005), at least 70 
natural product-related compounds were in clinical trials in 2004 in addition to 
launched  products.  The  exploration  of  the  bioactivity  of  natural  products 
continues to provide novel chemical scaffold for further drug inventions (Butler, 
2005; Chin et al., 2006; Harvey, 2007). 
In  the  treatment  of  cancers,  plant-  derived  compounds  have  played  an 
important role and some of the promising and better drugs have come up from 
plant  sources  like  Taxol®  (Wani  et  al.,1971),  campthothecin  (Wall,  1998), 
combrestatin (Cirla and Mann, 2003), epipodophyllotoxin (Canel et al., 2000), 
and vinca alkaloids - vinblastine and vincristine (Johnson et al., 1963).  Over 60 
compounds were tested as anticancer drugs from plant sources at the National 
Cancer Institute in 2007 (Saklani and Kutty, 2007).  
 
1.4.2  Plant derived anti-tubercular plant compounds 
Mischer  and  Baker  (1998)  described  potential  anti-tubercular  plant-derived 
compounds such as berberine, lichoisoflavone, erygibisoflavone, phaseollidin, 
erythrabyssin II and tryptanthrin (Gautum et al., 2007).  Copp (2003) reviewed 
plant-derived  antimycobacterial  natural  products  which  covered  a  large 
proportion of phytochemicals such  as lipids/fatty acids and simple aromatics, 
phenolics  and  acetogenic  quinones,  peptides,  alkaloids,  terpenes 
(monoterpenoids, diterpenes, sesquiterpenes, sesterterpenes) and steroids.   
Highly active compounds from these plants  included; the lactone - containing 
tubelactomicin  A,  phenolics  drummondins  and  ferulenol,  xanthone, 
brasiliquinones A and B, (Figure 1.6) the alkaloids celastramycin A, sampagine 
and the manzamines and steroids fusidic acid, saringosterol and ergosterol-5,8-
endoperoxide which all exhibited antimycobacterial activity with MIC values ≤ 4 
µg/mL.  These  compounds  show  the  chemical  diversity  and  complexity 
displayed  by  plants  compared  to  first-line  and  second  –  line  drugs  used  in 
therapy (Figure 1.5) 
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Fig. 1.7  Chemical structures of plant derived anti-tubercular compounds 
                                             
Though  they  are  not  drugs  per  se,  the  structural  skeletons  could  provide 
scaffolds or templates for the development of new anti-TB drugs (Copp, 2003). 
 
1.4.3   Drug development from plant sources 
1.4.3.1  Commercial consideration 
Present  day  drug  discovery  efforts  depend  to  a  great  degree  on  lead 
compounds  from  natural  products  and  synthetic  molecules  (Nicolaou  et  al., 
2011). The choices of disease states being targeted are market - driven such 
that  diseases  like  cancer  and  arthritis  with  enormous  potential  markets  are 
considered rather than anti-malarial or anti-tubercular drugs which are greatly 
needed  among  poor  and  developing  countries  with  less  purchasing  power 
(Heinrich et al., 2004).          
The  declining  interest  of  pharmaceutical  industries  in  developing  new  drugs 
from  plant  sources  is  also  associated  with  the  risky  nature  of  the  business. 
Generally, the process of drug development  is recognised as a high risk or high 
pay-off endeavour  and according to the experience of  Merck Company for 
every 10,000 substances that are evaluated in a battery of biological assays, 20 
are selected for animal testing. Of these 20, 10 will be evaluated for in humans Page | 32  
 
and  only  one  will  be  approved  by  the  Food  and  Drug  Administration  in  the 
United States for sale as a drug. According to the report, Merck claimed that the 
process requires about 12 years at a cost of US$231 million (Vagelos  1991; 
Farnsworth, 1994).  
Another  important  reason  accounting  for  declining  interest,  was  difficulty 
associated    with  sourcing  authenticated  plant  materials  as  well  as  failure  to 
confirm earlier activities demonstrated when they went on to development and 
commercialisation of the product (McChesney et al., 2007). There was also the 
issue of measurement of biological activities of complex mixtures of materials 
and  interaction  properties  leading  to  misleading  results.  The  strongest 
impediment  experienced  as  described  by  some  scientists,  is  the  continuous 
provision and reliable supply of the active constituents for the pharmaceutical 
industry (McChesney and Farnsworth, 1994).  
In the case of TB drugs, the gap in drug development exists for many cited 
reasons such as, the lack of animal models which closely resemble the disease 
in humans, availability of containment facilities for carrying out such studies, the 
slow growth of the bacteria in question and the costs involved in carrying out the 
research.  The lack of committed investigations into new anti-tubercular drugs 
by  drug  companies  has  also  been  attributed  to  the  difficulty  associated  with 
clinical  trials  involving  multi-component  drug  therapy  especially  for TB  which 
requires at least 6-month for treatment of drug-sensitive strains (Tomioka and 
Namba, 2006). Tomioka and Namba (2006) suggest that it would be difficult 
and  costly  to  convincingly  prove  that  newer  drugs  have  better  effects  than 
existing ones since clinical trials would require monitoring treatment for at least 
six-months with follow- up studies thereafter.   
Chemically, isolation of pure, pharmacologically active constituents from plants 
remains a long and tedious process (Hostettmann, 1997).   However advances 
in  separation  science  and  structure  elucidation  technology  such  as  coupled 
liquid  chromatography-mass  spectrometry  and  2D  NMR  techniques  have 
provided  potent  and  powerful  methodologies  for  assignment  of  structure  to 
complex natural products (McChesney et al., 2007).  Highly automated, very 
specific and selective bioassays are now available to carry out the evaluations 
of natural products efficiently and economically (Gross, 2006). Page | 33  
 
 
1.4.3.2  Biological  consideration 
M.  tuberculosis  is  highly  infectious  and  difficult  to  work  with  requiring 
containment facilities. The organism grows slowly requiring three to four weeks 
and mutant cells often require even more time  than the wild-type (Hatfull and 
Jacobs, 2000).  
Genetic tools to transform the M. tuberculosis DNA were unavailable up until 
1998  when  the  full  genomic  structure  was  elucidated  (Hatfull  and  Jacobs, 
2000).  New  drugs  with  novel  mechanisms  of  actions  are  being  rationally 
designed using molecular tools (Tomioka and Namba, 2006). In spite of the 
progress being reported, it may take a while before drugs targeting specific sites 
are  available  commercially  and  such  high  technology  tools  are  not  readily 
accessible in countries with high TB burden. 
 
1.4.4  Rationale for choosing plants used in  research study 
The World Health Organisation (2006) estimated that 80% of the population in 
Africa use traditional medicine for primary health-care. Since medicinal plants 
form the ‘backbone’ of traditional medicine, it strongly implies that more than 
3300 million people in the less developed countries utilise medicinal plants on a 
regular basis. Thus for such indigenous populations  generally unable to afford 
expensive ethical drugs, the need to study these plants for safety and efficacy 
and to develop galenical products that are standardised and stable is imperative 
(Farnsworth, 1994).  
In  the  search  for  new  compounds  needed  for  TB  treatment,  a  number  of 
indigenous herbal remedies were screened in Nigeria against clinical isolates of 
M.  tuberculosis  and  shown  to  have  activities  at  different  levels.  The  herbal 
components investigated during the research programme were selected based 
on  the  inhibitory  activities  observed  on  testing  for  in  vitro  drug  susceptibility 
against Mycobacterium tuberculosis (the causative organism of tuberculosis) by   
Lowenstein-Jensen method. The recipe which consists of  Ximenia americana 
(root bark) and Pavetta crassipes (leaf) is used as a hot water preparation in 
combination  to  treat  respiratory  and  chest  infections  by  traditional  medical Page | 34  
 
practitioners in the Middle belt region of Nigeria (personal communication with 
traditional healer). In the preliminary testing, water extracts of X. americana and 
P. crassipes exhibited  minimum inhibitory concentration (MIC) of 100 µg and 
200 µg/mL respectively against clinical isolate of M. tuberculosis (Odumosu, et 
al., unpublished data). 
Literature search on both plant materials showed no reported data on the anti-
tubercular  activities.  The  objective  of  the  research  project  was  therefore  to 
evaluate  the  extracts  chemically  and  biologically  against  M.  tuberculosis  to 
confirm the therapeutic value. 
 
1.5  Research Aims and Objectives 
The  main  aim  of  the  study  was  to  evaluate  the  anti-tubercular  properties  of 
various plant extracts of both plants extracted by sequential extraction and then 
to isolate and characterise the relevant and promising constituents/leads based 
on  bioactivity  directed  approach  using  analytical  chromatography  and 
spectroscopic tools.   
The  secondary  aim  was  to  determine  the  general  antimicrobial  spectrum  of 
activity  against  gram  positive,  gram  negative  and  fungal  organisms  as  the 
occurrence of opportunistic infections in TB has been reported in literature. 
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Chapter 2       LITERATURE  REVIEW: Medicinal Plants
 
2.1    Introduction 
 
2.1.1  Description - X. americana 
Botanical names: Ximenia americana (Named after F. Ximenes, a 17
th century 
Spanish botanist)  
Family: Olacaceae 
Common  names:  Wild  Olive,  Seaside  plum, 
Tsada (Hausa, Nigeria). 
Habitat: It is found in the savannah; occurring 
also near the coast 
 
X.  americana  Linn.  Family  Olacaceae  is  a 
common white flowered shrub or small tree up 
to 5 m tall. The bark is grey to dark brown or 
almost black flaking off in rectangular patches. The spines are 0.25 - 0.5 inch 
long, straight and sharp, sometimes bearing leaves or the lateral shoots ending 
in a spine (Figure 2.1). Leaves are 1.5 - 2.5 inch long by 0.75 - 1 inch long. It is 
broad, elliptic tapering to both ends with the mid-rib slightly projecting or the 
apex slightly notched with 5-6 pairs of thin faint up curving lateral nerves. The 
stalk is 0.25-0.5 inch long. Flowers are usually in season  January – May, they 
are  white, fragrant; usually in a small cluster at the end of a common stalk 0.25 
- 0.5 inch long, the whole inflorescence is 0.5 -1 inch long. Fruits  are in season,  
April - June, ellipsoid, 0.75 -1.25 inch long, yellow, with a thin skin, sweet flesh Page | 36  
 
and hard stone; with the remains of the style forming a sharp tip. The wood is 
yellow  or  reddish-yellow,  hard,  heavy  and  fine  grained  (Keay  et  al.,  1964; 
Dalziel, 1956). 
 
   
Fig.2.1 Photo of Ximenia plant in its habitat and as shown in  Kew Gardens 
herbarium catalogue (http://www.kew.org) 
 
2.1.2  Medicinal uses 
The  preparation  of  branched  leaves,  barks,  peelings  and  roots  is  used  for 
headaches, toothaches, mumps and conjunctivitis in frontal applications. The 
solutions  are  reserved  for  washing,  massaging  and  instillations  or  gargles 
(Sofowora,  1982).  The  root  has  been  used  for  febrile  headache  (local 
application) and venereal diseases in West Tropical Africa. The pulverised bark 
and  root  are  used  as  a  dressing  for  ulcers,  craw-craw  (pruritic  popular  skin 
eruption  which  may  lead  to  ulceration,  some  cases  caused  by  onchocerca) 
(Dalziel, 1956). 
In  Northern  Nigeria,  the  root  along  with  that  of  Anona  senegalensis  or  A. 
chrysophylla is used in the treatment of sleeping sickness (trypanosomiasis). 
In  Senegal,  the  maceration  of  roots  is  used  in  treating  leprosy  and  applied 
internally and externally for mental sickness. It is also a remedy for impotence. Page | 37  
 
The inhalation of dry root powder and bark mixed with other ingredients is used 
to treat oedema of the face (Sofowora, 1982). 
In Tanzania, the root is used as a febrifuge and diarrhoea remedy (Watt and 
Breyer-Brundwijk, 1962; Dalziel, 1956). A decoction of the leafy twigs is given 
for febrile  colds  and cough  and  as a  laxative  in  Zimbabwe  (Kokwaro,  1976; 
Dalziel, 1956; Burkill, 1985). 
 
2.1.3 Constituents and Pharmacology 
The bark yields 16-17 per cent of tannins. Finnemore et al. (1958) analysed the 
leaves of X. americana in Australia and showed the presence of sambunigrin 
while Earle and Jones (1962) obtained positive results for alkaloids in the seeds 
(Sofowora,  1982).  Almagboul  et  al.  (1985)  screened  the  chloroform  and 
methanol  plant  extracts  for  antibacterial  activity  and  observed  some  activity.  
Ogunleye  and  Ibitoye  (2003)  evaluated  the  ethanolic  leaf  extract  for 
antimicrobial  activity  and  it  was  reported  to  be  active  against  S.  aureus,  P. 
aeruginosa and C. albicans.  
Mwangi et al. (1994) isolated polymeric proanthocyanidin mixture, epicatechin 
(major flavan-3-ol), catechin, gallic acid and procyanidins from the root of  X. 
americana var. caffra.  A MIC of 1000 µg/mL against Staphylococcus aureus 
was  obtained  for  crude  extract  of  polymeric  proanthocyanidins  while  no 
antimicrobial activity was observed for epicatechin and catechin. D’Agostino et 
al.  (1994)  investigated  the  chloroform  –  methanol  extract  of  the  roots  and 
isolated  an  oleanolic  acid  saponin  identified  as  3-β-O-[ʱ-L-rhamnopyranosyl-
(1→2)-β-D-galactopyranosyl-(1→3)-β-Dglucopyranosyl-uronic  acid]  oleanolic 
acid 28-O- β-D-glucopyranoside.   
Fatope et al. (2000) in their study isolated C18 acetylenic fatty acids, tariric acid 
and a novel fatty acid, 10Z, 14E, 16E-octadeca-10, 14, 16-triene-12-ynoic acid 
from  the  chloroform  root  extract  of  X.  americana.  Omer  and  Elnima  (2003) 
investigated the antibacterial activity of methanol and water extracts of the root 
which  was  reported  to  show  some  activity  against  B.  subtilis,  S.  aureus,  P. 
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inhibition.  Mevy et al. (2006) analysed the volatile oil of the leaves by GC-MS 
and identified 33 components representing 98% of the total oil. Runyoro et al. 
(2006) screened the methanol root bark extract from Morogoro and Tanga in 
Tanzania using bioautographic agar overlay technique. No activity was reported 
against Candida.  
Voss  et  al.  (2006)  identified  and  characterised  riproximin,  a  new  type  II 
ribosome – inactivating protein with anti-neoplastic activity from the whole plant 
of X. americana.  Araujo et al. (2009) isolated ximonicane, a new sesquiterpene 
compound and stigmastane steroid from the stem bark extract of the plant. 
 
 
Table 2.1. Summary of chemical constituents reported in X. americana from 
literature. 
plant part  constituents  Reference 
leaf  sambunigrin  Finnemore et al., 1958 
stem bark  tannins  Sofowora, 1982 
seeds  alkaloids  Earle and Jones, 1962 
whole plant  riproximin (var. caffra)  Voss et al., 2006 
root bark  polyphenols (var. caffra)  Mwangi et al., 1994 
root bark  oleanolic acid saponin  D'Agostino et al., 1994 
stem bark 
 
root bark         
 
ximonicane, stigmastane 
 
C18 acetylenic fatty acids 
Araujo et al., 2009 
 
Fatope et al., 2000 
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2.1.4      Description - Pavetta  crassipes 
Botanical  name:  Pavetta  crassipes 
K. Schum  
Family: Rubiaceae 
Common names:Mupembe (Kenya), 
Rubatari (Hausa, Nigeria) 
 
The shoots are covered with whitish corky bark. Corolla lobes are 5 - 8 mm long 
and  the  leaves  has  a  main  lateral  nerve  on  each  side  of  the  mid-rib.  The 
stipules and bracts are pilose inside, bracelets are stout, and the leaves are 
often in three subsessile, glabrous, and narrowly elongated oblong-lanceolate 
and rounded at the apex. The leaves are 15 - 25 cm long and 3 - 5 cm broad 
(Figure 2.2). 
 
   
Fig.2.2 Photos of Pavetta crassipes in its habitat and as shown in Kew Gardens 
herbarium catalogue (http://www.kew.org) 
 
The flowers are sub-sessile in clusters on very short lateral shoots. The corolla 
tube is about 12-18 mm long while the lobes are about 5 mm long.  The Calyx is 
glabrous. Approximately, 91 genera and 531 species are reported to be present 
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2.1.5   Medicinal uses 
The leaves are used by some people as food pounded up with other foods or 
boiled in slightly fermented water in which cereals have been left to steep and 
mixed  with  a  corn  meal.  The  sap  is  useful  for  coagulating  rubber  latex 
(Hutchinson and Dalziel, 1954).  
Leaf extracts have been used as anti – malarial remedy against Plasmodium 
falciparum and for coughs in Tanzania and Burkina Faso. The roots are also 
eaten  as  food  when  cooked  with  chicken  in  soups  and  as  anti-convulsant 
(Chabra et al., 1991; Gessler et al., 1994; Nadembega et al., 2011) while the 
fresh or dry fruits are eaten in East Africa as anti-helminthics (Kokwaro, 1976; 
Chabra et al., 1991). 
 
 2.1.6  Constituents and pharmacology 
Constituents  such  as  alkaloids  and  polyphenols  have  been  reported  to  be 
present in Pavetta owariensis, a closely related species (Weniger et al., 2004; 
Baldé et al., 1990, 1991). Mild anti-plasmodial activity against reference clones 
of Plasmodium was observed for the alkaloid extracts of P. crassipes leaf and 
P.  corymbosa  aerial parts. The alkaloid extracts  exhibited moderate    in-vitro 
activity  and  weak  cytotoxicity  against  three  human  cell  lines  (THP1,  normal 
melanocytes, HTB-66 (Sanon et al., 2003, Weniger et al., 2004).  
Sanon  et  al.  (2005)  reported  the  presence  of  indolomonoterpenic  alkaloids, 
elaeocarpidin  and  hydroxyl-elaocarpidin,  rutin,  acanthospermol 
galactosidopyranoside  in  P.  crassipes  leaf.  Hydroxy-elaeocarpidin  was 
demonstrated to have good anti-malarial activity with an IC50 of 1.83 µg/mL and 
they observed synergistic effects in combination with Mithragyna inermis. Baldé 
et al. (2010) investigated the alkaloid fractions of the leaf with reported in vitro 
activities  against  bacteria,  trypanosomes,  leishmania, falciparum,  and  cancer 
cells.  
Amos  et  al.,  (1998a)  investigated  the  effects  of  the  aqueous  extracts  of  P. 
crassipes on gastrointestinal and uterine smooth muscle preparations isolated 
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The  scientists  observed  a  concentration  dependent  inhibition  of  the 
spontaneous motility or elevated tone in the preparations.  
Another study by Amos et al., (2004) demonstrated a dose-dependent decrease 
of  spontaneous  motor  activity  in  mice  with  attenuated  amphetamine-induced 
hyperactivity.  They  suggest  that  the  bioactive  compounds  might  be  acting 
centrally through the inhibition of dopaminergic pathway or a system linked to 
this pathway to mediate the observed pharmacological effects. The aqueous 
leaf  extract  was  also  shown  to  have  anti-inflammatory  and  muscle  relaxant 
activity  and  hypotensive  activity  on  rat  muscles  (Amos  et  al.,  1998b;  2003). 
Mustapha and Bala (2007) investigated the antimicrobial activity against some 
respiratory tract pathogens and observed moderate activity at mg levels.  
 
 
Table 2.2. Summary of chemical constituents reported in   P. crassipes from 
literature 
 
plant part  constituents  Reference 
Leaf  Indolomonoterpenic alkaloids  Sanon et al., 2005 
Leaf    polyphenols  Sanon et al., 2005 
 
 
Following literature review of both plants material, general antimicrobial 
screening of the extracts was commenced. 
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Chapter 3   General Antimicrobial Screening of Plant Extracts Against 
Bacteria and Fungi 
 
 
3.1         Background 
Owing to the fact that opportunistic organisms have been found to co-exist with 
M.  tuberculosis  infection,  the  general  focus  of  the  studies  described  in  this 
chapter was focused on the methods used in testing organisms known to be 
representative of the bacterial and fungal classes (Ghannoum, 1997; Vazquez, 
2000;  Runyoro,  2006).    It  was  hoped  that  this  aspect  of  the  work  would 
demonstrate  other  bacterial  activities  of  the  plant  extracts  in  addition  to  the 
antitubercular action. This in effect would provide an overview of the general 
activity of the plant extracts. 
 
3.1.1       Introduction 
Infectious diseases caused by bacteria, fungi, viruses and parasites are still a 
major  threat  to  public  health,  despite  the  tremendous  progress  in  human 
medicine (Cos et al., 2006). The effect is significant in developing countries due 
to  the  relative  unavailability  of  medicines,  cost  constraints  of  more  effective 
newer agents and the emergence of widespread drug resistance. Investigations 
on finding new antimicrobial substances needs to be continued for this reason 
utilising all possible avenues to finding low cost effective solutions (Okeke et al., 
2005).   
Besides synthesised small molecules arising from medicinal chemistry studies, 
natural  products  are  still  major  sources  of  innovative  therapeutic  agents  for Page | 43  
 
various conditions, including infectious diseases (Clardy and Walsh, 2004). The 
primary target of natural product research is on plants since they can be easily 
sourced and selected on the basis of their ethno-medicinal use (Verpoorte et 
al., 2005). 
It is extremely important to design in vitro experiments that resemble the target 
disease (Kariba et al., 2002). Thus a plant used topically for fungal infections 
should be tested against dermatophytic fungi rather than the ‘classic’ genera 
such  as  Aspergillus  and  Penicillium.  In  the  same  way  extracts  which  are 
claimed to have antibacterial activity should be tested against bacteria of clinical 
relevance (Cos et al., 2006). 
With better understanding of the underlying aetiology of disease states, it has 
become apparent that a range of different diseases may have common factors. 
For conditions associated with excess inflammation such as asthma, eczema, 
arthritis, in vitro tests associated with inhibition of one of the many biochemical 
processes related to inflammation are often used. Common examples of these 
are tests for lipoxygenase inhibition, inhibition of eicosanoid synthesis. Activity 
in one or more of these systems may indicate the anti-inflammatory property of 
the extract but to specify activity in a particular disease based on the response 
is often an extrapolation too far (Houghton et al., 2007). 
The traditional antibacterial and antifungal test methods are classified into three 
main groups, i.e. diffusion, dilution and bio-autographic methods. A relatively 
new method is the conductimetric assay which detects microbial growth as a 
change in the electrical conductivity or impedance of the growth medium (Sawai 
et al., 2002).   
Many research groups have modified these methods for specific samples, such 
as essential oils and non-polar extracts and these small modifications make it 
almost impossible to directly compare results. It is therefore a ‘must’ to include 
at least one reference compound or as many as possibly can be accessed in 
each assay (Cos et al., 2006). 
 
3.1.2  Agar diffusion methods 
In the diffusion technique, a reservoir containing the test compound at a known 
concentration  is  brought  into  contact  with  an  inoculated  medium  and  the Page | 44  
 
diameter of the clear zone around the reservoir (inhibition diameter) is measured 
at the end of the incubation period.  
In order to enhance the detection limit, the inoculated system is kept at lower 
temperature for several hours before incubation to favour compound diffusion 
over microbial growth, thereby increasing the inhibition diameter (Cole, 1994). 
Different types of reservoirs can be used, such as filter paper discs, stainless 
steel cylinders placed on the surface and holes punched in the medium. The 
hole-punch method is the most suitable diffusion technique for aqueous extracts, 
because  interference  by  particulate  matter  is  less  than  with  other  types  of 
reservoirs. To ensure that the sample does not leak under the agar layer, fixed 
agar is left on the bottom of the hole. The small sample requirements and the 
possibility of testing up to six extracts per plate against a single micro-organism 
are  specific  advantages  of  the  method  (Hadacek  and  Greger,  2000).  The 
diffusion method is not appropriate for testing non-polar samples or samples that 
do not easily diffuse into agar.  
Etest® is reported to be a well-established method for antimicrobial testing in 
microbiology laboratories. Etest® consists of pre-defined gradient of antibiotic 
concentrations on a plastic strip which is used in susceptibility testing against 
bacterial, fungal and mycobacterial organisms. It possesses the advantage of 
being able to provide quantitative MIC data which is of great importance in the 
management of critical infections such as sepsis. Etest® is recognised as a cost 
effective  tool  for  generating  MICs  across  15  dilutions.  It  has  been  used  in 
resistance detection and over 100 antibiotics are available for testing aerobic 
bacteria,  fastidious  organisms,  anaerobes,  fungi  and  mycobacteria 
(http://www.boimerieux-usa.com).  The test is used to promote rational use of 
antibiotics by providing results to guide individual therapy and to validate empiric 
drug  regimens.  According  to  the  report,  E test®  is widely  used  in  resistance 
surveillance programmes and clinical trials.   
In  one  study  (Di  Bonaventura  et  al.,  1998)  the  evaluation  of  E  test  for 
antimicrobial  susceptibility  testing  of  P.  aeruginosa  showed  88  and  92.5  % 
correlation of E test MICs with those determined by the agar dilution and disc 
diffusion reference methods respectively. 
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i)   
 
ii)        
 
Fig.3.1 i) Guide showing how to read the MIC of antibiotic E test gradient strip  
(http://abbiodisk.com) ii) Examples of plates prepared experimentally showing 
ampicillin  test  strips  with  no  inhibition  against    E.  coli  but  inhibition  with  S. 
aureus (MIC of > 256 µg/mL and 8 µg/mL respectively). 
In  general,  the  relative  antimicrobial  potency  of  different  samples  may  not 
always be compared, mainly because of differences in physical properties, such 
as solubility, volatility and diffusion characteristics in agar. Furthermore, agar-
diffusion methods are difficult to run on high-capacity screening platforms (Cos 
et al., 2006). 
Ampicillin E- test strip against 
E. coli  
Ampicillin E-  test  strip  against 
S. aureus Page | 46  
 
3.1.3 Dilution methods 
Dilution methods are used to determine the minimum Inhibitory concentrations 
(MICs) of antimicrobial agents and are the reference methods for susceptibility 
testing  against  which  other  methods,  such  as  disc  diffusion  are  calibrated 
(EUCAST,  2000).  In  the  dilution  methods,  test  compounds  are  mixed  with  a 
suitable medium that has previously been inoculated with the test organism. It 
can be carried out in liquid as well as in solid media and growth of the micro-
organism can be measured in a number of ways (Cos et al. 2006).  
In the agar-dilution method, the MIC is defined as the lowest concentration able 
to inhibit any visible microbial growth. In liquid- or broth-dilution methods, turbidity 
and  redox-indicators  are  most  frequently  used.  Turbidity  can  be  estimated 
visually or obtained more accurately by measuring the optical density at 600 nm. 
However,  test  samples  that  are  not  fully  soluble  may  interfere  with  turbidity 
readings,  emphasising  the  need  for  a  negative  control  or  sterility  control,  i.e. 
extract dissolved in blank medium without micro-organisms.  
The liquid-dilution method also allows assessment of whether a compound or 
extract  has  a  cidal  or  static  action  at  a  particular  concentration.  The  minimal 
bactericidal or fungicidal concentration (MBC or MFC) is determined by plating-
out samples of completely inhibited dilution cultures and assessing growth (static) 
or no-growth (cidal) after incubation. In most investigations, the redox indicators, 
MTT  and  resazurin  are  frequently  used  to  quantify  bacterial  (Eloff,  1998; 
Gabrielson et al., 2002) and fungal growth (Jahn et al., 1995; Pelloux-Prayer et 
al.,  1998).  Resazurin  has  the  advantage  of  not  forming  precipitates  upon 
reduction  thereby  allowing  for  direct  interpretation.  Easy  and  reproducible 
measurements can be obtained with a microplate-reader, but visual reading may 
also be used in cases where spectrophotometry is not available.  
Another assay which can be used is based on the principle that only living cells 
convert  fluorescein-diacetate  to  fluorescein,  producing  a  yellowish-green 
fluorescence under UV light (Chand et al., 1994). However, it requires a more 
significant investment in equipment and validation is not easy  e.g. Sabouraud 
liquid medium can quench up to 95% of fluorescence, and sodium phosphate 
buffers hydrolyse fluorescein-diacetate. Fluorescent constituents present in crude 
plant extracts may also interfere (Clarke et al., 2001).  Page | 47  
 
In  general,  dilution  methods  are  suitable  for  analysing  polar  and  non-polar 
extracts or compounds for determination of MIC and MBC/MFC-values. Using 
redox  indicators  or  turbidimetric  endpoints,  dose–response  effects  allow 
calculation  of  IC50-  and  IC90-values,  which  are  the  concentrations  required  to 
produce 50 and 90% growth inhibition. 
 
3.1.4 Bio-autographic methods 
Bio-autography localises antimicrobial activity on a chromatogram using three 
approaches:  
(a) Direct bio-autography, where the micro-organism grows directly on the thin-
layer-chromatographic (TLC) plate 
(b) Contact bio-autography, where the antimicrobial compounds are transferred 
from the TLC plate to an inoculated agar plate through direct contact and  
(c)  agar-overlay  bio-autography,  where  a  seeded  agar  medium  is  applied 
directly  onto  the TLC  plate  (Hamburger and  Cordell,  1987;  Rahalison  et  al., 
1991) .  
Despite high sensitivity, its applicability is limited to micro-organisms that easily 
grow  on  TLC  plates.  Other  problems  are  the  need  for  complete  removal  of 
residual  low  volatile  solvents,  such  as  n-butanol,  trifluoroacetic  acid  and 
ammonia and the transfer of the active compounds from the stationary phase 
into  the  agar  layer  by  diffusion.  Because  bio-autography  allows  localising 
antimicrobial activities of an extract on the chromatogram, it supports a quick 
search  for  new  antimicrobial  agents  through  bioassay-guided  isolation. 
However,  this  technique  is  not  directly  applicable  in  current  high  capacity 
screening  designs.  The  choice  of  test  organisms  depends  on  the  specific 
purpose of the investigation. In a primary screening, drug-sensitive reference 
strains are preferably used and should represent common pathogenic species 
of different classes.  
Various combinations are possible, but the panel should at least consist of a 
gram-positive and a gram-negative bacterium. Based on  literature data, it has 
been well-established that gram-positive bacteria are much more sensitive to 
drug action than gram-negative bacteria, which is reflected by a higher number Page | 48  
 
of random ‘hits’ during a screening campaign. Extracts with prominent activity 
against gram-positive cocci should also be tested against methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), 
as  they  cause  diseases  which  are  clinically  difficult  to  manage  (Cos  et  al., 
2006).  ATCC strains are well-characterised and very popular for that purpose, 
but clinical field isolates may also be used if fully characterised by antibiogram.  
A  small  set  of  reference  fungi  is  used  for  primary  screening  and  includes 
Trichophyton  mentagrophytes  and  Epidermophyton  floccosum  as 
representatives  of  the  dermatophytes  and  opportunistic  filamentous  fungi, 
Aspergillus niger and Fusarium solani (Cos et al., 2006). 
 
3.1.5  Inoculum 
The  inoculums  should  give  semi-confluent growth  of  colonies  after overnight 
incubation.  A  semi-confluent  growth  can  easily  be  recognised  as  shown  by 
Figure 3.2.  A heavier inoculum may result in reduced inhibition zones while a 
lighter inoculum may give increased inhibition zones (Andrews, 2010). 
 
i)   ii)   
 
Fig.3.2 i) The plate on the left side shows an incorrect procedure while the one 
on the right ii) shows semi-confluent growth within an acceptable range. 
 
3.2    Aims and Objectives 
The  purpose  of  this  initial  work  was  to  determine  MIC  values  against 
representative  gram  positive  and  gram  negative  bacteria,  as  well  as  fungal 
organisms  in  order  to  establish  the  antimicrobial  spectrum  of  activity  and  to 
determine  fractions  with  prominent  activity  against  bacterial  or  fungal Page | 49  
 
organisms. The results would provide an indication of potential usefulness in 
treating opportunistic infections associated with TB disease. 
 
3.3      Experimental  
3.3.1   Materials 
Iso-Sensitest agar (ISA), broth powder (CM 0473), Sabouraud dextrose agar 
were purchased from Oxoid, U.K. Other compounds such as dimethyl sulfoxide, 
gentamicin,  erythromycin,  miconazole,  amphotericin  B  were  purchased  from 
Sigma  Aldrich,  U.K.  Other  compounds  used  in  the  study  were  griseofulvin 
(Acros Organics), D-glucose (BDH, Sigma), and glycerol (BDH).  
 
3.3.2   Equipment 
Class II microbiological safety cabinet was supplied by Atlas labs, U.K. while 
Spectrophotometer (Spectronic 20) and microplate reader (Thermo) were also 
utilised. 
 
3.3.3  Bacterial and fungal strains 
Control organisms which were representative of bacteria and fungi were chosen 
according to British Society for Antimicrobial Chemotherapy (BSAC) guidelines. 
The  listed  typed  organisms  were  used  in  the  antimicrobial  screening 
Staphylococcus  aureus  (ATCC  25823),  Bacillus  subtilis  (NCIB  8054), 
Escherichia  coli  (ATCC  11560),  Pseudomonas  aeruginosa  (ATCC  10662), 
Candida  albicans  (NCTC  1363),  Aspergillus  niger  (UoS  strain),  Penicillium 
chrysogenum  (UoS  strain)  Trichophyton  mentagrophytes  (ATCC  9129), 
Propionibacterium acnes. 
 
3.3.4 Preparation of reagents and media 
3.3.4.1 Turbidity standard for inoculum preparation- McFarland standard 
The standard was prepared by adding 0.5 ml of 0.048 M barium chloride (1.17% 
w/v  BaCl2.2H2O)  to  99.5 ml of  0.18  M  sulphuric  acid  (1%  v/v)  with  constant 
stirring  and  transferred  to  a  tube  similar  to  that  used  in  growing  the  broth 
culture. The accurate density of the turbidity standard was determined by taking 
the  absorbance  reading  at  625  nm  on  the  spectrophotometer.  Absorbance 
values  of  0.008  to  1.10  were  considered  to  be  equivalent  to  0.5  McFarland Page | 50  
 
(BSAC 2010; Lalitha, 2004). The standard was vigorously agitated on a vortex 
mixer each time before use. 
 
3.3.4.2 Nutrient agar/broth 
One litre of deionised distilled water was added to a conical flask weighing 28 g 
of powder (25 g for broth) and dispersed. This was allowed to soak for about 10 
minutes, swirled to mix and dispensed into sterile bottles in 9 mL portions. This 
was then sterilised in an autoclave at 121 ˚C for 15 minutes.  For agar, the 
sterilised  liquid  was  allowed  to  cool  to  50  ˚C,  mixed  and  poured  into  petri 
dishes.  After  solidification,  plates  were  stored  at  2  –  8  ˚C  until  use 
(manufacturer’s instructions). 
 
3.3.4.3 Iso-Sensitest agar/broth 
One litre of deionised distilled water was added to a conical flask weighing 31.4 
g of dehydrated agar powder (23.4 g for broth) and heated on a hot plate to 
dissolve. The solution was then distributed into tubes in 9 mL aliquots, sterilised 
and dispensed as described for nutrient agar. 
 
3.3.5 Isolation and cultivation of bacterial and fungal species 
E. coli, S. aureus and P. aeruginosa were routinely grown on nutrient agar at 37 
˚C and kept at 4 ˚C until required.  Overnight cultures were grown on slopes or 
plates and used for carrying out susceptibility testing against plant extracts and 
reference  antibiotics.  Tricophyton  mentagrophytes,  Propionibacterium  acnes, 
Aspergillus niger, Candida albicans and Penicillium crysogenum were grown on 
sabouraud  dextrose  agar  and  incubated  at  30  ˚C  for  7-10  days.  Working 
suspensions were prepared from the cultures for the tests. 
 
3.3.6 Determination of minimum inhibitory concentration by agar dilution 
The dried plant powdered materials were sequentially extracted by maceration 
and soxhlet extraction  with hexane, dichloromethane, methanol and water to 
obtain  crude  plant  fractions.  Crude  ethanol  extracts  were  also  obtained  by 
percolation with 80 % ethanol at room temperature to give total extraction.  
The crude plant extracts were weighed in 1 g batches and diluted in dimethyl 
sulfoxide (DMSO) and sterile water to obtain 200 mg/mL solutions. Doubling Page | 51  
 
dilutions  were  done  in  sterile  distilled  water  successively  to  obtain  lower 
concentrations.  
After diluting, 1 mL of each extract dilution was transferred to 19 mL of molten 
Iso-Sensitest agar in universal containers (held at 45 – 50 ˚C). This was gently 
mixed and poured into agar plates. This was left for about 30 minutes to solidify. 
Plates were incubated in air at 37 ˚C for 18 - 24 hours.  
The organism was allowed to grow on the antibiotic-free control plate before 
readings  were  taken.  Griseofulvin  and  miconazole  were  used  as  reference 
antifungal  antibiotics  to  monitor  positive  control  growth  against  the 
dermatophyte while erythromycin and gentamicin were used to monitor positive 
control growth against bacteria i.e. to show growth inhibition for comparison with 
extracts.  DMSO (solvent control plate) was used to show the lack of solvent 
effect on the growth of the organisms.  
MIC  was  defined  as  the  lowest  concentration  of  the antimicrobial agent  that 
completely inhibited visible growth as seen with the naked eye, disregarding 
single  colony  or  fine  haze  within  the  area  of  inoculated  spot  (European 
Committee on Antimicrobial Susceptibility testing, EUCAST  2000; BSAC 2010). 
 
 
3.3.7 Antifungal susceptibility testing by agar dilution method 
The crude plant extracts were weighed in 1 g batches and diluted in DMSO and 
sterile water to obtain 200 mg/mL solutions. Doubling dilutions were done in 
sterile  distilled  water  successively  to  obtain  lower  concentrations.  After  the 
dilutions,  1  mL  of  each  extract  solution  was  transferred  to  19  mL  of  molten 
sabouraud dextrose agar in universal containers (held at 45 - 50˚C). This was 
gently mixed and allowed to solidify for 30 minutes.  
A suspension was prepared from a 7-10 day culture of dermatophyte grown at 
30˚C using 0.45 % saline and the spore concentration was determined with the 
aid of a Neubauer haemocytometer to give a suspension density equivalent to 1 
- 2 x 10
6 CFU/mL (Aberkane et al., 2002; BSAC, 2010).  An inoculum volume of 
20 µL ≡ 2 x 10
4 CFU was placed on each plate and incubated at 30 ˚C for at 
least 48 hours.  Miconazole and griseofulvin were used for determining positive 
control growth while agar containing no plant extract or antibiotic was used as 
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as solvent and sterility controls respectively in order to validate results obtained. 
Duplicate plates were observed for growth or no growth for each dilution. 
 
3.4    Results and Discussion 
The crude solvent fractions of X. americana and P. crassipes  obtained from 
were  subjected  to  susceptibility  testing  against  selected  control  organisms 
representative  of  bacteria  and  fungi  by  the  agar  dilution  method  as 
recommended by BSAC (2010) guidelines  (Tables 3.1 - 3.5). The plant extracts 
were screened against the listed organisms in order to demonstrate its activity 
against a wide spectrum of organisms.  
Opportunistic  bacteria  have  been  reported  to  be  present  alongside  M. 
tuberculosis in TB and known to exacerbate HIV infection (Ghannoum, 1997; 
Vazquez, 2000; Runyoro, 2006). Opportunistic microorganisms cause relatively 
minor disease that is not normally serious but it can become pathogenic or life-
threatening when the host has a low level of immunity. TB and HIV infections 
are associated with low immunity with TB being a leading cause of death in HIV 
so  testing  against  the  microorganisms  was  performed to determine  activities 
that may be beneficial in treating TB patients with mixed infections. 
Both  plant  extracts  exhibited mild  antibacterial activity  against  representative 
gram positive and gram negative at mg levels. In contrast, the hexane extract of 
X. americana root was most active at 62.5 µg/mL against P. acnes. Two LC 
fractions labelled as fraction 1 and 2 obtained from the hexane extract were 
further tested against P. acnes with fraction 1 showing inhibitory activity at MIC 
value >100 µg/mL and fraction 2 (MIC = 100 µg/mL). Fractions 1 and 2 from the 
hexane extract had MIC values greater than the crude extract suggesting the 
possibility of synergism between the bioactive constituents.  All other solvent 
fractions had MIC values of 125 - 500 µg/mL against P. acnes compared to 
erythromycin (MIC value of 0.195) the reference standard (Table 3.4).  
The methanol, chloroform and hexane extracts of X. americana root had MIC 
values of 250 - 500 µg/mL against T. mentagrophytes with the hexane extract 
(most active) having a MIC value of 250 µg/mL compared to miconazole and 
griseofulvin  reference standards which had MIC values > 0.2 and 3.125 µg/mL Page | 53  
 
respectively  (Table  3.4).  MIC  values  were  means  of  three  replicate 
measurements.   
Amos et al., 1998 in their study reported anti-inflammatory and muscle relaxant 
effects  of  the  aqueous  extract  of  P.  crassipes  which  supports  the  ‘herbal 
shotgun’  principle  where  components  play  different  functions  in  achieving 
therapy.  
 
 
 
Table 3.1.  Antimicrobial testing of  X. americana root extracts (MIC mg/ml) 
 
 
 
 
 
 
 
 
 
 
Bacteria  hex  dcm  meth  H2O 
 
S. aureus 
  
0.5 
  
0.5 
  
 0.25 
  
 2.5 
 
B. subtilis 
 
0.5 
 
0.25 
  
1.0 
 
> 2.5 
 
E. coli 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
P. aeruginosa 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
Gentamicin 25 µg/mL -  positive control Page | 54  
 
 
Table 3.2.  Antimicrobial   testing of  P. crassipes  leaf extracts (MIC mg/mL) 
 
Bacteria  etha    meth   H2O 
 
S. aureus 
   
2.5 
  
 5.0 
 
5.0 
B. subtilis  2.5   5.0  2.5 
E. coli  5.0   5.0  5.0 
P. aeruginosa  5.0   5.0  2.5 
Gentamicin 25 µg/mL - positive control 
 
 
 
 
 
Table 3.3.  Antifungal   testing of X. americana root extracts (MIC mg/ml) 
 
Fungi   hex   dcm    meth 
 
C. albicans 
 
 > 2.5 
 
> 2.5 
 
> 2.5 
 
A. niger 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
P. chrysogenum 
 
> 2.5 
 
> 2.5 
 
> 2.5 
 
Amphotericin B 25 µg/mL - positive control 
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Table  3.4.  Anti-dermatophyte  and  anti-acne  testing  of  X.  americana  root 
extracts MIC (µg/mL) 
 
Organism  Erythro 
 
Hex  CHCl3  Meth  H2O  Fr1           Fr2 
              
>100       
 
 
 
 
 
 
P. acnes 
 
 
 
T. 
mentagro 
-phytes 
0.195 
 
Micon 
 
 
>0.2 
62.5 
 
Hex 
 
 
250 
125 
 
Chloro 
 
 
250 
500 
 
Meth 
 
 
500 
>100 
 
Griseo 
 
 
3.125 
100 
 
  
 
DMSO - Negative control          Fr – Fraction from crude hexane extract 
 
 
Table 3.5.  Antimicrobial susceptibility testing of P. crassipes leaf extracts MIC 
(µg/mL) to P. acnes 
 
Extract/drug  MIC (µg/mL) 
hexane  > 1000 
dichloromethane  > 100 
Erythromycin 10 mg  0.5 
 
 
Hexane and dichloromethane extracts of Pavetta leaf were also tested against 
P.  acnes  and  the  extracts  had  MIC  values  of  1000  and  >  100  µg/mL 
respectively  compared  to  erythromycin  (MIC  0.195)  the  reference  standard 
(Table  3.5).  The  screening  against  P.  acnes  and  T.  mentagrophytes  was 
performed  to  determine  the  dermatological  properties  since  information 
obtained from literature describes the use of the plant material in dermatological Page | 56  
 
conditions such as ringworm and craw - craw and could be of potential benefit 
in treating opportunistic infections in TB (Dalziel, 1956; Sofowora, 1982).  
From  the  results  of  the  experiments,  P.  crassipes  leaf  extracts  were  not  as 
active when compared to the reference antibiotics or X. americana root extracts. 
The inclusion in the preparation could be justified by the principle of synergy 
where  an  extract  is  added  to  enhance  the  activity  of  the  actives,  such  as 
stabilising  the  actives  through  anti-oxidant  action,  enhancing  bioavailability 
rather than anti-bacterial action. 
 
3.5   Conclusion 
The  results  of antimicrobial  susceptibility  testing  of both plant  crude  extracts 
revealed weak activity at concentrations (mg levels) considered to be high by 
literature  standards.  However,  X.  americana  root  extract  exhibited  moderate 
activity  (µg  levels) against  gram  positive  bacteria  such as  S.  aureus  and B. 
subtilis and P. acnes.  The extract could potentially have good activity against 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococci (VRE) since it is effective against the gram positive organisms (Cos 
et al., 2006).  
Essentially,  the  in  vitro  experiments  were  designed  to  resemble  the  target 
disease  and  associated  symptoms  so  testing  against  representative  bacteria 
helps in determining potential activities against organisms which may co-exist 
with TB infections (Kariba et al., 2002). 
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Chapter 4      Drug Susceptibility Testing of Plant Extracts against 
Mycobacterium aurum 
 
 
4.1      Background 
In  general,  saprophytic,  non-pathogenic  strains  of  mycobacteria  are  used  in 
preliminary screening assays in order to obtain quick results and/or because of 
biosafety concerns in working with virulent M. tuberculosis.  The non-pathogenic 
strains  have  advantages  such  as  rapid  growth  and  the  use  of  Class  1  or 2 
laboratory facilities which is readily available in most institutions (Newton, 2002; 
Franzblau et al., 1998).  
 
4.1.1     Introduction 
M. aurum is a non-pathogenic strain of the genus Mycobacteriaceae.  It is an 
aerobic,  acid  fast,  gram  positive  organism  (HPA,  2008).  The  colonies  are 
smooth and shiny in appearance, yellow in colour, convex, entire and cells are 2 
µm in length.  It is easily emulsifiable and grows on glucose agar or nutrient 
broth  at  37°C.  Investigations  on  M.  aurum  are  restricted  to  WHO  Class  2 
laboratories  (HPA,  2008).  M.  tuberculosis  H37Ra  (avirulent)  strain  has  also 
been used as a substitute or test model for the more virulent H37Rv  strain in 
the initial assay  determination  for  molecules with potential activity against 
MTB    though  both  are  slow  growing  (Collins  and  Franzblau,  1997).  M. 
smegmatis,  M.  bovis,  M.  chelonae  and  M.  fortuitum  are  other  examples  of 
common  species  used  in  preliminary  anti-TB  screening  tests.  Newer,  rapid 
assays  for  M.  tuberculosis  (including  MABA),  however,  have  significantly 
lessened the time differential in obtaining results for slow growing and rapidly 
growing mycobacteria.  Page | 58  
 
The vital point to be considered would appear to be the degree of similarity in 
drug  susceptibility  between  any  surrogate  mycobacterium  and  virulent  M. 
tuberculosis with special care needed over species or strains which might be 
less sensitive (Collins and Franzblau, 1997). Chung et al. (1995) carried out a 
study in which they investigated uracil uptake in Mycobacterium aurum and M. 
tuberculosis H37Rv in the bid to develop a high-through put screen for detecting 
anti-TB compounds. Their observations of the relative susceptibilities to anti-TB 
drugs showed that M. aurum had high predictive ability for high throughput anti-
TB screening. 
Reports  of  a  study  by  Collins  and  Franzblau  (1997)  using  an  agar  dilution 
technique suggested that rapidly growing mycobacteria such as Mycobacterium 
smegmatis, Mycobacterium phlei, Mycobacterium fortuitum, and Mycobacterium 
neoaurum were a little different to (and usually less sensitive than) H37Rv when 
compared  to    the  slow-growing  Mycobacterium  bovis  BCG  and  H37Ra  with 
respect to MICs of fifteen compounds.  
Studies  by  Arain  et  al.  (1996)  have  demonstrated  the  similarity  in  drug 
susceptibility between M. bovis BCG and H37Rv. However, the observation that 
M. bovis BCG was not sensitive to pyrazinamide in the primary testing could 
lead to compounds with anti-TB activity being missed.  It was suggested that 
utilising a less virulent strain of M. tuberculosis such as H37Ra may be a better 
option (Collins and Franzblau, 1997).  Pascopella et al. (1993) in their study 
described how difficult it was to differentiate the physical and genetic make-up 
of  the  virulent  H37Rv  and  avirulent  H37Ra.  In  the  study  by  Collins  and 
Franzblau  (1997),  H37Ra  appeared  more  sensitive  than  H37Rv  and  they 
suggested that the use of H37Ra for primary screening in a TB drug discovery 
program might result in a few false leads but would present a situation where it 
was less likely to miss active compounds. Thus, M. tuberculosis H37Ra would 
appear to  be  a  suitable  surrogate for the  virulent  H37Rv  strain  in  a  primary 
screening assay, thereby decreasing biosafety concerns and the required level 
of containment.  
In summary, Visual MABA when used with M. tuberculosis H37Ra provides a 
primary anti-TB screen which can be conducted inexpensively in the most basic 
biosafety Level 2 laboratory. However, M. aurum was used in the initial screen 
for  this  study  because  it  was  readily  available  from  the  Health  Protection Page | 59  
 
Agency, U.K and MTT (redox dye) was found to be a cheaper and equally good 
alternative. 
 
4.2   Aims and Objectives 
The aims of the work described in this chapter were to use M. aurum as an 
initial screen to demonstrate the anti-tubercular properties of the various plant 
extracts,  to  identify  active  fractions  and  determine  MIC  values.  It  was  also 
meant to be used as a tool to monitor biological activity during the isolation and 
purification process of any active fractions. 
 
4.3    Experimental 
4.3.1 Materials  
M.  aurum  NCTC  10438  was  purchased  from  Health  protection  Agency,  UK. 
Other materials  used were glucose powder (Sigma and BDH), glycerol (BDH), 
filter  paper  (Whatman  No  1),  nutrient  agar  and  broth  powder  (Lab  M  Ltd),  
dimethyl sulfoxide (Sigma Aldrich), flat bottom 96 well microplate (Iwaki, Japan),  
MTT-[3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide]  powder 
(Sigma) and   streptomycin powder (Sigma).  
 
4.3.2 Equipment (The equipment used was same as that described in section 
3.3.1) 
4.3.3   Preparation of reagents and media 
 
4.3.3.1   McFarland standard (The preparation is described in section 3.3.4.1) 
4.3.3.2   Glucose agar 
1L of deionised distilled water was added to a conical flask containing 28 g of 
dehydrated agar powder (25 g for broth) and 10 g of glucose powder.  This was 
allowed to soak for about 10 minutes, swirled to mix and dispensed into sterile 
bottles in 9 ml portions. These were then sterilised at 121˚C for 15 minutes.  For 
agar, the sterilised liquid was allowed to cool to 50˚C, mixed and poured into 
petri dishes and after solidification, stored at 2-8˚C until use. The plates were 
used for sub-culturing and disc assays while glucose broth was used for the 
micro dilution assays. 
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4.3.3.3 Stock storage medium for bacterial culture 
M.  aurum  was  grown  in  glucose  broth  for  72  hours.  This  was  spun  and  a 
mixture of double strength nutrient broth and glycerol (50% v/v) added to the 
micro-tube. This was frozen and stored at - 20 ˚C for subsequent use. 
 
4.3.4 Isolation and cultivation of M. aurum 
M.  aurum  NCTC  10438  was  inoculated  into  glucose  broth  and  incubated  at 
37˚C for 72 hours. Working suspensions were prepared from dilutions of 72- 
hour cultures made by comparison to 0.5 McFarland turbidity standard. 
 
4.3.5   Determination of MIC by micro broth dilution assay 
A concentration range of 31.25 -1000 µg/mL of the plant extracts were prepared 
directly on the multi-well plate for MIC determination. This was incubated with a 
bacterial suspension of M. aurum prepared from a fresh colony maintained on 
glucose agar and adjusted to a turbidity equivalent to that of a 0.5 McFarland 
tube. A dilution of 1 in 100 was made in broth and 100 µL transferred to wells 
containing 100 µL of extracts which had 2 x the final concentration.   
 
                         
 
Fig. 4.1 Conversion of MTT to formazan by succinic dehydrogenase enzyme 
(www.roche-applied-science.com/prod_inf/manuals) Page | 61  
 
 
Fig.4.2  A 96 multi-well plate for conducting redox colorimetric assay (Martin et 
al., 2006). 
 
After 3 - 5 days of incubation, 20µL of MTT [3(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium  bromide]  was  added  to  each  well  and  the  plate  re- 
incubated for a few hours followed by visual reading (Figure 4.2). The method is 
based on the reduction of a coloured indicator MTT which changes from yellow 
to  purple. The  colour  change  indicates  the  growth  of  bacteria  and  MIC  was 
defined as the lowest concentration of the extract that prevented the change in 
colour. 
 
 
4.3.6    Determination of drug susceptibility by disc diffusion assay  
The disc method was used when the extract concentrations required were high 
and  MICs  difficult  to  visualise  with  the  broth  dilution  method  due  to  their 
coloured nature. Filter paper discs (6 mm) impregnated with plant extracts (100 
– 3.125 mg/mL) were prepared by placing 10 µL volumes of dilutions to give a 
final concentration range of 1000 - 31. 25 µg/mL). The discs were dried on a hot 
plate at a mild temperature of 40 ˚C.  
Agar plates were inoculated with adjusted bacterial suspensions using cotton-
wool  swab  within  15  minutes  of  preparation.  Sterile  cotton-wool  swab  was 
dipped  into  the  suspension  and  excess  liquid  removed  by  turning  the  swab Page | 62  
 
against the side of the tube. The swab was then used to spread the inoculum 
evenly  across  three  directions.  The  plates  were  allowed  to  dry  at  room 
temperature before applying the discs containing plant extract dilutions firmly to 
the  dry  surface.  Thereafter,  plates  were  inverted  and  incubated  within  15 
minutes of disc application. The negative control plate was observed for semi-
confluent growth and measurements of the zones of inhibition to the nearest 
millimetre taken with a ruler. 
 
 
4.3.7 Determination of active fractions by agar overlay bio-autography 
TLC was performed on fractions obtained from preparative HPLC in order to 
localise activity and to aid isolation of the active constituents (Section 7.5).  The 
plates were dried to ensure complete removal of solvents. Molten glucose agar 
which  had  been  maintained  at  45  –  50  °C  was  seeded  with  M.  aurum 
suspension (1 in 100 dilution of 0.5 McFarland turbidity standard) and poured 
over the TLC plate aseptically. This was allowed to solidify and the plate was 
then incubated overnight at 37° C for 72 hours.  Bio-autograms were sprayed 
with 2.5 mg/mL of MTT solution and incubated for 4 hours at 37 °C. Zones of 
inhibition were seen as clear yellow areas while areas with microbial growth 
were seen as purple areas (Figure 4.5). 
 
 
4.4     Results and Discussion 
The results of the initial susceptibility testing of the crude extracts are presented 
in Table 4.1. The plant extracts were tested against M. aurum prior to testing of 
bioactive fractions against M. Tuberculosis.  As already discussed, M. aurum 
was used as a test model system for the anti-TB screening because it is a non-
pathogenic, saprophytic rapidly growing mycobacterium which has been shown 
to have similar drug susceptibility and genetic composition as M. tuberculosis 
although M. smegmatis and a number of other saprophytic organisms are also 
used as test models in the initial screening process (Chung et al., 1995; Newton 
et al., 2002). The colorimetric in vitro micro dilution assay method by Palomino Page | 63  
 
et al. (2002) was used to determine crude drug susceptibility (Figures 4.1 and 
4.2).  
The preliminary microplate assay results showed  inhibitory activity against M. 
aurum at MIC of 125 µg/mL for the hexane and dichloromethane extracts of X. 
americana  while the methanol extract of  X. americana had an MIC  value of 
1000 µg/mL against M. aurum.  Hexane and dichloromethane extracts of  P. 
crassipes leaf exhibited no inhibitory activity at the concentration range used 
(125 -1000 µg/mL) while the methanol extract had inhibitory activity with an MIC 
value of 1000 µg/mL.  The reference standard streptomycin (positive control) 
was initially used at a concentration of 10 µg/mL but was subsequently shown 
to have an MIC value of 4 µg/mL while ampicillin (100 µg/mL) was used as 
negative control. 
Growth control (culture medium and M. aurum with no extract), blank (culture 
medium only) and solvent control (DMSO and culture medium) were also added 
to validate the results (Newton et al., 2002). The assays were carried out in 
triplicate to obtain MIC values. Streptomycin and ampicillin were also used as 
positive and negative controls in addition to a blank (culture medium only) and a 
growth control (control medium and bacteria without the presence of drug) to 
validate the results (Martin et al., 2006; Newton et al., 2000). Due to solubility 
problems encountered with dissolving the active non-polar fractions in DMSO 
by the micro dilution method, disc assay procedures were subsequently used to 
screen the HPLC fractions to localise the activity.  
Ximenia  extract  in  particular  is  highly  coloured  at  high  concentration  ranges 
making it difficult to visualise the colour change from yellow to purple with MTT. 
Solutions of the extracts were made up to a concentration of 1000 µg/mL from 
which 100 µg was spotted on discs and subjected to drug susceptibility testing 
by  disc  assay  method.  Hexane  and  dichloromethane  extracts  of  Ximenia 
exhibited inhibitory activity against M. aurum comparable to streptomycin (10 
µg) at  10  times  its  concentration  (Figure  4.3).  The  tests  were  carried  out in 
triplicate and solvent control discs were subjected to the same treatment as the 
extracts. 
Due to the difficulties experienced with structure determination of LC fractions 
by  NMR  and  mass  spectrometry,  further  testing  of  fractions  obtained  from Page | 64  
 
preparative  HPLC  extracts  of  crude  XAH  and  XAD  to  localise  activity  was 
demonstrated  by  disc  diffusion  assay  and  bio-autography  (Figures  4.4,  4.5). 
From  bioautograms,  activity  was  shown  to  reside  in  the  spot  (Rf  -  0.35)  in 
fractions,  XD3  and  XD4  obtained  from  TLC  separation  as  well  as  HPLC 
fractions.  Efforts  to  characterise  LC  fractions  were  not  successful  so  the 
fractions were subjected to TLC to further purify the extracts and to localise the 
activity. Separation details are described in chapter 7.   
 
 
 
Table 4.1. M. aurum  testing at test concentrations of 1000  – 125 µg/mL by 
micro plate agar dilution method 
  
   CODE     EXTRACT SOURCE   MIC (µg/mL) 
 
XAH 
 
X. americana hexane 
 
125 
XAD  X.  americana dichloromethane  125 
XAM  X. americana methanol  1000 
XAW  X. americana water  > 1000 
PCH  P. crassipes hexane  > 1000 
PCD  P. crassipes dichloromethane  > 1000 
PCM  P. crassipes methanol  250 
PCW  P. crassipes water  > 1000 
STM  Streptomycin  10 
AMP  Ampicillin  100 
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i)      
ii)    
 
 
Fig. 4.3 i) Plates showing M. aurum control plate (growth) and discs  containing 
10 µg streptomycin (clear zone) and control discs (solvent).  ii) Plates showing 
growth inhibition zones of 10 µg STM (top right), 100 µg XAD (top left), 100 µg 
XAH (bottom left) and solvent control disc (bottom right). 
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i)         
 
 
 
 
 ii)   
 
 
Fig.4.4 i) TLC plate (5 x 7 cm) spotted with crude XAD (most active fraction 
against  MTB)  and  streptomycin  (positive  control)  visualised  with  iodine  after 
development with methanol: dichloromethane (2:98 v/v) solvent system. 
 ii)  Duplicate  TLC  bio-autogram  visualised  with  MTT  solution,  yellow  regions 
show areas of inhibition while purple regions show areas with bacterial growth. 
The active spot had Rf value of 0.5. 
xad 
stm 
 
 
 
stm 
 
xad 
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iii)   
 
iv)   
 
Fig.4.4 iii) TLC plate (20 x 20 cm) spotted with XAD (crude DCM extract), XD1, 
XD2, XD3, XD4 from TLC fractions, XAH (crude hexane extract), XH4, XH5 
from  LC  analysis  and  STM.  Developed  with  hexane:  chloroform:  methanol 
(4:4:1, v/v/v) and visualised with 2-DNP.  iv) Yellow areas show  inhibition zones 
of  active fractions  and  reference  drug  streptomycin  while  purple  areas  show 
regions of bacterial growth on spraying with MTT.      
xad
d  xd3  xd4  xah  xh4 and  
xh5 
STM 
xad    xd1    xd2   xd3   xd4    xah    xh4   xh5   stm    Page | 68  
 
    i)    
ii)      
 
Fig.4.5 i) TLC bioautogram control plate. ii) TLC bioautogram spotted with LC 
fractions XD1 – 5 (section 7.4.5). Spots XD3 (36 µg) and XD4 (72µg) (Rf-0.35) 
show zones of inhibition. 
xd3   xd4 
xd1         xd2        xd3      xd4     xd5       xd 
Blank/ control plate Page | 69  
 
4.5     Conclusion 
 M. aurum was easy to grow and maintain on glucose agar and results could 
later be correlated with anti-TB testing. The results obtained using the micro 
dilution  method  exhibited  higher  MIC  values  compared  to  the  disc  assay 
method. However, it is possible that this might result in a few false leads as 
suggested  with  some  of  the  values  (Table  4.1). The  methanol fraction  of  P. 
crassipes initially showed some inhibitory activity at 1000 µg/mL with M. aurum 
but testing against M. tuberculosis at a concentration of 64 µg/mL exhibited no 
inhibitory activity (Table 6.1, Section 6.4). On the other hand, the hexane extract 
of  P.  crassipes  which  showed  no  inihibition  against  M.  aurum  in  the  initial 
screening had 86.7 % inhibition at 64 µg/mL on testing against M. tuberculosis. 
The advantage of subjecting the false positive extracts to further testing is that 
the  probability  of  missing  possible  active  fractions  or  compounds  would  be 
greatly  reduced  since  all  fractions  were  tested.  Bioautography  proved  to  be 
useful in localising active fractions from the crude extract.The active fractions 
from TLC separations looked promising and would be followed up with further 
TB testing against M. tuberculosis. 
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Chapter 5   Synergy and Efflux Studies on Methanol Extracts of  X. 
americana Root and P. crassipes Leaf 
 
 
5.1     Background 
Following  general  antimicrobial  screening  with  representative  bacteria  and 
fungi,  it  was  thought  necessary  to  conduct  synergistic  interaction  and  efflux 
studies  since  the  antibacterial  activity  showed  mild  to  moderate  spectrum 
activity which was not potent enough to warrant further exploration of individual 
extracts as stand-alone anti-bacterial agents. Drug interaction and efflux studies 
were  performed  in  order  to  explore  efflux  pump  inhibitory  properties  of  the 
methanol extracts and to possibly identify mechanisms of action. The methanol 
fractions were considered for the study because extraction  yield was high for 
both  plant  materials  and  also  because  literature  review  of  isolated  and 
characterised constituents revealed the presence of phenolic compounds such 
as flavonoids which have been reported by other investigators to exhibit efflux 
inhibitory activities (Lechner et al., 2008; Gibbons et al., 2003).  
The activity of over expressed efflux pumps in bacteria has been reported to be 
a major mechanism by which multi drug resistant bacteria exercise their ability 
to evade killing by antibiotics (Viveiros et al., 2008). Bacterial efflux pumps are 
reported to protect the organisms from antibacterial compounds or xenobiotics. 
They also serve as transport tools in uptake of essential nutrients as well as 
maintaining cell activities (Paulsen et al., 2006).  
The reasoning was that, if constituents were found to have synergistic or efflux 
inhibitory action against drug resistant bacteria, it could possibly point to the 
relative contribution of the fractions having no antibacterial properties and the 
possible reason for the inclusion in the herbal remedy. 
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5.1.1   Introduction 
5.1.2  Synergy studies 
Synergy  studies  have  been  conducted  in  order  to  explain  activities  seen  in 
herbal  products.  The  concept  of  synergism  in  phytomedicines  arose  out  of 
difficulties experienced in isolating bioactive compounds from herbal products or 
in adducing clinical effects to single constituents in phytomedicines (Williamson, 
2001). 
The therapeutic efficacy of single or multicomponent herbs is thought to reside 
in synergistic interactions between the bioactive constituents. Often, long-lasting 
drug  administration  is  required  to  achieve  the  desired  clinical  effect  with 
reduction in severity of symptoms (Heinrich et al., 2004). This mode of drug 
administration can be likened to treatment of conditions such as depression, 
cancer, HIV in orthodox medicine where clinical effects become evident after a 
number of weeks (Williamson, 2001). 
Another identical characteristic of phytomedicines and orthodox medicine is the 
need for drug combinations in treating chronic conditions. According to Heinrich 
et al (2004), many phytomedicines are yet to have their mechanisms of action 
elucidated. The article reports that there are examples of total herb extracts 
showing  better  effects  than  equivalent  doses  of  isolated  compounds. 
Justification for the biological effect observed has been attributed to synergy, 
enhanced bioavailability, cumulative effects or simply the additive properties of 
the constituents. 
Overall, synergy is considered to be positive with the low doses used being 
seen  as  an  advantage.  Some  ingredients  which  form  part  of  herbal  drug 
combinations have been investigated and reported to enhance bioavailability of 
other constituents. For instance, addition of black pepper, Piper longum which 
contains the alkaloid piperine to an anti-asthma recipe has been reported to 
increase  the  bioavailability  of  the  mixture  (Johri  et  al.,  1992)  and  also  the 
addition  of  clavulanic acid  to  amoxicillin  used  to  increase  susceptibility  to  β-
lactamase  producing  organisms    in  conventional  antimicrobial  chemotherapy 
(Flores et al., 2005).  
Bapela  et  al.  (2006)  investigated  the  activity  of  a  combination  of  7-
methyljuglone, a naphthoquinone and first-line drugs, isoniazid and rifampicin in Page | 72  
 
which  they  reported  a  four  to  six-fold  reduction  in  the  MICs  of  both  drugs 
suggestive of synergy.  
In some other cases, negative or unwanted effects have also been observed to 
interfere with absorption of active constituents leading to decreased therapeutic 
concentrations.  Ernst  et  al.  (1999) investigated  drug  interactions  between  St 
John’s  Wort,  Hypericum  perforatum  and  oral  contraceptives  with  negative 
effects.  
 
 
5.1.2.1 Philosophy of herbal therapy 
Practitioners  of  herbal  medicines  have  been  described  as  using  the  ‘herbal 
shotgun’ approach as opposed to the ‘silver bullet’ method of orthodox medicine 
because  no  particular  enzyme  or  cellular  system  is  targeted  during  therapy 
(Heinrich et al., 2004; Duke and Bodenschutz-Godwin, 1999). 
Some additions to recipes are essentially not for synergy but as a supportive 
measure for instance, certain components which promote bowel movement are 
added to recipes used in the treatment of piles. The special properties of phyto-
medicines are being investigated to attempt to justify the therapeutic effect of 
combinations of individual constituents (Williamson, 2001).  
   
5.1.3 Synergy testing 
Demonstration of synergy can be costly due to the requirement for constituents 
to be tested individually and then going on further to compare the effect given 
with the same dose in a mixture (Williamson, 2001).  
The expression “polyvalent action” has been used to describe better or greater 
effects  seen  with  a  combination  of  substances  than  expected  from  single 
component contribution (Berenbaum, 1989). On the other hand, antagonism is 
defined  as  an  opposite  effect  of  synergy  and  from  reports  it  is  more  easily 
demonstrated than the other effects.  
Synergy testing by checkerboard assay technique is also called the fractional 
inhibitory concentration testing (Fidai et al., 1997). The FIC method is referred 
to as the checkerboard because of the 8 x 8 pattern of wells used.  Page | 73  
 
The compounds tested in combination are used at concentrations above and 
below their MIC’s determined individually against the bacteria in question. The 
results of a checkerboard assay after overnight incubation demonstrates a non-
dynamic growth inhibition (Kamicker et al., 2008). The results obtained can be 
interpreted as synergy, indifference or antagonism depending on the FIC index 
calculated for the two drugs in combination. Synergy is defined as ∑FIC index ≤ 
0.25, indifference 0.5 to 4.0 and antagonism as > 4.0 (Viveros et al., 2010; Fidai 
et al., 1997).  
 
5.2       Aims and Objectives 
The  principal  aim  then  of  the  next  part  of  the  research  programme  was  to 
conduct synergy and interaction studies to aid prediction of possible mechanism 
of  action,  synergistic  or  additive  activities.  The  study  was  also  aimed  at 
identifying and evaluating the relative contribution of the bioactive constituents 
to the antimicrobial effects exhibited by the plant extracts. 
 
5.3     Experimentals  
 
5.3.1   Materials (Section 4.3.1) 
In addition to materials already described in Section 4.3.1, Mastring - S M13 
and M14 antibiotics were purchased from Mast Diagnostics, Merseyside, UK 
and standard antibiotics from Sigma Aldrich, U.K. 
 
 
5.3.2 Determination of minimum inhibitory concentration by broth dilution 
method 
The overnight  cultures of the bacterial micro-organisms were grown on agar 
plates or in broth. The inoculum was prepared by picking four or five colonies 
and  emulsifying  in  saline  to  give  a  density  equivalent  to  0.5  McFarland 
standard. The suspension was visually compared to the standard and adjusted 
to a density approximately equivalent to 1 x 10
8 colony forming units (CFU)/mL. 
To aid comparison, test suspension and standard were viewed against a white 
background  with  a  contrasting  black  line.  From  the  0.5  McFarland  standard Page | 74  
 
culture suspension, a 1 in 100 dilution was made up in broth medium to give a 
final  inoculum  of  ca.  5  x  10
5  CFU/mL.  The  suspension  was  used  for  the 
macrodilution and microdilution tests. 
 
Macrodilution: 
Antibiotic ranges of 0.5 - 256 µg/mL were prepared so that the addition of an 
equal volume of inoculum would give final dilution range of 0.25 – 128 µg/mL. 
Sterile capped tubes (75 x 12 mm) were arranged for each antibiotic and plant 
extract in duplicate (preparation and table of MIC values obtained are shown in 
Appendix A). Aliquots (1 mL) of the test organisms were added to 1 mL of the 
antimicrobial  agents  diluted  in  broth.  The  tubes  were  agitated  with  a  vortex 
mixer and incubated at 37˚C for 18-24 hours in air. MIC endpoint was read and 
interpreted as the lowest concentration of antibiotic which showed no visible 
growth (EUCAST, 2000; BSAC, 2006).  
 
Microdilution: 
A 96 well sterile microtitre plate was labelled with the appropriate plant extract 
dilution and 100 µL of each extract added to 100 µL of test organism.  
Inoculated and un-inoculated wells of plant extract-free broth served as growth 
control  and  sterility  check  to  validate  the  results  observed.  The  plate  was 
covered  with  the  lid  and  inoculated  at  37˚C  for  18  -  24  hours  in  air.  MIC 
endpoint was read and interpreted as described above. 
 
 
5.3.3  Determination  of  minimum  inhibitory  concentration  by  disc  assay 
method (details are already described in Section 4.3.6). 
 
5.3.4  Drug interaction assay using Mastring S antibiotic strips 
Mastring S-14 (antibiotic containing strips) were placed on agar plates without 
plant extracts (control plates) and duplicates incorporated with plant extracts to 
achieve a final concentration of 50, 100, 5000 and 10,000 µg/mL.  The assays 
were conducted as four different experiments. The plates were inoculated with 
S.  aureus, E.  coli  and  P.  aeruginosa  as  already  described  in  Section  4.3.6. 
Plates containing solvent used in sample solution and negative control plates Page | 75  
 
were  added  to  validate  the  results.  Inhibition  zones  were  measured  and 
percentage  differences  calculated  in  order  to  determine  which  antibiotics 
showed  some  interaction  in  the  preliminary  assessment  (Tables  5.4a  -  c, 
Figures 5.2 a - c). Tests were carried out in triplicate.  
 
 
5.3.5  Checkerboard  (FIC)  assay  of  X.  americana  methanol  extract  and 
streptomycin 
After  determining  streptomycin  and  plant  extract  MICs  by  agar  dilution  (0.5 
µg/mL and 3 mg/mL respectively), the checkerboard assay was then carried out 
in  duplicate  by  testing  solutions  of  X.  americana  methanol  extract  and 
streptomycin  in  combination.  The  concentration  range  of  streptomycin  and 
extract used in the experiment was 0.031 x MIC to 4 x MIC in an 8 x 8 format 
depicted in Table 5.7. Stock solutions of streptomycin (4 µg/mL) and the extract 
(24 mg/mL) were prepared in DMSO and further doubling dilutions done in broth 
before being transferred to the wells.  Positive and negative control plates to 
assess presence and absence of turbidity were also tested (Bonapace et al., 
2002). 50 µL of each drug dilution was added to 100 µL of organism suspension 
to make up a volume of 200 µL in each well.  Plates were then gently mixed and 
incubated at 37 °C for 18 - 24 hours.  
The micro- titre plate turbidity was read at 595 nm using the micro-plate reader 
but variable results were observed so plates were subjected to visualisation by 
MTT as it was found to give more consistent results. The tests were carried out 
in duplicate with negative and positive growth controls. 
 
 
5.3.6  Computation of drug interactions 
Fractional inhibitory concentration (FIC) is a term used to describe the extent of 
interaction or synergy between drugs tested. FIC is calculated as MIC of drug in 
combination  divided  by  the  MIC  determined  for  each  individual  drug  or 
compound. The sum of the FIC’s of XAM and STM was calculated to express 
the extent of interaction. Four methods were used to interpret the synergy data.  
The first method (Mean FIC) involved calculation of the FIC index using clear 
wells  found  in  each  row  and  column.  The  second  method  (full  row/column) Page | 76  
 
involved calculating FIC index for each drug using row and column with lowest 
concentration of drug and clear wells i.e. no growth. The third method (lowest 
FIC index) involved taking lowest FIC index of clear well along the clear and 
turbid border. The fourth method (two well) defines synergy as no growth in the 
two wells having 0.25 x MIC of the two drugs, STM and XAM (Bonapace et al., 
2002).  
FIC index was calculated using the formula, FIC index = A/(MIC A) + B/(MIC B), 
where  A  =  concentration  of  drug  A  in  the  micro-titre  well  that  is  the  lowest 
inhibitory concentration of A in its row (Fidai et al., 1997). (MIC A) is the MIC of 
drug  A  alone.  Synergy  was  regarded  as  ∑FIC  value  ≤  0.5,  additivity  or 
indifference  has  ∑FIC  value  0.5  to  4  and  antagonism  as  ∑FIC  index  value 
greater than 4. 
 
5.3.7 Statistical analysis 
Statiscal  analysis  of  the  results  obtained  from  drug  interaction  studies  were 
subjected  to  evaluation  by  SPSS  Inc.  version  18  (Chicago,  IL).    The  drug 
interaction studies between standard antibiotics and extracts, PCM and XAM 
were analysed by One - Way ANOVA (analysis of variance). Tukey was used 
for post-hoc testing in order to carry out multiple comparisons.  The alpha value 
of p < 0.05 was considered significant.  The precision of the measurements was 
determined by calculating the standard deviation, standard error of mean and 
the  coefficient  of  variation  (CV).    The  CV  represents  the  ratio  of  standard 
deviation to the mean and is useful for describing the variation in a test (Zady, 
1999). Standard error was calculated to obtain a measure of the precision of the 
sample  means  (Altman  and  Bland,  2005).  The  formula  CV  =  standard 
deviation/mean x 100 was used to calculate the coefficient of variation as a 
percentage while standard error (SE) was calculated by the formula: standard 
deviation / square root of n where n is the number of observations. 
 
5.4 Results and Discussion 
 
5.4.1 Preliminary synergy testing 
Several antibiotic compounds (Mastring S antibiotic strip) were tested against 
organisms, S. aureus and P. aeruginosa, E. coli by agar containing the plant Page | 77  
 
extracts. Extracts were incorporated to a final concentration of 50, 100, 5000 
and 10,000 µg/mL.  There were no changes in zones of inhibition with 50 and 
100  µg/mL  but  with  a  final  concentration  of  5000  µg/mL,  some  antibiotics 
exhibited synergistic interactions.  Interestingly, there was no growth with 10000 
µg/mL of extracts incorporated into agar which could possibly result from toxicity 
leading to cell death or potency of the active constituents  (Figure 5.6 i). The 
zones of inhibition measured for antibiotics alone and with extract (PCM and 
XAM)  incorporated  to  give  final  concentration  of  5000  µg/  mL  were  used  to 
calculate the percentage difference in inhibition zone diameter. A difference of ≥ 
3mm was considered as inhibitory interaction.  
XAM exhibited moderate activity with streptomycin against  S. aureus but the 
inhibitory effect was greater with colistin sulphate (CO) and sulphatriad (ST). 
Initial screening of CO and ST showed no inhibitory activity but the presence of 
XAM enhanced its activity by approximately 3,000 %. In comparison, PCM did 
not show appreciable activity against S. aureus (Table 5.2a, Figure 5.1a).  In 
clinical settings, sulphatriad (an anti-metabolite) which consists of a mixture of 
suphathiazole,  sulphadiazine  and  sulphamerazine  is  used  as  a  combination 
product  to  reduce  the  risk  of  crystalluria  associated  with  sulphonamide  use. 
However,  it  is  not  commonly  used  in  clinical  practice  due  to  the  associated 
kidney damage from accumulation of crystals in urine (Mitscher et al., 2008). 
The factor in favour of  its  continued  use  in  certain  conditions  is the  relative 
cheapness compared to newer antibiotics.  
Chemically,  colistin  sulphate  is  a  cyclic  polypeptide  antibiotic  from  Bacillus 
colistinus and consists of polymixins E1 and E2 which act as a detergent to 
disrupt bacterial cell membrane. It has been found useful for treating infections 
with P. aeruginosa but like the sulphonamides, it has been largely abandoned in 
the  clinical  setting  with  the  development  of  newer  penicillins  and 
cephalosporins.  Some  investigators  (Knox  et  al.,  2011; Wishart  et  al.,  2008; 
Wishart et al., 2006) reported the usefulness of colistin in treating multi-drug 
resistant pulmonary infection in cystic fibrosis patients. PCM had strong positive 
effect on antibiotics, ampicillin and cephalothin against  P. aeruginosa and E. 
coli (cephalothin only) and to a lesser extent on tetracycline (Tables 5.1b - c, 
Figures 5.1b – c). Ampicillin and cephalosporin Decrease in inhibition zones Page | 78  
 
were observed with streptomycin against E. coli and S. aureus in the presence 
of PCM unlike XAM which had a positive effect.  
 
5.4.2 Synergy test with combination of streptomycin and XAM against S. 
aureus 
Based on the research interest on anti-tubercular activities, further experiments 
on synergistic interactions were conducted with a combination of streptomycin, 
an anti-tubercular antibiotic and XAM against  S. aureus as a model of gram 
positive organism. Using four different methods as described in Section 5.3.7,  
the results of the checkerboard assay were interpreted as additive for methods 
1 and 2 and as synergy with methods 3 and 4 (Table 5.5). The FIC index gives 
the level of synergistic interaction which is shown in Table 5.5. The mechanism 
of the interaction may be through binding to the same sites or through other 
receptors. Initial tests with both compounds revealed inhibitory activity against 
S. aureus which was corroborated by the checkerboard analysis. 
 
5.4.3 Synergy testing of combination of gentamicin and methanol extracts 
(PCM and XAM) against E. coli SR 
Initial tests of the plant extracts (5 mg /mL) in combination with streptomycin (10 
µg on disc) showed antagonism with streptomycin but synergy with gentamicin 
against E. coli sensitive strain NCTC 11560 (Figure 5.2c). Both drugs belong to 
the aminoglycoside class of antibiotics and the objective was to see whether the 
presence of the extracts could enhance susceptibility of streptomycin resistant 
E. coli to streptomycin or gentamicin.  However, on determining the MIC of the 
same extracts with streptomycin resistant strain (UoS strain) by the disc assay 
method, no activity was exhibited as shown in Figure 5.8.  Further testing was 
carried out using gentamicin (10 µg disc) on agar incorporated with a serially 
diluted XAM and PCM extract since tests carried out earlier had shown synergy 
with the sensitive strain. There was a greater reduction in inhibition zone with 
increase  in  extract  concentration  when  compared  to  the  control  plate  (Table 
5.6).  The  extracts  showed  no  effect  on  the  activity  with  streptomycin  or 
gentamicin.  The  changes  observed  are  likely  due  to  active  efflux  by  the 
streptomycin resistant E. coli which was not overcome by the extracts. Page | 79  
 
5.4.4  Statistical analysis 
One - Way ANOVA procedure was used to test for significance between means 
of zone diameters of inhibition of control antibiotic gentamicin and test groups 
containing extracts, PCM and XAM against E. coli SR.  The analysis showed 
significant differences among the groups in Table 5.6 at p < 0.05.  Tests for 
significance  between  control  groups  containing  colistin  sulphate,  sulphatriad 
and  test  groups  containing  extracts,  PCM  and  XAM  against  S.  aureus  were 
determined  and  shown  to  be  significant  at  p  <  0.05  (details  are  shown  in 
Appendix A).  
 
Table 5.1.  Mastring S M-14 antibiotic discs content with code  
 
 
 
Legend for summary of in vitro interaction studies charts:  
OC – antibiotic alone with organism 
SC - antibiotic with organism (contains solvent used in dissolving extract)  
PCM - methanol extract of P. crassipes 
XAM - methanol extract of X. americana 
Increased zone diameter of inhibition - (change of ≥ 3mm) 
Decreased zone diameter of inhibition - (change of ≥ 3mm) 
Code  Antibiotic  Colour  Disc content (µg) 
AP  ampicillin  grey  10 
KF  cephalothin  primrose  5 
CO  colistin SO4  white  25 
GM  gentamicin  salmon  10 
S  streptomycin  white  10 
ST  sulphatriad  mauve  200 
T  tetracycline  brown  25 
TS  cotrimoxazole  white  25 Page | 80  
 
Table 5.2a.  Data of in vitro drug interaction studies using S. aureus. Extracts 
were  incorporated  into  agar  to  give  final  concentration  of  5  mg/mL.  Values 
recorded are average of three replicates (n = 3). *SE values were ≤ 0.57 
 
 
  AP  KF  CO  GM  S  ST  T  TS 
OC  27*  20.3*  0  17  11.7*  0  24  19.7* 
SC  26  20  0  16*  12  0  24  20.7* 
OC,SC,PCM  30  30  0  15.7*  0  0  32  20 
OC,SC,XAM  30  30  30  30  30  30  30  30 
 
Zone diameter of inhibition was measured in mm. SE – standard error 
MIC’s of PCM = 5 mg/mL , XAM = 0.031 mg/mL 
 
 
 
Fig.5.1a Chart showing percentage differences in zone diameter of inhibition 
between antibiotics alone and in combination with extracts, PCM and XAM. Page | 81  
 
Table  5.2b.  Data  of  in  vitro  drug  interaction  studies  using  P.  aeruginosa. 
Extracts  were  incorporated  into agar to  give final concentration of  5  mg/mL. 
Values recorded are average of three replicates (n = 3). *SE values were 0.0 
 
  AP  KF  CO  GM  S  ST  T  TS 
OC  0  0  15  16  12  17  10  12 
SC  0  0  15  16  12  17  10  12 
OC,SC,PCM  30  30  0  16  0  0  30  12 
OC,SC,XAM  0  0  8  12  14  0  0  0 
 
MIC’s of PCM = 5 mg/mL, XAM = > 2.5 mg/mL 
 
 
 
Fig.5.1b Chart showing percentage differences in zone diameter of inhibition 
between antibiotics alone and in combination with extracts, PCM and XAM. Page | 82  
 
Table 5.2c. Data of in vitro drug interaction studies using E. coli. Extracts were 
incorporated into agar to give final concentration of 5 mg/mL. Values recorded 
are average of three replicates (n = 3). *SE values were ≤ 0.66 
 
  AP  KF  CO  GM  S  ST  T  TS 
OC  0  0  15  11*  9  0  8  15 
SC  0  0  14.6*  12  9.7*  0  8  13.3* 
OC,SC,PCM  0  10  17.6*  13.5*  0  0  0  16 
OC,SC,XAM  0  0  11  19  0  0  8  18 
 
MIC’s of PCM = 5 mg/mL, XAM = > 2.5 mg/mL 
 
 
 
Fig.5.1c Chart showing percentage differences in zone diameter of inhibition 
between  antibiotics  alone  and  in  combination  with  extracts,  PCM  and  XAMPage | 83  
 
 
Table 5.3a.  Summary of in vitro interaction studies of antibacterials with P. crassipes methanol extract (5 mg/mL final conc.) 
 
 
 
 
Organism  Increased zone of 
inhibition 
Inhibition 
cancelled 
Inactive  antibiotic 
active  with extract 
Indifference  Decreased  zone 
of inhibition 
S. aureus  ampicillin,  
cephalothin 
tetracycline 
streptomycin    colistin SO4, sulphatriad 
cotrimoxazole 
 
P. 
aeruginosa 
tetracycline  colistinSO4,  
streptomycin 
sulphatriad 
ampicillin, cephalothin 
 
 
gentamicin 
 cotrimoxazole 
 
E. coli    streptomycin 
tetracycline 
cephalothin  ampicillin, colistin SO4, gentamicin, 
sulphatriad, cotrimoxazole 
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Table 5.3b. Summary of in vitro interaction studies of antibacterials with X. americana methanol extract (5 mg/mL final conc.) 
 
Organism  Increased inhibition zone  Inhibition 
cancelled 
Inactive  antibiotic 
active with extract 
Indifference  decreased 
inhibition zone 
S. aureus  ampicillin,    cephalothin 
gentamicin, tetracycline 
cotrimoxazole, streptomycin 
  colistin SO4, 
sulphatriad 
   
P. 
aeruginosa 
  sulphatriad 
tetracycline 
cotrimoxazole 
  ampicillin, cephalothin 
streptomycin 
colistin SO4, 
gentamicin 
E.coli  gentamicin, cotrimoxazole  streptomycin    ampicillin,  cephalothin, 
sulphatriad, tetracycline 
colistin SO4 Page | 85  
 
i)   
ii)  
iii)  
 
Fig.5.2 i) Plates showing X. americana  disc assay with S. aureus control and  
with  extracts on paper discs (100 - 12.5  µg/mL) showing zones of inhibition at 
100 and 50 µg/mL.  
 ii) E. coli control plate and plate with extracts on discs showing no activity at 
100 - 12.5 µg/mL. iii)  P. aeruginosa control plate and with extracts showing no 
activity at 100 - 12.5 µg/mL. 
100 µg/mL  
50 µg/mL  
 
S. aureus 
E. coli 
P. aeruginosa 
S. aureus with extracts on 
discs Page | 86  
 
 
 
 
 
 
 
 
Fig. 5.3 Plates showing P. crassipes disc assay with S. aureus, E. coli and P. 
aeruginosa.  No inhibitory activities were observed at 100 - 12.5 µg/mL for the 
extracts. 
 
 
 
S. aureus  
E. coli 
P.  aeruginosa 
With PCM extracts on discs Page | 87  
 
i)    ii)    
 
 
Fig.5.4. i and ii).  MIC determination of P. crassipes and X. americana methanol 
extracts by disc assay against S. aureus using higher concentration range (1 - 
6, = 1000 – 31.25 µg/mL).  P. crassipes showed no inhibition zone at higher 
concentrations while X. americana (right) exhibited inhibition at all concentration 
ranges. 
 
i)  
 
Fig.5.5  Plates show examples of E. coli inoculated plates containing no plant 
extracts, with extracts (50 µg /mL) and Mastring antibiotic strips. The preliminary 
tests showed no differences in inhibition zones when measured. 
PCM against S. aureus  XAM against S. aureus 
 
 
Control plate   
 
Solvent control plate 
 
 With XAM incorporated 
 With PCM incorporated Page | 88  
 
i)      
 
       ii)   
 
       iii)    
 
Fig.5.6 i) Plates show examples of E. coli inoculated control plates containing 
no plant extracts (control) and with 10 mg/mL XAM.  ii) with 10 mg/mL PCM 
incorporated  into  agar  iii)  a  combination  of  PCM  and  XAM  in  a  1:1  ratio  (5 
mg/mL).
Control plate  With 10 mg/mL XAM 
extract- no growth 
Control plate  With 10 mg/mL PCM 
extract – no growth 
 
Control plate  With PCM and XAM 5 mg/mL 
1:1 ratio - growth 
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i)     ii)    
     iii)      iv)                                                       
 
 
Fig.5.7 Streptomycin vs. X. americana methanol extract  micro dilution synergy 
assay (8 x 8) with S. aureus.  Plates visualised with MTT solution. Purple wells 
show bacterial growth while clear wells show inhibition. 
 i) wells with streptomycin alone. ii) wells with X. americana extract alone.   
iii and iv)  combination of streptomycin and X. americana extract in duplicate 
plates. 
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Table 5.4. Schematic drawing to show methods used to calculate FIC index for 
each well. Micro-dilution synergy assay (8 x 8) involving Streptomycin (µg/mL) 
vs. XAM (mg/mL)   - S. aureus. 
 
  x MIC 
STM 
1  2  3  4  5  6  7  8  Conc. 
in well 
A  4.00        2          2 
B  2.00        2          1 
C  1.00  1, 2  1, 2  1,  2  2  2  2  2  2  0.5 
D  0.50        1, 2          0.25 
E  0.25        1,2,4          0.13 
F  0.13        1, 2          0.06 
G  0.06        1, 2          0.03 
H  0.03        1,2,3           0.015 
  x MIC 
XAM 
0.03  0.06  0.13  0.25  0.50  1.00  2.00  4.00   
  Conc. 
in well 
0.09  0.19  0.38  0.75  1.5  3.0  6.0  12.0   
 
Gray wells represent wells with turbidity (growth). 
Numbers in wells 1- 8, A - H represent methods used to calculate FIC index  
 
 
Table  5.5.  Checkerboard  results  showing  differences  among  methods  of 
interpretation (average values calculated for plates in duplicate). 
 
method  FIC index  interpretation 
1   0.68  additivity 
2  1.25  additivity 
3  0.28  synergy 
4  NA - Two wells clear  synergy 
NA- Not applicable 
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Table 5.6. Table of values showing inhibition zone diameters (mm) for P. crassipes and X. americana against E. coli streptomycin 
resistant strain at a final concentration range of 5 – 0.625 mg/mL. Each sample was combined with gentamicin 10 µg. The values 
displayed are for six replicates. Individual MICs of PCM and XAM were ˃ 2 mg/mL against E. coli SR.  
 
  CONTROL  SOLVENT 
CONTROL 
PCM  
5.0 
PCM  
2.5 
PCM  
1.25 
PCM  
0.63 
XAM  
2.5 
XAM  
1.25 
XAM 
 0.63 
  28  28  24  24  27  27  15  20  20 
  28  28  24  24  26  27  17  19  20 
  28  28  24  25  26  27  17  19  20 
  28  28  23  24  25  27  15  19  20 
  28  28  23  24  26  27  15  17  20 
  28  29  23  24  26  27  15  17  20 
Mean  28.0  28.2  23.5  24.2  26.0  27.0  15.7  18.5  20.0 
SD  0.0  0.4  0.5  0.4  0.6  0.0  0.9  1.1  0.0 
SE  0.0  0.2  0.2  0.2  0.2  0.0  0.4  0.5  0.0 
%CV  0.0  1.4  2.1  1.7  2.3  0.0  5.7  5.9  0.0 
% 
change 
0.0  0.6  -16.6  2.8  7.6  3.8  - 42.0  18.1  8.1 
         
 SD - Standard deviation, SE - standard error, % change – percentage decrease or increase between control and test samples Page | 92  
 
i)   
ii)     
 
Fig.5.8 i) Plate shows XAM and PCM MIC determination at high concentrations 
(1  -  XAM  2  mg/disc,  2  -  XAM  1  mg/disc,  3  –  PCM  2  mg/disc,  4  –  PCM  1 
mg/disc,  SC – solvent/disc) against E. coli SR (UoS strain). Tetracycline (30 µg 
disc) was used as positive control. ii) MIC was determined for PCM and XAM 
using extract concentration range of 1000 -125 µg (1- 3) on discs).  
Based on the results obtained, X. americana methanol extract (XAM) exhibited 
strong synergy with colistin sulphate and sulphatriad against S. aureus (Tables 
5.2 – 5.3 and Figures. 5.1- 5.6) while P. crassipes methanol extract (PCM) had 
strong synergistic effects with ampicillin and cephalothin against gram negative 
organisms, P. aeruginosa and E. coli. Negative effects were observed with both 
plant extracts against E. coli SR. Analysis by One-Way ANOVA for the groups 
show  significance  at  p  <  0.05.  The  synergy  results  suggest  that  some 
constituents in the non -TB active fraction may have additive effects on active 
TCN 30 µg 
disc  1 
2 
3 
4 
SC 
1  2 
 
3  SC 
1  2 
3  STM Page | 93  
 
fractions.  This  part  of  the  work  was  then  followed  up  with  efflux  inihibitory 
studies to evaluate potential efflux properties. 
 
 
5.5 Evaluation of efflux pumps inhibitory property by Rotor - Gene 3000 
Microorganisms have been reported to have the ability to protect themselves 
from  xenobiotic  by  efflux  pumps.  They  also  serve  as  mechanisms  for 
maintaining  normal  physiological  functions  and  uptake  of  essential  nutrients 
(Fernandes  et  al.,  2003;  Lynch,  2006;  Paulsen  et  al.,  1996).  A  major 
mechanism  of  resistance  observed  in both  microbes  and  cancer  cells  is the 
membrane protein-catalysed extrusion of drugs from the cell.  
Resistant cells utilise proton-driven anti-porters and/or ATP- driven ABC (ATP- 
binding cassette) transporters to extrude cytotoxic drugs that usually enter the 
cell by passive diffusion.  Although some of these drug efflux pumps transport 
specific substrates, many are transporters of multiple substrates. These pumps 
are  often  termed  H
+  anti  porters  and  can  be  categorised  into  a  number  of 
families such as major facilitator superfamily (MFS), small multidrug resistance 
family  (SMR),  resistance  nodulation  cell  division  family  (RND),  and 
drug/metabolite efflux family (DME – The family is an addition which is reported 
to be poorly defined). The proteins in DME have been shown to possess some 
similarity to the SMR family (Borges-Walmsley et al., 2003).  
The predominance of these H
+ anti porters in bacteria is shown clearly by E. 
coli, which is predicted to have 19, 7 and 3 drug transporters belonging to the 
MF, RND and SMR families respectively but only 7 belonging to the ABC (ATP-
binding cassette) transporter family.  All of these well known drug transporters 
have been investigated and shown to be expressed in a strain of E. coli that is 
hypersensitive to drugs, to test whether they could confer drug resistance. It 
was found that 21 of the proton anti porters, including 11 MF, 6 RND, and 2 
SMR  transporters,  conferred  drug  resistance,  but  only  one  ABC  transporter 
conferred drug resistance (Nishino and Yamaguchi, 2001). The tripartite AcrAB-
TolC  system  which  consists  of  three  sections;  inner  membrane  transporter 
(AcrB), a protein (AcrA) in the middle and outer membrane channel (TolC) has 
been well characterised in E. coli as an intrinsic MDR efflux pump system. The 
presence of a number of resistance pumps provides E. coli with the ability to Page | 94  
 
pump  out  a  wide  variety  of  substrates  (Viveiros  et  al.,  2008;  Amaral  et  al., 
2007). 
One of the major antibiotic resistance mechanisms utilised by more than 15 
species of gram - negative bacterial cells is RND efflux pump which eliminates 
several  classes  of  antibiotics  such  as  penicillins  and  cephalosporins, 
macrolides, aminoglycosides, fluoroquinolones, and tetracyclines (Kamicker et 
al., 2008). Compounds which inhibit efflux pumps are identified by measuring 
the  accumulation  of  ethidium  bromide  (EtBr)  in  bacterial  cells.  Ethidium 
bromide, an aromatic compound with a phenanthridine core acts as a substrate 
for efflux pump (Figure 5.9). It has a structure resembling DNA base pair and 
this similarity enables it to insert itself into a DNA strand.  
 
 
 
 
Fig.5.9 Chemical structure of ethidium bromide. 
 
The fluorescent nature of the complex formed with nucleic acids makes it useful 
as a nucleic acid fluorescent tag in various techniques. Ethidium bromide can 
be  detected  using  excitation  wavelength  of  300  nm  and  520  nm  with  an 
emission  peak  of  600  nm.  EtBr’s  intense  fluorescence  results  from  the 
hydrophobic environment found between base pairs as a result of binding. The 
movement  into  this  environment  and  away  from  water  molecules  allows  the 
EtBr cation to shed any water associated molecules and to fluoresce (Berthold 
product insert, www.berthold-jp.com).  
In  synergism  studies,  antagonism  or  indifference  can  be  established  in  a 
bacterial  organism  by  using  a  combination  of  an  antibiotic  and  a  generally 
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efflux systems because it has the advantage of containing single efflux pump 
unlike  P.  aeruginosa  and  E.  coli  which  have  multiple  pumps.  The  ability  to 
circumvent the resistance to antibiotics through treatment in conjunction with 
efflux  inhibitors  has  implications  for  setting  new  drug  therapies  for  bacterial 
infections (Kamicker et al., 2008).  EtBr is believed to be efficiently effluxed by 
the pumps and can only accumulate in the presence of an efflux pump inhibitor 
(EPI).   
Potential  EPI’s  are  tested  for  antimicrobial  susceptibility  in  order  to  rule  out 
intrinsic activity and synergy due to combined antibacterial activity (Kamicker et 
al., 2008).  Furthermore, compounds with no intrinsic antimicrobial activities are 
then tested for synergy with a range of antibiotics against organisms with efflux 
pumps using a single concentration of inhibitor. According to Kamicker et al. 
(2008), any compound showing reduced MIC values or synergy of eight-fold in 
combination  with  a  single  EPI  concentration  can  then  be  subjected  to  more 
rigorous investigation by fractional inhibitory concentration (FIC) method.  
As part of the on going assay, the FIC assay is followed by the protonophore 
assay which involves using radiolabelled lactose which accumulates in the cell 
via the proton motive force. Any compound which allows this accumulation is 
believed  to act  through  disruption  of  the  proton motive  force  (PMF)  and  not 
through efflux pump mechanisms. This test is also used to exclude compounds 
thought to be potential EPIs.  As a final step in the in vitro investigation of active 
EPI,  kinetic  kill  studies  over  24  hours  are  finally  carried  out  to  show  the 
antibacterial effects in the presence of antibiotic alone and in combination with 
the EPI.  
 
 
5.6 Aims and Objectives 
Since PCM and XAM extracts were shown to have no intrinsic activity against 
E. coli SR the efflux experiment was aimed at determining the potential efflux 
properties of the extracts using E. coli as a bacterial model.  The accumulation 
and  efflux  of  EtBr  as  an  efflux  pump  substrate  was  monitored  by  real-time 
fluorimetry using the semi-automated Rotor-Gene 3000 PCR analyser. 
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5.7 Experimental 
5.7.1  Materials 
E. coli SR broth (grown to mid – log phase, O.D of 0.6), microtubes (200 µL), 
0.22 µm syringe, filters, cuvettes, pipettes, sterile tubes, PBS, ISB, 0.8 % v/v 
glucose  in  PBS,  distilled  water,  ethidium  bromide  stock  solution  (1  mg/mL), 
Chlorpromazine  (CPZ)  in  distilled  water  filtered  with  0.22  µm  syringe  filters, 
streptomycin, MTT (5 mg/mL in PBS filtered with 0.22 µm filter). All chemicals 
were obtained from Sigma – Aldrich except otherwise stated. 
 
5.7.2  Equipment 
The Rotor - Gene 3000 PCR analyser (Corbett Research Sydney, Australia) 
incorporating  the  following  diodes  and  filters  [excitation  source:    LED  high 
power diodes, 470 nm, 530 nm, 585 nm and 625 nm; detection Filters: 510 nm 
(FAM), 555 nm (JOE), 610 nm (ROX) and 660 nm (Cy5)] was used to monitor 
the fluorescence on a real-time basis. Spinning and absorbance readings were 
performed using micro - centrifuge (Centaur) and spectrophotometer. 
      
5.7.3 Determination of MIC by E test
® and macro-dilution 
Plastic strips containing pre-defined gradient of antibiotic concentrations were 
placed on agar plates inoculated with bacterial organisms to determine their 
MICs.  Inoculum  preparation,  inoculation  and  incubation  were  carried  out  as 
described under disc diffusion assay. The MIC determination was carried out for 
ampicillin, gatifloxacin and rifampicin antibiotic strips.  
Ampicillin  was  tested  against  S.  aureus,  E.  coli  and  P.  aeruginosa  while 
gatifloxacin  and  rifampicin  were  tested  against  M.  aurum  in  duplicate.  MIC 
values were determined for compounds, EtBr, STM and CPZ against  E. coli 
(streptomycin resistant) by the macro-dilution method to determine the intrinsic 
activity before conducting the efflux experiments as described in Section 5.8.7. 
 
5.7.4  One concentration synergy testing 
It  is  expected  that  potential  efflux  pump  inhibitors  would  have  no  intrinsic 
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streptomycin  was  tested  against  E.  coli  (SR)  in  the  presence  of  a  single 
concentration of CPZ (standard reference EPI), XAM and PCM.  A compound 
which has efflux pump inhibitory properties would allow an antibiotic to have a 
lower MIC value in its presence. An eight – fold decrease or larger in the MIC 
values would lead to further testing by checkerboard method. 
 
5.7.5  EtBr concentration curve 
A serial dilution of EtBr was made up in PBS to obtain a concentration range of 
1-  6 µg/mL.  The  fluorescence  was  read  using  Rotor-Gene  3000  analyser  in 
order to determine the concentration of EtBr which gives maximal absorption 
(Viveiros et al., 2010; Rodrigues et al., 2008). 
 
5.7.6   EtBr accumulation assay      
E. coli (streptomycin resistant) was grown to mid- log phase (O.D600nm of 0.6) 
from an overnight culture by placing 1 mL of inoculum into 50 mL ISB in a flask 
on a shaker at 37° C. This was monitored by taking aliquots and measuring the 
absorbance. The   OD600nm of 0.6 was attained in about 4 – 4.5 hours.  10 mL of 
the broth culture was centrifuged at 4,000 rpm for 10 minutes.  
The supernatant was discarded and the pellets washed twice with the same 
volume of PBS. The cellular suspension was then adjusted to O.D600nm of 3.0. 
Glucose (0.8 % v/v) was added to give a final concentration of 0.4% v/v from 
which 95 µL of the suspension was added to 200 µL micro tubes. This was then 
made up to 100 µL volume by adding 5 µL of EtBr to obtain final concentration 
range of 1- 6 µg/mL. The instrument was programmed to obtain 30 cycles in 30 
minutes  according  to  the  instruction  manual.  The  excitation  and  emission 
wavelengths were selected by using Joe (source 530 and detector 555) channel 
with a gain of 5.  
Thereafter, the micro tubes were placed in the Rotor-Gene 3000 analyzer to 
monitor  the  fluorescence  at  37 
°C  for  30  minutes.  These  conditions  are 
designed to maximise the level of fluorescence as the EtBr equilibrates in the 
periplasmic space of the cells where its fluorescence is enhanced. 
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5.7.7 EtBr efflux assay 
After  carrying  out  the  accumulation  procedure,  2  µg/mL  EtBr  solution  was 
selected to be tested with a concentration of CPZ (8 µg/mL) to  give maximal 
absorption under conditions which promote maximal accumulation such as the 
lack of energy source (glucose), and a temperature of 25 °C. The cells were 
incubated  for  60  minutes  after  which  the  tubes  were  centrifuged  and  re-
suspended in EtBr - free PBS. The tubes were placed on ice to prevent efflux 
before monitoring fluorescence. Glucose was added to a final concentration of 
0.4 % and tubes with PBS containing glucose, without glucose and with CPZ 
were used as controls.  Graphs show real-time fluorescence of the tubes. 
 
5.8 Results and Discussion  
5.8.1 MIC determination against E. coli streptomycin resistant strain 
The MIC values were determined for ethidium bromide (8 µg/mL), STM (> 128 
µg/mL),  Chlorpromazine,  CPZ  (16  µg/mL)  to  ensure  that  the  concentrations 
used in further experiments would not affect the growth of the bacteria. Half the 
MIC of each compound was used for the procedure.  MIC determination of XAM 
and PCM exhibited values of > 1000 µg on disc (Figure 5.8).  
The test against M. aurum using gatifloxacin (MIC 0.008 µg/mL) and rifampicin 
(1.5  µg/mL) was conducted in the hope that the same extracts in combination 
would be tested to determine synergy and efflux by Rotor-Gene 3000 but this 
was not followed up due to  economic and time constraints.  
 
5.8.2 One concentration synergy testing 
The MIC of streptomycin (256 - 0.5 µg/mL) was determined in the presence of a 
single concentration of CPZ (24 µg/mL) and observed to have MIC of 32 µg/mL 
in combination.  Streptomycin by itself showed no inhibition at 256 µg/mL. XAM 
and PCM at an arbitrary single concentration of 64 µg/mL had no effect on the 
MIC of streptomycin against E. coli SR. 
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5.8.3   EtBr concentration  curve 
EtBr at different concentrations were assayed to determine the concentration 
which gives maximal absorption. According to Paixão et al (2009), a minimum 
concentration of 1 µg/mL EtBr can be used for accumulation assay where one is 
unable to carry out a concentration assay.  The graph shows a concentration-
dependent response in fluorescence (Figure 5.10). 
 
a) 
 
 
b) 
 
 
 
Fig. 5.10 Graph (a)  shows the different concentrations of ethidium bromide  
with different ratios of E. coli and glucose control.  Graph (b) shows controls, 
EtBr and EtBr with E. coli.  Results display traces of two replicates for EtBr 
tests (a) and three replicates for E. coli  tests and control (b). Page | 100  
 
5.8.4 Demonstration of accumulation of EtBr 
Accumulation  of  EtBr  was  demonstrated  by  comparing  E.  coli  cells 
suspended  in  PBS  and  glucose  alone  and  in  the  presence  of  CPZ  after 
incubation  at  25  °C  for  60  minutes  (Figure  5.11).    Fluorescence  was 
monitored  at  37  °C.    In  the  presence  of  glucose, fluorescence  decreased 
when compared to the sample in PBS as shown in Figures 5.10a and b. 
 
 
 
a)   
 
 
 
b)   
 
 
 
Fig.5.11  a)  Graph  showing  E.  coli  cells  loaded  with  EtBr  (1  µg/mL)  in  the 
presence of PBS and glucose with controls (30 min cycle). b)  Graph showing 
E. coli cells loaded with EtBr (1 µg/mL) in the presence of PBS and glucose with 
controls  (60  min  cycle).  Results  display  traces  for  five  replicates  for  test 
samples and two replicates for control. Page | 101  
 
5.8.5 Demonstration of efflux of EtBr mediated by E. coli efflux pumps 
The absence of glucose results in an increase in EtBr accumulation within the 
bacterial cells as shown in Fig. 5.11. A greater increase in fluorescence occurs 
with the addition of 8.0 µg/mL of CPZ after incubation at 25
°C indicating that 
efflux  is  inhibited  (Figure    5.12a)  however,  fluorescence  was  reduced  for 
samples at 37
°C in glucose though differences in fluorescence are not easily 
distinguished for cells in glucose with different concentrations of CPZ (Figure 
5.12 a and b). 
 
 
a) 
 
             
 
 
 
b)       
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Fig.5.12  a)  Graph  of  efflux  experiment  showing  the  influence  of  different 
concentrations  of  EPI  (CPZ)  on  fluorescence  and  b)  graph  showing  steep 
reduction  in  fluorescence  when  compared  to  cells  loaded  with  EtBr  alone. 
Results display two replicates of test samples and controls. 
 
5.8.6 Demonstration of accumulation and efflux in M. aurum   
Accumulation and efflux was demonstrated in M. aurum by Figure 5.12. The 
accumulation of EtBr was greater with the higher the concentration of EtBr but a 
concentration  of  3  µg/mL  EtBr  gave  reasonable  fluorescence  so  this  was 
subsequently used in the experiment. There was a reduction in fluorescence in 
the presence of CPZ (8 µg/mL) when cells were loaded in glucose compared to 
cells in PBS.  
 
 
 a)   
 
 
 
 
1 µg/mL EB   
 
6 µg/mL EB 
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b)   
 
 
Fig.5.13 a) Graph showing M. aurum cells loaded with EtBr (1- 6 µg/mL) in PBS 
and in glucose. b) M. aurum cells loaded with 3 µg/mL EtBr in PBS and glucose. 
Results display duplicate traces for test samples and controls. 
 
5.9 Conclusion 
E.  coli  and  M.  aurum  cells  loaded  with  efflux  pump  inhibitor,  CPZ  in  PBS 
exhibited greater inhibition of EtBr efflux indicated by the level of fluorescence 
compared to cells loaded with glucose (Figures 5.11; 5.12). The presence of 
glucose and temperature of 37 
°C provided an energy source for cells to extrude 
EtBr leading to a decrease in fluorescence. Real-time fluorescence analysis is 
shown by these results to be a valid and sensitive method to determine the 
potential of materials to show efflux inhibition of antimicrobial compounds. Trials 
with E. coli  were conducted to standardise the procedure and indicated that 
cells  accumulated  ethidium  bromide  to  an  equilibrium  level  within  30  to  40 
minutes  as  shown  in  Figures  5.  10a  and  b.  Cells  incubated  with  ethidium 
bromide  and  glucose  demonstrated  lower  fluorescence  than  cells  incubated 
with ethidium bromide in PBS buffer. The influence of glucose agrees with that 
found  by  other  workers  and  supports  the  view  that  glucose  as  a  source  of 
cellular  energy  aids  the  efflux  of  antimicrobial  agents  (Paixão  et  al.,  2009; 
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The effect of glucose is further shown when a standard efflux inhibitor, CPZ, is 
added to E. coli cells with ethidium bromide (Figure 5. 11). In the absence of 
glucose, levels of fluorescence rise rapidly while in the presence of glucose they 
remain at much lower levels suggesting that glucose is assisting efflux. The real 
time fluorescence analysis produces similar results when applied to M. aurum 
as shown in Figure 5.12.  Here, the incubation of cells with ethidium bromide 
produces increases in fluorescence as the dye is absorbed into the cells. In the 
presence of glucose, levels of fluorescence are reduced (Figure 5.12 a). The 
inclusion of CPZ increases the level of fluorescence considerably.  
The results from this study show that E. coli SR contains an efflux pump sytem 
which extrudes EtBr and is influenced by CPZ. This analysis could thus be used 
as a rapid test to determine whether extracts have efflux inhibition and could be 
applied to M. aurum for the extracts considered in this report.  
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Chapter 6     Drug Susceptibility Testing of Plant Extracts against M. 
tuberculosis 
 
 
6.1. Background 
The main aim of the study is to evaluate the anti-tubercular properties of the 
plant extracts. However, M. aurum test model was utilised as a monitoring tool 
in  the  initial  screening  to  enable  chemical  characterisation  to  go  on  while 
appropriate arrangements were being made for the testing against the target 
organism. The biological testing against M. tuberculosis H37Rv (virulent strain)  
could not be carried out at the University of Sunderland due to the infectious 
nature of the bacterium and the inaccessibility of the  appropriate  bio safety  
level  3  facilities  required  for  laboratory  activities  in  the  propagation  and 
manipulation of cultures of M. tuberculosis. 
 
 
6.1.1. Introduction 
The most suitable  target organism in an anti-TB discovery effort is the actual 
etiologic agent,  M.  tuberculosis,  a  well  characterized  virulent  strain  available 
from the American Type Culture Collection (ATCC, Rockville, MD) denoted as 
M. tuberculosis H37Rv (ATCC 27294). It has a drug susceptibility profile which 
is fairly representative of the majority of drug susceptible clinical isolates (those 
which have not developed drug resistance as a result of prior treatment with 
one or more clinical TB drugs).  
Testing against drug-resistant and MDR strains of M. tuberculosis is not critical 
in  primary  screening,  because  these  strains  are  not  ‘‘superbugs’’,  which  are 
resistant to multiple antibiotics by virtue of a single mechanism, such as the 
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step-wise mutations to individual drugs. Thus, they would be expected to be 
susceptible to any novel compound, which does not act at the same site as 
existing TB drugs (Pauli et al., 2005). 
However,  because  M.  tuberculosis  H37Rv  is  a  virulent  strain,  investigations 
involving  it  should  only  be  handled  in  a  Biosafety  Level  3  laboratory  (BL-3) 
requiring negative air pressure relative to an anteroom and hallway, a pass-
through autoclave and a Class 2 biosafety cabinet. Personnel working within the 
BL-3 lab must wear protective gear, most importantly a respirator, which will 
minimize  the  risk  of  infection  by  aerosolized  M.  tuberculosis.  Since  few 
institutions have a BL-3 laboratory, most investigators either collaborate with an 
institution, which does possess such a facility or work with avirulent surrogate 
organisms (Pauli et al., 2005). 
Many natural products researchers have chosen to work with rapidly growing, 
avirulent, saprophytic mycobacteria. One such species is M. smegmatis (ATCC 
607), which has been extensively used and been referred to erroneously as M. 
tuberculosis  607  in  several  publications.  These  organisms,  however,  only 
possess a limited degree of similarity to  M. tuberculosis with regard to drug 
susceptibility.  Another  alternative  to  working  with  virulent  strains  of  M. 
tuberculosis  is  to  use  the  slow  growing,  avirulent  strain  known  as  M. 
tuberculosis H37Ra (ATCC 25177) or the commonly used vaccine strain, M. 
bovis BCG (ATCC 35743).  
These organisms are  reported  to  be  more  closely  related to  M.  tuberculosis 
H37Rv  than  the  rapid-growing  mycobacteria  with  respect  to  both  drug 
susceptibility profile and genetic composition. It is suggested that working with 
these organisms requires only the use of a Class 2 biosafety cabinet and sound 
microbiological technique (Pauli et al., 2005). 
Several  methods  have  been  used  to  screen  samples  for  MTB  in  biological 
samples  and  for  drug  susceptibility.  Many  investigators  in  the  area  of  TB 
research have utilised drug susceptibility testing methods such as the absolute 
concentration  method,  resistance  ratio  and  proportion  methods  in  diagnosis, 
treatment  and  resistance  surveillance  of  TB  universally  (Drobniewski  et  al., 
2007).  However, these methods require two to four weeks to obtain results and 
with some other specialised methods, it requires expensive equipment which is 
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The method (MABA) used in determination of minimum inhibitory concentration 
for  this  study  is  a  sensitive,
  rapid,  inexpensive,  and  non-radiometric  which  
offers the potential for
 screening a large number of compounds against slow 
growing mycobacteria (Franzblau et al., 1998). 
The Alamar blue oxidation-reduction dye is a general indicator of cellular growth 
and/or  viability;  the  blue,  non-fluorescent,  oxidized  form  becomes  pink  and 
fluorescent  upon  reduction.  Growth  is  easily  measured  by  the  use  of 
fluorometers,  spectrophotometer  or  visually  (deFries  and  Mitsuhashi,  1995; 
Collins  and  Franzblau,  1997).  The  proposed  mechanism  by  which  the  dye 
detects  living  cells  involves  metabolic-based  reduction  via  reactions  of  the 
respiratory chain (Voytik-Harbin et al., 1998). 
The  method  has  also  been  used  in  the  assay  of  lymphocyte  proliferation, 
detection of methicillin resistant Staphylococcus aureus (MRSA) and a variety 
of  other  assays  (deFries  and  Mitsuhashi,  1995;  Pfaller  and  Barry,  1994; 
Zabransky, Dinuzzo, and Woods, 1995).  Collins and Franzblau (1997) in their 
extensive  research  study  suggested  that  fluorimetric  MABA  facilitates  data 
acquisition  for  large-scale  efforts  while  visual  MABA  is  a  very  inexpensive 
alternative, providing nearly identical results. 
 
 
6.2   Aims and Objectives 
This aspect of the study was directed at screening and determination of the MIC 
values  of  the  different  plant  fractions  against  M.  tuberculosis  H37Rv  ATCC 
(virulent  strain)  using  the  micro  plate  Alamar  Blue  assay  (MABA)  in 
collaboration  with  Professor  S.G.  Franzblau  (Institute  for  TB  Research, 
Chicago, Illinois).  
 
6.3     Experimental 
6.3.1  Materials 
M.  tuberculosis  H37Rv  ATCC  27294,  Middlebrook  7H12  medium  (Difco 
Laboratories, MI, USA), Middlebrook 7H11 agar (Difco), Middlebrook 7H9 broth, 
(Difco Laboratories, MI, USA), Alamar blue (Trek Diagnostic, Westlake, OH), 
Tween 80 and the reference drug compounds were purchased from Sigma. 
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6.3.2  Equipment  
BioStatQ fermentor by Braun Biotech was used for simulating a low oxygen 
medium. 
 
6.3.3 Preparation of reagents and media 
Reagents and media used are described in Lilienkampf et al., 2009. 
 
6.3.4    Methods   
 
6.3.4.1   Isolation and cultivation of M. tuberculosis H37Rv 
All  mycobacterial  species  were  grown  in  Middlebrook  7H9  broth  (Difco 
Laboratories, MI, USA) supplemented with 10% albumin–dextrose complex and 
0.05  %  (v/v)  Tween  80  or  on  Middlebrook  7H12  agar  (Difco  Laboratories) 
supplemented  with  10  %  oleic  acid–albumin–dextrose  complex  (Collins  and 
Franzblau, 1997, Falzari et al., 2005, Franzblau et al., 1998). Stock solution of 
MTB H37Rv was prepared by comparison to McFarland No. 1 turbidity standard 
and diluted to yield 2 x 10
5 CFU/mL.  
 
6.3.4.2 Determination of MIC against M. tuberculosis H37Rv 
All crude fractions of X. americana and P. crassipes were evaluated for MIC 
against  M.  tuberculosis  H37Rv  (ATCC  27294)  using  the  Micro-plate  Alamar 
Blue  assay  (MABA)  in  7H12  medium  (Collins  and  Franzblau,  1997).  Stock 
solutions of the various plant extracts were prepared in DMSO  and two – fold 
dilutions of each  stock  extract solutions  were prepared in  Middlebrook 7H12 
medium in a volume of 100 µL in 96 well micro-plates (black view plates).  MTB 
H37Rv (100 µL of 2 x 10
5 CFU/mL) was added to make up 200 µL in the micro-
plates.  
Positive control drugs were diluted in deionised water or DMSO as appropriate. 
Compounds were tested in ten 2-fold dilutions, typically from 128 - 0.25 µg/mL 
for  crude  extracts  and  100  -  0.19  µg/mL  for  pure  compounds.  Plates  were 
incubated at 37 
°C for 7 days. On the 7
th day, 12.5 µL of 20 % Tween 80 and 20 
µL  of  Alamar  Blue  were  added  to  the  test  plates.  The  plates  were  then 
incubated at 37 
°C for 16 – 24 h and fluorescence measured at excitation and 
emission wavelengths of 530 and 590 nm (Lilienkampf et al., 2009). The MIC Page | 109  
 
value against MTB H37Rv was defined as the lowest concentration effecting a 
reduction in fluorescence (or luminescence) of ≥ 90% relative to bacteria only 
controls. Reported values are means of two replicate measurements. 
 
 
6.4    Results and Discussion 
The crude non-polar and polar fractions of X. americana and P. crassipes were 
evaluated for in vitro drug susceptibility against M. tuberculosis H37Rv (virulent 
strain) ATCC 27294 using the Micro-plate Alamar Blue Assay (MABA) on 7H12 
Middlebrook  medium  (Franzblau  et  al;  1998).    Hexane  and  dichloromethane 
extracts of X. americana displayed good anti-TB activity of over 94% inhibition 
at 60.6 and 30.5 µg/mL respectively at the test concentration range of 128 - 0.5 
µg/mL  (Table  6.1).    In  contrast,  P.  crassipes  fractions  demonstrated  weak 
activity (below 90%) against M. tuberculosis H37Rv at an MIC value 128 µg/mL 
except for the hexane fraction which had an inhibition of 86.7% at 64 µg/mL. 
The results from the testing of crude extracts show that the fractions possibly 
contain compounds with potential  activity against  MTB H37Rv compared to 
reference drugs RMP, INH, MOX and PA- 824 which had MIC values between  
0.06 – 0.77 µg/mL.  The results from MTB testing show correlation with findings 
from initial screening of aqueous plant materials against clinical isolate of M. 
tuberculosis in which X. americana and P. crassipes displayed MIC values of 
100 and 200 µg/mL based on the Lowenstein- Jensen method (Metchock et al; 
1999) and with M. aurum results (Table 6.1, Figure 4.2). Activity was found to 
be in the lipid fractions and this may be due to the ability of the extracts to 
penetrate  the  cell  wall  in  high  enough  concentration  to  have  an  effect.  The 
methanol fractions containing polyphenols such as 5-O-caffeoyl quinic acid and 
rutin with anti-oxidant properties showed mild or no effects in vitro against MTB 
H37Rv  but  may  be  acting  to  stabilise  or  enhance  the  actives.  Some 
polyphenolic  compounds  have  been  reported  by  other  investigators  to  have 
anti-oxidant,  efflux  pump  inhibitory,  muscle  relaxant,  anti-inflammatory, 
resolving pleural effusion, and lymphoedema (Amos et al., 1998; Michalet et al., 
2007; Kopko, 2005).  
TB in the lungs (common manifestation) is characterised by symptoms such as 
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the  other  constituents  may  be  working  in  concert  or  synergy  with  the  anti-
tubercular  compounds  to  achieve  resolution  of  symptoms  and  successful 
therapy  (WHO,  2010).  According  to  Pauli  et  al.,  (2005),  the  MIC  of a  crude 
natural  extract  may  or  may  not  be  a  reliable  inidicator  of  the  chances  for 
success in isolating a potent anti-mycobacterial agent from that extract. 
The possibility exists that an extract with a relatively low MIC (high activity) may 
contain large quantities of only very few moderately active major constituents, 
while  moderately active crude materials could lead to minor compounds with 
high  activity.  This  was  observed  with  an  anti-TB  compound  ergosterol-5,  8- 
endoperoxide isolated from the methanol extract of Ajuga remota which had an 
MIC of approximately 100 µg/mL against MTB H37Rv in the initial study with the 
crude extract  but was subsequently demonstrated to have an of MIC 1 µg/mL 
on  further  purification  (Cantrell  et  al.,  1999).  Also,  compounds  with  weak 
antibacterial activity have been reported to be significantly enhanced by other 
constituents in the same species (Michalet et al., 2007). 
 
 
 
 
 
Table 6.1. Table of results showing the anti-TB activity of plant fractions 
Extract  Stock 
(mg/mL) 
Test Conc.  
(µg/mL) 
%Inhibition  
at  
highest  
concentration 
MIC  
(µg/mL) 
PCH  6.4  64 - 0.25   86.7  > 64  
XAH  6.4  64 - 0.25  94.3  60.6 
PCD  12.8  128 - 0.5  52.1  > 128  
XAD  6.4  64 - 0.25  96.4  30.5 
PCM  12.8  128 - 0.5   0.0  > 128  
XAM  12.8  128 - 0.5   0.0  > 128  
PCW  12.8  128 - 0.5   0.0  > 128 
XAW  6.4  64 - 0.25   5.4  > 64 
PCE  12.8  128 - 0.5   79.5  > 128  
XAE  12.8  128 - 0.5  71.3  > 128  Page | 111  
 
 
 
 
Legend: 
 
 
PCH, PCD, PCM, PCW, PCE - HEXANE, DICHLOROMETHANE, METHANOL, 
WATER EXTRACTS OF P. crassipes 
XAH, XAD, XAM, XAW, XAE - HEXANE, DICHLOROMETHANE, METHANOL, 
WATER EXTRACTS OF X. americana 
RMP,  INH,  MOX,  PA824  –  RIFAMPICIN,  ISONIAZID,  MOXIFLOXACIN, 
NITRO-IMIDAZOPYRAN 
 
 
6.5 Conclusion 
Hexane and dichloromethane extracts of X. americana were most active with 
94.3  and  96.4  %  inhibition  at  60.6  and  30.5  µg/mL  respectively  against  M. 
tuberculosis H37Rv (virulent strain).  The hexane extract of  P. crassipes had 
86.7 % inhibition at 64 µg/mL and could possibly have better activity at higher 
concentrations.  
Herbal  therapy  is  characterised  by  multi-component  constituents  directed  at 
resolving  signs  and  symptoms  of  diseases  i.e.  holistic  as  opposed  to 
conventional medicine which emphasizes target - directed therapy. The in vitro 
test results lend some credence to the use of the plants in traditional medicine.  
Consequently, chromatographic and spectroscopic analyses were focused on 
the  hexane  and  dichloromethane  fractions  of  X.  americana  after  biological 
testing. 
 
 
 
 
RMP           0.06 
INH           0.20 
MOX           0.77 
PA824           0.49 Page | 112  
 
           
 
 
 
 
Chapter 7     Chromatographic and Spectral Characterisation of Plant 
Extracts 
 
 
7.1   Background 
Chemical characterisation of the plant extracts was performed using a variety of 
tools  particularly  high  performance  liquid  chromatography  (HPLC),  thin-layer 
chromatography (TLC) and gas chromatography (GC) to separate and isolate 
fractions after testing the crude fractions to check that there was activity against 
M. tuberculosis the target organism was retained and to find out which isolates 
were  active.  Molecular  characterisation  to  attempt  to  fully  elucidate  the 
structures was performed using mass spectrometry (MS) and nuclear magnetic 
resonance (NMR).  
Other fractions such as the methanol fractions which had some activity initially 
against M. aurum but no effect at concentrations tested against M. tuberculosis 
were also investigated by HPLC to provide LC fingerprint chromatograms which 
could  be  potentially  useful  for  subsequent  quality  control  work  especially 
bearing  in  mind  that  the  possibility  of  synergistic  effects  had  not  been 
completely ruled out. Another consideration was that well-known polyphenolic 
constituents previously identified by other researchers from both plant materials 
had been reported to have useful activities in other assay systems e.g. rutin 
with  reported  anti-oxidant  and  anti-inflammatory  properties  (Guardia  et  al., 
2001). Based on published literature, classes of chemically diverse compounds 
from  natural  products  have  been  investigated  and  shown  to  have  anti  - 
tubercular activities thus it was necessary to look at all potential compounds. 
 
7.1.1       Introduction 
Chromatography  is  a  versatile  tool  utilised  in  separating  and  isolating 
constituents in mixtures of compounds for identification, structure determination Page | 113  
 
and drug development purposes (Marston, 2007). It has been used in routine 
analysis  for  quality  control,  toxicological  and  clinical  studies  as  well  as  for 
standardisation of phytomedicines (Scott, 2008; Beesley, 2010).  HPLC has the 
capacity to separate, identify and quantitate compounds in solution.  However, 
because  liquids  are  viscous,  pressure  is  needed  in  the  columns  to  enable 
separation (Figure7.1).   
 
 
 
Fig.7.1 Agilent 1200 Preparative LC system with ChemStation data processing 
unit. 
 
 
Fig.7.2  Xevo QToF Mass Spectrometer. 
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Also,  advances  in  NMR  spectroscopy  and  MS  have  made  it  possible  to 
elucidate  structures  of  natural  products  in  minute  amounts  of  material.  A 
multidisciplinary approach is utilised in the elucidation of structure determination 
in natural product chemistry (Hostettmann et al., 1997). Apart from LC, GC and 
supercritical fluid chromatography (SFC) have also found use as techniques for 
assays  of  natural  products  and  pharmaceuticals.  However,  without 
derivatisation to improve volatility, GC is restricted to low molecular weight and 
thermo-stable compounds while LC/UV or SFC/UV is restricted to compounds 
containing a chromophore. Since capillary SFC employing carbon dioxide as 
mobile  phase  is  compatible  with  flame  ionization  detection,  it  is  possible  to 
analyse  many  solutes  at  trace  levels  with  high  chromatographic  efficiency. 
Supercritical carbon dioxide offers higher solute diffusivity compared with the 
inert carrier gas conventionally used in gas chromatography and has a lower 
viscosity than the liquid solvents used in HPLC. Thus, glycerides of fatty acids 
can be separated and eluted at a lower temperature and with shorter analysis 
time  in  SFC  (Giron  et  al.,  1992).  With  LC  and  SFC,  a  universal  detector 
compatible with these separation methods in both isocratic and gradient mode 
is necessary.  
Universal  detectors  such  as  flame  ionization  (FID),  refractive  index  (RI) 
detectors and mass spectrometers may be used as alternative detectors (Figure 
7.2).  FID  is  frequently  coupled  with  capillary  SFC  but  its  use  with  LC  and 
packed SFC is difficult to perform and nowadays, the commercial availability of 
such instrumentation is very limited. The RI detector has been described in the 
literature to be useful for carbohydrate detection but it has been reported to 
have poor sensitivity with gradient elution and easily affected by temperature 
(Kohler  et  al.,  1997).  This  detector  can  also  be  coupled  to  liquid 
chromatography  and  packed  supercritical  fluid  chromatography.  It  has  been 
reported that polysaccharides, not detected by spectrophotometry at 280 nm or 
higher wavelengths can be detected by this method (Barreira, 2010; Kohler et 
al., 1997). The evaporative light scattering detector allows direct detection of all 
non-volatile  compounds  regardless  of  their  functional  group  or  chromophore 
because the principle of operation is based on measurement of scattered light 
and  has  been  found  useful  as  a  detector  in  structure  determination  of 
compounds with poor UV chromophores. Also mobile phase systems used in an Page | 115  
 
LC/ELSD  separation  method  can  be  used  for  LC/MS  detection  especially  in 
structure determination of compounds (Jarrell, 2009; Kohler et al., 1997). 
 
7.1.2    Hyphenated techniques 
The  advantage  of  coupling  various  techniques  lies  in  the  rapid  and  efficient 
elucidation of known compounds which would prevent the often tedious process 
of isolating common constituents. Hyphenated techniques such as LC/MS or 
LC/MS/MS  and  LC/NMR  have  been  used  for  the  structural  determination  of 
small quantities of plant material (Hostettmann et al., 1997).  It must be noted 
though  that,  even  today,  such  expensive  online  technology  is  not  routinely 
available even in relatively well-equipped laboratories. 
MS is a powerful and sensitive tool for identifying unknown compounds by virtue 
of its ability to "weigh" ion fragments and relate them back to the compound of 
interest.  In  GC/MS  utilises  an  energetic  ionisation  method  (such  as  electron 
ionisation), which causes the parent compound to break into multiple fragment 
ions (Figure 7.2). The mass spectrum of the compound as well as its mass and 
location  in  the  chromatogram  can  be  used  for  its  identification.  This  is 
accomplished  by  comparing  the  fragment  pattern  with  a  library  database  of 
compounds e.g. National Institute of Standards and Technology (NIST) which 
helps to identify the chemical formula and possibly the chemical structure. In 
LC/MS,  the  common  ionisation  approach  (electrospray)  is  quite  gentle  and 
typically only produces a single parent ion.  
MS/MS can be used in a tandem system to help identify the compounds, or if 
more expensive equipment is accessible, accurate mass measurements alone 
can identify likely formula candidates. With MS/MS, the fragment ions can be 
identified  which  assists  the  deduction  of  structural  information  (Kuehl  and 
Wang, 2007; Atkins and Jones 1999).  Various ionisation methods are utilised in 
MS  depending  on  the  nature  of  the  compounds  being  analysed.  In  electron 
ionisation  (EI),  the  extensive  fragmentation  enables  the  elucidation  of  the 
structure  though  it  has  been  reported  to  have  the  disadvantage  that  the 
characteristic molecular ion could be absent and heat generated could lead to 
chemical  breakdown  of  the  sample  (Hill,  1972).  With  chemical  ionisation, 
fragmentation is not as extensive compared to EI but it is said to produce a 
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NMR as an analytical tool has been found to be useful in elucidating structures 
though when compared to other spectroscopic methods; it is considered to be 
relatively insensitive although the advent of high field instruments has increased 
its versatility (Williams and Fleming, 1995). NMR has the advantage of being 
non-destructive  and  non-selective  for  molecules  in  solution.  Moreover,  the 
sample  solution  can  be  dried  off  and  recovered  for  further  analyses  or 
alternatively, solutions in deuterated dimethylsulphoxide (DMSO) may be used 
directly for biological testing (Corcoran and Spraul, 2003). The NMR spectra of 
compounds are assigned chemical shifts and coupling patterns which are then 
compared  to  model  compounds  in  characterising  and  quantitating  molecular 
systems. Where molecular complexity occurs, higher magnetic field strengths 
are  used  to  resolve  overlapping  multiplet  patterns  thereby  allowing  for 
interpretation of more first-order like spectra. Multi - dimensional NMR in the 
form  of  J  -  spectroscopy  offers  a  way  to  resolve  even  highly  overlapping 
resonances  into  readily  interpretable  multiplets  and  permits  chemical  shift 
assignments to be made in a simple and direct manner (Gray, 1994). 
 
 
7.2    Aims and Objectives 
The aim of this phase was to attempt to separate and isolate the constituents of 
plant  extracts  of  X.  americana  and  P.  crassipes  using  appropriate  analytical 
tools  such  as  high  performance  liquid  chromatography,  thin-layer  and  gas 
chromatography.  This  would  provide  molecular  and  LC  fingerprints  of  the 
extracts which could be used for identification and serve as possible markers to 
aid  quality  control  of  the  herbal  products  in  particular  with  respect  to 
reproducibility of extracts produced. A further aim was to use NMR and mass 
spectral data to aid structural elucidation of isolated active constituents. 
 
7.3 Experimental 
General laboratory glassware was supplied by Schott (Germany), Pyrex and E-
MILboro (Englanda. Reagents and chemicals were of analytical reagent grade 
(Sigma) while solvents were HPLC grade (Sigma Aldrich, UK). Water used in Page | 117  
 
preparing solutions was purified by PURELAB® Bioscience purification system 
(Siemens). 
 
7.3.1    Materials 
Sample vials were obtained from Agilent, while PTFE (polytetrafluoroethylene) 
Acrodisc syringe filter (0.2 µm) were used for sample filteration.  HPLC columns 
used in the study were obtained from Hichrom Ltd, U.K.  
 
7.3.2   Equipment and accessories 
The  HPLC  systems  used  for  reversed  phase  analyses  employed  Hewlett 
Packard  HP  1090  LC  system, an  Agilent  1290  (analytical)  and Agilent  1200 
preparative systems equipped with detectors such as photodiode diode array, 
refractive index, evaporative light scattering and controlled by ChemStation data 
processing  software.  The  HPLC  system  used  for  normal  phase  screening 
employed  a  Shimadzu  (Milton  Keynes,  UK)  LC-6A  pump  and  SPD-6AV 
detector.  In  each  case,  a  manual  Rheodyne  (Kotati,  Ca,  USA)  7125  loop 
injection valve, fitted with a 20 µL loop, was used for loading samples. Data was 
collected using a Dionex (Leeds, UK) data system. The sonicator used to degas 
mobile phases was from GS Group-ULTRAWAVE Ltd, Cardiff. The Shimadzu 
LC  system  was  initially  used  for  normal  phase  LC  before  transferring  the 
methods to the Agilent 1290 systems. 
 
7.3.3 Reagents for TLC 
a) Sulphuric acid reagent (50 % H2SO4 in methanol): general spray reagent  
After spraying and drying, plates were heated at 105 °C for 10 minutes. Various 
compounds show different colourations. 
 
b) Dragendorff’s reagent for alkaloids:  Solution A: 0.85 g basic bismuth nitrate 
dissolved in 10 mL glacial acetic acid and 40 mL of water with heating. Solution 
B:  8 g potassium iodide in 20 mL water.  Page | 118  
 
Stock solution: Solutions A and B are mixed in equal proportions before use. 
After spraying, plates were observed in daylight for orange colouration when 
alkaloids are present (Stahl, 1969). 
 
c) Brady’s reagent (2, 4 - dinitrophenylhydrazine; 2, 4 - DNP): for aldehyde and 
ketone groups.  2 g of diphenylhydrazine was dissolved in 100 mL of methanol. 
Thereafter, 4 mL of concentrated H2SO4 was added carefully to the mixture. 
TLC plates were sprayed and heated in the oven. The presence of red-orange 
colouration indicates the presence of a carbonyl group. 
 
d) Fehling's reagent: Fehling’s solution I and II are added to the sample extract 
in equal volumes to form a deep blue solution. The formation of a brick - red 
precipitate indicates the presence of reducing sugars. 
i)  Fehling’s  solution  I:  Prepared  by  dissolving  7  g  of  hydrated  copper  (II) 
sulphate in 100 mL of water. 
ii) Fehling’s solution  II : prepared by   dissolving 35 g of potassium sodium 
tartrate and 10 g of sodium hydroxide in 100 mL of  water. 
 
e) Lieberman Burchard’s test:  A few drops of acetic anhydride were added to 
samples dissolved in chloroform and the tube containing the mixture was boiled. 
On cooling, concentrated sulphuric acid was added carefully down the sides of 
the tube. The formation of a brown ring at the junction of the two layers was 
suggestive of a steroidal nucleus. 
 
7.3.4   Methods 
7.3.4.1 Collection and preparation of plant materials 
X.  americana  root  and  P.  crassipes  leaves  obtained  from  Nigeria  were 
authenticated  by  Prof.  Olorede  of  the  Department  of  Biological  Sciences, 
University  of  Abuja  and  identities  further  confirmed  by  Dr  Martin  Cheek  in 
comparison with voucher specimens (K000411874 and K000657947) at Royal 
Botanic Gardens, Kew, Surrey, London. The plant parts were pulverised and 
100 g of each was sequentially extracted by cold maceration to obtain crude Page | 119  
 
hexane (yield - 1.14%), dichloromethane (yield - 0.3%), methanol (yield - 10%) 
and water (yield - 5%) extracts.  
The extracts were also subjected to extraction by Soxhlet apparatus but due to 
the  fact  that  no  difference  was  observed  during  the  biological  testing  cold 
maceration was subsequently used for extractions.  Water samples were freeze 
dried and organic extracts concentrated using a Buchi rotavapor under reduced 
pressure at less than 40˚C and stored in a refrigerator at - 20 ˚C until use.  This 
procedure was carried out a number of times to obtain fresh crude fractions for 
biological testing and other chemical analyses. Crude extracts of hexane and 
dichloromethane were submitted for NMR and mass spectral analyses based 
on positive results of initial screening against M. aurum, the test model system 
for TB. 
 
7.3.4.2    Preparation of mobile phases 
Mobile phase solvents were degassed by helium out-gassing for analyses on 
Agilent  1200  preparative  and  Hewlett  Packard  1090  LC  systems  and  by 
membrane in-line degassing on the Agilent 1290 system. Analytical work on 
Shimadzu LC systems required solvents to be degassed by sonication at room 
temperature. 
 
7.3.4.3 UV analysis 
The  crude  extracts  of  both  plant  materials were  individually  dissolved  in  the 
appropriate  solvents  for  hexane,  dichloromethane,  methanol,  and  water 
extracts. The double beam UV-Vis spectrophotometer was used to obtain the 
UV profile of the extracts (Figure 7.3). 
 
7.3.4.4 HPLC analysis 
Normal phase HPLC analysis was performed on Hewlett Packard 1090 system 
using three analytical columns; Luna NH2, ACE 5 CN and ACE 5 SILICA, 250 x 
4.6  mm.  Initially  dichloromethane  was  used  to  elute  two  fractions  from  the 
hexane fraction on an ACE 5 CN, 250 x 10 mm i.d column and analysed by Page | 120  
 
NMR to confirm purity.  Hexane and dichloromethane crude extracts exhibited 
similar chromatograms and NMR spectra so they were both subjected to the 
same  experiments.  After  a  number  of  experiments  were  carried  out  using 
various ratios of mobile phase and columns with different selectivity to optimise 
separation,  methanol:  dichloromethane  (2:98,  v/v)  mobile  phase  system  was 
used on an ACE 5 silica column to elute the crude hexane and DCM extracts of 
X. americana (Figure 7.3). Detection was by means of a Hewlett Packard diode 
array detector at 245, 254 and 280 nm. 
Analytical and preparative reversed phase HPLC was performed on the Hewlett 
Packard HP1090 LC system and the  Agilent 1200 series systems equipped 
with a photodiode array detector with ChemStation data processing software, 
using three analytical columns; Luna NH2, Luna SCX  and ACE 5 C18 silica. 
Several ratios of mobile phases were tested using methanol – water and with 
ammonium acetate buffer on ACE 5 C18 silica column and Luna NH2, and Luna 
SCX columns. Methanol and water fractions of X. americana and P. crassipes 
were  subjected  to  the  same  reversed  phase  experiments.  Based  on 
optimisation, a gradient system of methanol and water (A-15, B - 85) was finally 
used to elute P. crassipes crude methanol extract to obtain eight fractions.  The 
fractions  were  analysed  by  NMR  and  two  fractions  by  accurate  mass 
spectrometric measurements.  The crude methanol extract was also subjected 
to LC/MS using the same gradient profile. 
 
7.3.4.5 Fractionation of X. americana crude extracts and isolation of active 
constituents by HPLC 
Fractionation of the crude hexane extract of X. americana was performed using 
repetitive semi-preparative HPLC (ACE 5 CN; 250 x 10 mm i.d column). NMR 
spectra  of  the  two  fractions  obtained  could  not  be  used  in  structure 
determination  so  further  experiments  were  performed  on  crude  hexane  and 
DCM  fractions  with  methanol:  dichloromethane  (2:98  v/v)  mobile  phase  to 
obtain four fractions. The fractions were subjected to NMR and mass spectral 
(MS)  analysis.  However,  MS  and  NMR  did  not  match  suggested  structures Page | 121  
 
based  on  the  data.  TLC  analysis  was  also  used  to  obtain  isolates  as  an 
alternative procedure. 
 
7.3.4.6  Isolation  of  active  fractions  from  X.  americana  hexane  and 
dichloromethane LC fractions by thin layer chromatography (TLC) 
Thin layer chromatographic analysis of crude hexane, DCM and LC fractions 
was carried out on Silica gel 60Å F254nm TLC 20 x 20 mm analytical plates for 
comparative purposes.  Preparative TLC was carried out on crude hexane and 
DCM  extracts  using  20  x  20,  500  µm  plates  (Merck).    Solvents  used  in 
developing  TLC  were  HPLC  grade  and  purchased  from  Sigma  Aldrich.    β-
sitosterol and stigmasterol were used as TLC reference standards based on the 
NIST data base search of the extracts MS data. 
 
7.3.4.7 Gas chromatography of X. americana hexane and dichloromethane 
extracts 
Initial GC measurements were carried out using Hewlett Packard 5890 series II 
system and DB - 624 capillary column (30 m x 0.32 mm, 1.8 µm).  Further GC 
analysis employed Agilent 7820 GC system and HP- 5 capillary column. The 
following conditions below were utilised in conducting the experiments using β-
sitosterol, stigmasterol, cholesterol and stearic acid as reference standards. 
General details: 
HP- 5 capillary column: 30 m (L) x 0.32 mm (i.d) x df 0.25 µm (Agilent J and W) 
Flow: 5.5528 mL/min 
Pressure: 23.03 psi (constant pressure) 
Average velocity: 76.106 cm/sec 
Hold up time: 0.65697 
Run time: 102 minutes 
Oven: 
Initial temperature:  100 °C for 1 min, 2 °C/min to 300 °C Page | 122  
 
Equilibration time: 1 min 
Max. Oven temperature: 325 °C 
FID: 
Heater: 300 °C 
H2 flow: 30 mL/min 
Airflow: 400 mL/min 
Make-up flow (N2): 25 mL/min 
Constant column + make-up: 30.553 mL/min 
Back signal (FID): 50 Hz/0.004 min 
 
7.3.4.8  HPLC analysis using refractive index (RI) detector 
NMR spectra of the active fraction obtained were not resolvable but results from 
mass spectral measurements were suggestive of a sterol-like fragment which 
had a base peak with the same molecular mass as stigmast -3, 5 - diene and 
sitosterol. Due to the poor UV absorbing properties of some spots on the TLC 
plate developed with IPA-hexane (5:95 v/v) the RI detector was then considered 
as an alternative in addition to detection by ELSD. Agilent 1290 infinity series 
LC system  equipped with  an  RI  detector was  used  to  separate hexane  and 
DCM  extracts  in  comparison  to  reference  standards,  β-sitosterol  and 
stigmasterol using methanol-dichloromethane (2:98 v/v) mobile phase system 
on ACE 5 SIL column, 250 x 4.6 mm. X. americana total water extract was also 
analysed  by  the  same  system  using  IPA:hexane  (2:98  v/v)  on  ACE  5  CN 
column, 150 x 4.6 mm and UV detection at 210 and 254 nm for comparative 
purposes. 
 
7.3.4.9  HPLC  analysis  of  XD3  and  XD4  (sub-fraction  of  M.  tuberculosis 
active   fraction monitored with M. aurum) 
Due  to  the  difficulties  encountered  in  identifying  components  of  the  active 
fractions separated by HPLC and analysed by NMR and MS, bioautography Page | 123  
 
was utilised in order to localise the activity and to further purify the fraction by 
TLC. Bio-autographic analysis of dichloromethane LC fractions of  X. americana 
showed that the anti- tubercular activity was localised in band 3 and 4 zones on 
the TLC plate with Rf 0.35 (chapter 4, Figure 4.4 iii).  Water - methanol (30:70 
v/v) (isocratic) and gradient analysis (methanol: water (15/85 v/v) was used to 
separate  the  constituents  by  Hewlett  Packard  HP  1090  equipped  with  PDA 
detector.  The mobile phase gradient profile is detailed below; 
Column: ACE 5 C18, 250 x 4.6 mm (Hichrom Ltd, U.K) 
Mobile phase:  water - methanol (30:70 v/v) 
Flow rate: 1 mL/min 
Injection volume: 20 µL 
Wavelengths: 210, 230, 254, 280 nm 
Run-time:  30 minutes (isocratic), 45 minutes (gradient) 
Temperature: ambient 
 
Gradient time-table: 
% A (15) – methanol 
(Time in minutes) 
% B (85) - water 
0  90 
15  70 
20  70 
21  80 
25  80 
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7.4    Results and Discussion 
7.4.1   UV analysis of crude   X. americana extract 
The samples were subjected to UV spectrophotometry to obtain the UV profiles. 
The UV profiles showed prominent absorption peaks at 210, 230, 245, 265, 280 
nm.  However, UV spectrophotometry lack specificity and is prone to spectral 
interference  so  cannot  be  used  for  characteristic  identification  without 
comparison  to  known  compounds  or  a  UV  library  database.  Subsequent 
experiments showed that extracts exhibited UV properties when visualised under 
UV light at 254 nm.  In Figure 7.3 i  the crude extract UV spectrum is shown by 
the red trace and three peaks obtained from preparative LC of hexane extract 
using 100 % DCM. From Figure 7.3 ii it can be seen that the UV spectrum of the 
dichloromethane extract is similar to the hexane extract spectrum. Subsequent 
LC analyses gave similar chromatograms for XAH and XAD and testing with TB 
revealed higher activity with XAD so further experiments were focused on XAD. 
 
i)            
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ii)   
 
 iii)   
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iv)   
 
Fig. 7.3  i) UV spectrum of hexane extract and fractions obtained from elution 
with  DCM  on  an  ACE  5  CN  semi-preparative  column.    ii)  UV  spectrum  of 
dichloromethane extract.  iii) UV spectrum of methanol extract. iv) UV spectrum 
of water extract. 
 
7.4.2 Initial separation of X. americana extracts by HPLC 
The plant fractions were subjected to LC to obtain LC fingerprints and to help 
develop  conditions  for  preparative  chromatography.  Polar  extracts  (methanol 
and  water)  were  analysed  by  reversed  phase  LC  while  hexane  and 
dichloromethane fractions were analysed by normal phase LC. The methanol 
extracts of both plant materials were also subjected to analysis by  analytical 
and  preparative  reversed  phase  HPLC  on  HP  1090  and  Agilent  1200 
preparative  systems  respectively.  The  chromatograms  show  the  LC  profiles 
obtained  using  different  mobile  phase  systems  (Figures  7.4  -7.5).  Other  LC 
chromatograms  under  different  conditions  are  shown  in  Appendix  2.  LC 
chromatograms  of  the  most  active  fractions  of  X.  americana  against  TB,  T. 
mentagrophytes,  P.  acnes  (hexane  and  DCM)  and  S.  aureus  (methanol 
fraction) are shown in Figures 7.4 and 7.5. Page | 127  
 
i)       ii)   
       
Fig. 7.4 i and ii)   Normal phase analytical LC profile of   X.  americana (hexane 
and dichloromethane) extracts on ACE 5 SILICA column, 250 x 4.6 mm, 5 µm  at 
254 nm using methanol - dichloromethane (2:98, v/v) mobile phase on HP 1090 
LC system with PDA detector. 
  
iii)     iv)   
 
Fig.7.4 iii) Normal phase semi-preparative LC profile of X. americana  (hexane) 
extract separated  with 100 % DCM on ACE 5 CN column (250 x 10 mm) at 254 
nm using the LC-6 system with UV/vis detector collected in three fractions, 1,2,3.  
iv)  Analytical  LC  profile  of  peak  1  from  XAH  preparative  analysis  on  ACE  5 
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SILICA column, 250 x 4.6 mm using DCM - hexane (80:20, v/v) mobile phase 
system. 
v.      vi.   
Fig.7.4 v and vi) Analytical LC profile of peaks 2 and 3 from XAH preparative 
analysis on ACE 5 SILICA column, 250 x 4.6 mm separated with DCM:  hexane 
(80:20, v/v) isocratic elution on HP 1090 LC system with PDA detector. 
 
 
 
Fig.7.5. Reversed phase analytical profile of X. americana methanol extract (1 
mg/mL)  on  ACE  5  C18,  250  x  4.6  mm  column  at  230  nm  separated  with 
methanol-water   mobile phase gradient system.  
Gradient time-table 
Time - % A (methanol) 
0  --------- 20 
5   --------- 50 
16 --------- 50 
17 --------- 20 
20 --------- 20 
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7.4.3 Purity checks for crude hexane and dichloromethane fractions of X. 
americana and identification. 
The NMR data for crude hexane and dichloromethane data are presented in 
Tables 7.2b and below 
1. XAD: 500 MHz (Table 7.2b) 
2. XAH 1: 300 MHz Proton NMR (Table 7.2b) 
1. XAD 
Brown viscous mass (50 mg):  MS (m/z) (662.5 - 664.6, M+), 396, 255, 218,109. 
13C NMR (75 MHz,CDCl3):13.82,14.12,19.34, 19.53,22.13,22.70,24.68, 28.23, 
28.63,  28.73,28.78,  28.84,  28.92,  28.96,29.33,  29.72,  30.90,  31.93,  32.90, 
33.82, 108.65, 128.28, 129.75, 129.78, 140.49, 143.41, 148.22, 173.83, 175.04, 
178.29, 206.98. 
 
2. XAH 1  
White waxy solid (22 mg): MS (m/z): 426.4 (M+), 411.4 (M-15), 397.4 (M-29). 
13C NMR (75 MHz, CDCl3): 11.87, 11.99, 14.11, 14.54, 15.22, 16.00, 16.18, 
16.59,  18.02,  18.24,  18.79,  19.07,  19.33,  19.82,  21.06,22.69,  23.12,  24.31, 
25.19,  26.17,  27.18,  27.24,  27.85,  27.99,  28.26, 29.12,  29.22,  29.27,  29.33, 
29.37,  29.47,  29.53,  29.60,  29.71,  29.79,  29.88,  31.94,  33.99,  34.26,  34.87, 
36.17,  36.63,  37.04,  37.13,  37.87,  38.10,  38.20, 39.77,  40.90,  42.35,  42.87, 
43.02,  45.89, 48.03, 48.34, 50.09, 56.09, 56.73, 73.69, 80.63, 109.36, 118.85, 
122.58, 129.78, 129.99, 139.76, 150.94, 173.26, 173.63.                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
Crude  hexane  and  dichloromethane  fractions  sequentially  obtained  by 
maceration  were  initially  analysed  by  NMR  and  mass  spectrometry  without 
chemical modification to prevent the formation of artefacts. Mass spectral data 
search did not match any compound in the NIST database and no molecular 
formulae  were  proposed  (Figure  7.6g).  However  there  were  similarities  in 
fragmentation patterns of steroid-like compounds with the base peak (m/z 396) 
matching stigmast-3, 5-diene, a dehydration product of sitosterol. Comparison 
of NMR spectra of standard compounds (β-sitosterol and stigmasterol) to crude 
extracts (XAD and XAH) spectra showed additional signals suggesting that the 
base peak (m/z 396) observed in the mass spectrum might be an aglycone 
fragment from a larger molecule in the extract. This is expected being that the Page | 130  
 
sample is a crude mixture (Figure 7.6a - d). The Proton NMR spectrum was 
crowded and overlapping especially at 1 - 2.5 ppm (aliphatic region) and not 
resolvable (Figure 7.6a, b). Very little information could be gleaned but signals 
observed  between  chemical  shift  values  (0.6  -  2.5  ppm)  are  indicative  of 
aliphatic chains (Silverstein, 2005).   
According to Croasmun and Carlson (1994) the 1  - 2.5 ppm region  in NMR 
spectra  for  steroids  is  crowded  with  only  the  C18  and  C19  angular  methyl 
singlets being shifted beyond the 1 – 2.5 ppm region (Table 7.2). Though the 
spectra showed similarities to steroids in the 1 - 2.5 ppm region, XAD exhibited 
signals for  protons in the region between 5.52 – 6.5 ppm which were better 
resolved and located away from the crowded 1 - 2.5 ppm region suggesting a 
spin  system  or  network  (Figure  7.6  a,  Appendix  D2.iv  ).  The  carbon  13 
spectrum of XAD run at 75 MHz was very noisy and DEPT spectrum did not 
provide a better picture. The sample was also run at 125 MHz but only signals 
in  the  olefinic  region  were  resolved  while  the  HSQC  spectrum  showed  that 
carbons within 15 - 60 ppm were not well resolved as well.  The region 0.7- 2.4 
ppm integrated for 58 protons while the olefinic region integrated for 25 protons 
giving a total of 83 protons (Figure 7.6, Table 7.2b). Signals suggestive of acyl 
carbon  (173.83  ppm),  alkene  carbon  (108  -140  ppm)  were  observed  in 
13C 
spectrum  of  XAD  run  at  75  MHz.  Stigmasterol  signals  were  assigned  using 
NMRanalyst  software  and  by  comparison  to  literature  values  (Dunkel,  2011; 
Zhang et al. , 2005). 
Efforts to purify the extracts by preparative LC were pursued by using cyano 
and  silica  columns  for  different  retentivity  and  possibly  alternate  selectivity.  
Initial separation and isolation of XAH by LC on cyano column (250 x 10 mm, 5 
µm using 100 % DCM resulted in three fractions which were checked for purity 
by  analytical  LC  and  NMR.  (Table  7.1,  Figure  7.4  iii  -  vi).  Fraction  1  which 
looked fairly pure with one major peak, was analysed by NMR and compared to 
sitosterol  and  stigmasterol  NMR  spectra.    XAH1  proton  spectrum  exhibited 
similar signals to sitosterol and β-amyrin in addition to other signals. The proton 
spectrum showed a total of 58 protons with most of the signals in the aliphatic 
region. There were two signals consistent with alkene protons at 4.52 and 5.52 
ppm  integrating  for  a  proton  each.    The 
13C  NMR  spectrum  had  additional 
signals at 173 ppm suggestive of an acyl carbon and the 3 - OH signal of a Page | 131  
 
triterpene alcohol which appears at about 3 – 4 ppm signal was not observed, 
instead there was a deshielded signal at 4.52 ppm.  On expansion of the 
13C 
spectrum, signals were observed at 150 and 208 ppm (suggestive of a C=O 
group in acids, esters, anhydrides and keto-compounds).  
Mass analysis gave ion peaks at 426.4 (M)+, 411 (M – 15), 397 (M – 29) (Figure 
7.6h). This mass resembles C-30 terpenoids such as β-amyrin, cycloartenol, 
lupeol,  friedelin  with  molecular  formula,  C30H50O  (MW  -  426.72).  However, 
comparison  of  β-amyrin  NMR  predicted  by  NMR  predictor  (www.nmrdb.org) 
shows that XAH1 may actually be a conjugated terpene fatty acid ester with 
close similarity to β-amyrin palmitate, C48H80O2 (MW - 664.62). The ion peak 
665.6 was observed in the high molecular weight region of the mass spectrum 
(Figure  7.6).  Compounds  such as  terpenes,  fatty  acids  and  phytosterols  are 
reported to be common constituents of non-polar fractions so the sample was 
tested  for  the  presence  of  a  steroidal  nucleus  using  Lieberman-Burchard 
reagent (Evans, 1996). The crude extract tested positive to the test.  
Based  on  the  results  of  anti-TB  studies,  steroidal  compounds  such  as 
saringosterol  have  been  demonstrated  to  have  anti-TB  activities  at  MIC’s 
ranging from 0.125 – 1 µg/mL. It has also been reported that anti-TB activities of 
a majority of natural products tested are attributed to secondary metabolites of 
terpenoid origin (Copp, 2003).  Saludes et al. (2002) identified the presence of 
E-phytol, cycloartenol, stigmasterol, sitosterol and other derivatives as the anti-
TB constituents from hexane extract of Morinda citrifolia while Okunade et al. 
(2004) reported anti-TB activities of sitosterol and stigmasterol at MIC - 128 and 
32 µg/mL respectively.  A number of triterpenes investigated for in vitro anti-TB 
and structure - activity studies suggest that the presence of structural features 
such as C-3 keto and/or β-hydroxy, cyclopropane ring and epoxide groups are 
essential for activity (Cantrell et al., 2001). 
 
Table 7.1. Preparative LC data of XAH 
 
Initial weight of crude  Peak 1  Peak 2  Peak 3 
200 mg hexane extract  38.5   mg      52.98 mg      34.61 mg Page | 132  
 
 
Table 7. 2a. 
13C and 
1H NMR assignments of stigmasterol at 75 and 300 MHz 
respectively 
 
Atom  stigmasterol   
 
13 C ppm 
1H ppm 
1  37.28  1.48 
2  31.67  1.59 
  3  71.78  3.51 
4  42.32  2.28 
5  140.76  - 
6  121.66  5.10 
7  31.92  1.93 
8  31.90  1.48 
9  50.20  1.01 
10  36.52  - 
11  21.08  1.48 
12  39.70  1.77 
13  42.23  - 
14  56.88  1.01 
15  24.36  1.01 
16  28.89  1.48 
17  55.99  1.01 
18  12.22  0.66 
19  21.06  1.01 
20  40.45  2.02 
21  21.22  1.01 
22  138.28  5.10 
23  129.30  5.35 
24  51.24  2.02 
25  31.87  1.48 
26  19.39  1.01 
27  18.99  1.01 
28  25.39  1.01 
29  12.05  1.01 
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Table 7.2b. 
1H  assignments of XAD (500 MHz) and  XAH1 (300 MHz) 
 
XAD  XAH1 
Chemical 
shift , ʴ (ppm) 
multiplicity  No  
of 
protons 
Chemical 
shift , ʴ (ppm) 
multiplicity  No of 
protons 
0.7- 2.39  u  58  0.68 – 0.79  s  1.07 
3.69  s  1  0.81 – 1.09  u  17.35 
5.15   u  5.65  1.13 – 1.68  u  32.22 
5.32 - 5.37  u  6.52  1.99 – 2.23  u  4.37 
5.45 - 5.52  u  4.79  2.26 – 2.32  u  2.59 
5.75 - 5.78  m  0.79       
6.05 - 6.10  m  2.19       
6.27 - 6.33  q or d,t  3.00       
6.47 - 6.52  d,d  1.00       
 
u-unresolved, s-singlet, m-multiplet, q-quintet, d-doublet, t-triplet 
 
Though  hexane  extract  exhibited  greater  inhibitory  activity  against  T. 
mentagrophytes and P. acnes at 250 µg/mL and 62.5 µg/mL respectively, XAD 
showed  stronger  anti-TB  activity  at  an  MIC  of  30.5  µg/mL  against  M. 
tuberculosis H37Rv (Tables 3.4 and 6.1). The anti-dermatophyte and anti-acne 
activities of hexane extract may be attributed to the presence of triterpenoidal 
compounds.  However,  more  rigorous  purification  is  required  to  aid  structure 
determination  by  NMR.    XAD  was  further  subjected  to  semi-preparative  LC 
using  methanol  -  DCM  (2:98  v/v)  mobile  phase  system  to  obtain  cleaner 
fractions  for  NMR  and  mass  spectral  analysis.Page | 134  
 
 
   
      
  Fig.7.6a Proton NMR spectrum of dichloromethane extract of X. americana (XAD) Page | 135  
 
      
  
 Fig. 7.6b  Proton NMR spectrum of XAH peak 1 (X. americana hexane extract fraction 1). Page | 136  
 
   
 
Fig. 7.6c Proton NMR  spectrum of β-sitosterol (reference standard) 
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       Fig.7.6d Proton NMR spectrum of stigmasterol (reference standard). 
 
 Page | 138  
 
   
  
Fig.7.6e  HSQC spectrum of X. americana dichloromethane fraction (XAD). Page | 139  
 
 
    
Fig.7.6f  Carbon 13 NMR spectrum of XAH peak 1 (X. americana hexane fraction 1). Page | 140  
 
          
         
        Fig. 7.6g  EI Mass spectrum of crude dichloromethane extract (XAD). Page | 141  
 
       
 
     Fig. 7.6h Mass spectrum of X. americana  hexane extract (peak 1 from preparative LC). 
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7.4.4  LC separation and mass spectral analysis of XAD fractions 
Dichloromethane  extract  of  X.  americana  was  separated  by  methanol-DCM 
(2:98 v/v) to obtain four fractions labelled as XD1, XD2, XD3 and XD4. The data 
obtained is shown in Table 7.3 and Figure 7.7.  The fractions were analysed by 
EI + MS and the fragmentation patterns showed similar ion peaks but due to the 
lack of molecular formulae and NMR data, it was difficult to predict structures 
based  on  the  nominal  masses  obtained.  XD1  showed  base  peaks  at  low 
frequency  regions  below  200  amu  indicative  of  aliphatic  or  alicyclic  chains.  
When compared to the data obtained by TOF MS EI, a consistent ion peak at 
396  was  observed  which  could  possibly  be  due  to  an  aglycone  or  genin 
(Appendix E4).  Other ion peaks observed were 446 (XD1), 428 (XD2), 571 
(XD3) and 280 (XDW). NIST data search matches showed some similarities to 
compounds  such  as  ergosta-6,  22-diene-3-ol,  5,  8-epidioxy  derivative 
(C28H44O3, MW- 428), ergosta- 4, 6, 22-trien-3-ʱ-ol (C28H44O, MW- 396).  The 
ion peak at 662 was also consistent in previous and subsequent experiments. 
The crude extract of XAD tested positive to Lieberman-Burchard reagent and 
the  ion  peak  at  662  –  664.6  is  possibly  a  mixture  of  fatty  acid  esters  of 
triterpenes  such  as  β-amyrin  palmitate  (C46H80O2  MW-  664.615).  Further 
experiments were carried out to obtain accurate mass measurements to enable 
structure determination in conjunction with NMR analysis. 
 
Table 7.3. LC semi-preparative data for XAD 
 
Peak  Peak  code  Volume of eluent  Dry weight (mg) 
1  XD1  100 mL  12.4  
2  XD2  60 mL  16.4 
3  XD3  100 mL  2.3 
4  XD4  1.2 L  34.6 
Initial weight of crude – 265 mg (5 mg/mL solution in methanol-DCM, 2:98 
v/v) 
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The  LC chromatograms  looked fairly  simple  but  the  results  showed  that  UV 
detection may not be picking up all the compounds in the mixture and there 
might have been several compounds under the peaks observed. The nominal 
masses  alone  could  not  be  used  for  identification  and  library  data  matching 
search  of  fragmentation  patterns  did  not  yield  positive  results.  Further 
purification procedures were continued to obtain cleaner samples for accurate 
mass measurements using a different ionisation technique and NMR analysis. 
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ii)     ii)   
 
 Fig. 7.7 i) Analytical and preparative LC profile of XAD on ACE 5 CN column (250 x 4.6 mm, 250 x 10 mm respectively)  at 1 and 5 
mL/min  developed with  methanol-DCM (2:98 v/v), injection volume of 1mL. Preparative fractions were collected and labelled as 1= 
XD1, 2= XD2, 3 = XD3, 4= XDW. 
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Fig. 7.7 ii)  EI mass spectrum of X. americana dichloromethane extract (XD 1) 
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Fig. 7.7 iii) EI mass spectrum of X. americana dichloromethane extract (XD 2). 
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Fig. 7.7 iv) EI mass spectrum of X. americana dichloromethane extract (XD 3). Page | 148  
 
   
 
Fig. 7.7 v) EI mass spectrum of X. americana dichloromethane extract (XDW). Page | 149  
 
 
7.4.5 TLC analysis of LC, crude hexane and dichloromethane fractions  
7.4.5.1 LC analysis  
The crude fractions were separated using ACE 5 SILICA column, 250 x 7.75 
mm in order to obtain cleaner samples for mass spectral analysis using a soft 
ionisation source (Time of Flight – Atmospheric Pressure Solids Analysis Probe, 
TOF-  ASAP  MS).  It was  expected  that ASAP  which  is a  modification of  the 
atmospheric  pressure  ion  (API)  source  would  give  molecular  ions  as  radical 
cations  M
+●  or  protonated  molecules  MH+  to  aid  identification  unlike  the  EI 
instrument which has the capacity for extensive fragmentation and is not likely 
to give a molecular ion (Ray et al., 2010).  
 
 
 
Fig.7.8 LC chromatogram of XAH on ACE 5 SILICA column using DCM 
 
The  crude  extracts  were  separated  with  100  %  DCM  and  collected  in  five 
fractions  (Figure  7.8).  The  fractions  were  tested  against  M.  aurum  by 
bioautography to localise the activity so as to focus on the bioactive component 
(Table 3.4).   
The mass spectral data of fractions showed many fragment peaks which when 
compared to fractions obtained from blank solvent runs showed similar peaks. 
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The peaks in the blank may have been due to a carry-over effect from previous 
analyses  or  contaminants.  The  mass  peaks  observed  were  similar  to  mass 
fragments seen with EI - MS (Figures 7.1-7.7). Detailed ASAP mass spectra are 
shown in Appendix E5/6. The mass spectra for the various fractions showed 
that  the  fractions  required  required  further  purification.  TLC  analyses  of  LC 
fractions were carried out to aid localisation of activity by bioautography and to 
possibly separate the components further such that better mass data could be 
obtained for easier interpretation. 
 
7.4.5.2 TLC analysis of fractions (LC and crude samples) 
Due to ambiguity in the data observed with EI - MS and ASAP- MS, isolation 
and purification by TLC was then considered. Thin layer chromatography was 
performed  on  analytical  silica  gel  60  F  254  plates.  Sample  extracts  and  β-
sitosterol (reference standard) were dissolved in chloroform to give 1 mg/mL 
solutions  and  spotted  in  10  -  20  µL  volumes.    Plates  were  developed  to  a 
distance of 7 cm for analytical plates and 15 cm for preparative plates (Figure 
7.9). Various solvent systems were used to develop the samples as shown in 
Figures  7.9  i  -  iii. The  plates  were  visualised  with  iodine  (Figure  4.4i) 2-  di-
nitrophenylhydrazine and sulphuric acid sprays as well as under UV lamp at 
254 and 366 nm.  Hexane – chloroform - methanol (4:4:1, v/v/v) solvent system 
gave better separation and sharper zones compared to hexane: IPA (95:5 v/v). 
The plates showed about seven bands (Figure 7.9.i).  
The standard, β-sitosterol, Rf 0.65 (lane 1) migrated to about the same position 
as one of the spots in XAH and XAD extracts, Rf 0.55 (Figures 7.9. i and ii). The 
LC  fractions  showed  no  spots  on  spraying  with  2-DNP  and  sulphuric  acid 
reagents (Figure 7.9 ii). The LC and TLC fractions were all subjected to testing 
with M. aurum and then re-subjected to TLC analysis. A hexane: chloroform: 
methanol solvent system was then used for preparative TLC of XAD. The spots 
were scraped off and re-constituted in chloroform for spots   1 and 2 while spots 
3  and  4  which  were  insoluble  in  chloroform  were  re-constituted  in  methanol 
(Figure  7.9.  iii).  Attempts  to  recrystallize  the  sample  with  acetone  or 
ethylacetate did not yield crystals. The samples were then filtered, dried and 
subjected to MS and NMR analyses. Page | 151  
 
 
    i.    
   
    ii.       
 
 
Fig.7.9  i)  TLC  plate  sprayed  with  2-DNP  (left)  and  H2SO4  (right)    with  β-
sitosterol  in  Lane1,  XH  in  Lane  2  (hexane  extract  of  X.    americana),  XD 
(dichloromethane extract of X. americana) in lane 3 developed with hexane-
chloroform-methanol (4:4:1, v/v/v) solvent system.  
ii) H2SO4 sprayed TLC plate with crude and LC fractions from XH and XD in IPA 
- hexane  (5:95 v/v) solvent system. (a = XH, b = XD, c =XH1, d =XH2, e =XH3, 
f =XH4, g =XH5, h = XH)  
 
  1       2       3  1        2         3 
 a   b   c  d   e  f   g  h  a   b   c   d  e   f   g   h  b Page | 152  
 
iii)              
                     
Fig.7.9 iii) Preparative TLC plate (20 x 20 cm) spotted with XAD and developed 
with hexane - CHCl3 - methanol (4:4:1, v/v/v) solvent system visualised with UV 
lamp at 254 and 365 nm. Four spots were observed and numbered as 1, 2, 3, 
and 4. Spot 3 fluoresced at 365 nm. 
 
 
7.4.5.3.  Identification  of  compounds  from  crude  dichloromethane  X. 
americana root extract by HR TOF-MS EI +   
The  results  obtained  from  accurate  mass  measurements  predicted  three 
compounds at < 5 ppm error from TLC spots 1 and 2 as stigmasten- 3,5-diene 
[1] (MW – 396.3751 calculated 396.3751 for C29H48 ), Stigmast-5-en-3-ol oleate 
[2] (MW - 678.6329, calculated 678.6315 for C47H82O2 ) and β-sitosterol [3] (MW 
– 414.3861, calculated 414.3862 for C29H50O) [Figure 7.10, 11a,b].  
Other  compounds  predicted  from  TLC  spot  2  and  3  having  an  error  margin 
greater than 5 ppm are shown in Table 7.4a.  
 
[1] Mass data (m/z): 41, 57, 69, 81, 147, 105,147, 283, 396 
[2] Mass data (m/z): 41, 69, 95, 105, 147, 161, 203, 283, 339, 678 
[3] Mass data (m/z):  41, 57, 81,145, 213, 255, 329, 414 
 
 
1 
 
 
2 
 
3 
4 
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Fig.7.10 Chemical structures of suggested compounds Page | 155  
 
Table 7.4. Properties of some of the predicted compounds 
 
Initial weight of crude used in TLC isolation - 223.1 mg 
 
TLC  
spot 
Description   Dry 
Weight 
mg 
Exptal. 
mass 
Calculated 
 mass 
Error 
margin 
ppm 
Predicted compound  
match 
Molecular 
formula 
Molecular  
weight 
2  Brown 
mass 
4.4  424.3733 
620.5483 
 
 
424.3680 
424.3705 
620.5380 
 
 
424.3705 
6.6 
16.6 
 
 
- 5.9 
[4] Olean-12-en-28-al 
[5]  2-hydroxy-3-[(Z)-octadec-
9-enoyl]oxypropyl](Z)-
octadec-9-enoate 
[6] 13,27-cycloursan-3-one 
C30H48O 
C39H72O5 
 
 
C30H48O 
424 
620 
 
 
424 
3  Yellow oily 
mass 
2.9  410.3852 
 
 
 
456.3650 
410.3913 
 
 
 
456.3603 
- 14.9 
 
 
 
10.3 
[7]4,4,14-trimethyl-9,19-
cyclo-9,10-secocholesta-
1(10),9(11)-diene 
 
[8]  5-ʱ-cholest-8-en-3-one, 
6-ʱ-hydroxy-14-methyl-
acetate 
C30H50 
 
 
 
C30H48O3 
410 
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The NMR proton and carbon spectra obtained for TLC spot 1 was overlapping 
and crowded at the aliphatic region but attempts  to account for the structures of 
the first three compounds from the data  proved challenging with the spectra 
obtained.  However,  the  proton  NMR  spectrum  is  presented  in  Figure  7.11d. 
Difficulties were also encountered in obtaining NMR data for TLC spots 2 and 3 
due to the amounts obtained which had to be subjected to mass, NMR and 
biological testings. Only proton and COSY spectra could be obtained for TLC 
spots 2 and 3 with insufficient material for 
13C and other 2D NMR spectra. 
Based on accurate mass measurements, three compounds were proposed at < 
5 ppm as stigmasten-3, 5-diene, stigmast-5-en-3-ol oleate and β-sitosterol. The 
results of accurate mass measurements indicated that the TLC spots were a 
mixture of compounds. Probably as a result of this, the inadequacy of the NMR 
data  obtained  made  the  task  of  proper  identification  of  the  structures 
challenging.   
Hyphenated techniques involving LC/NMR and SFC-UV/ELSD/MS were then 
considered  for  further  exploration  of  the  fractions  but  LC/NMR  involving  NP 
solvents was not practicable without a significant amount of initial development 
work and the fact that earlier separations and isolation using UV detector did 
not give good results.  GC/FID/MS was considered as an alternative technique 
when the Faculty of Applied Sciences in Sunderland University acquired new 
equipment such as the triple quadruple mass spectrometers linked to GC with a 
library database. Subsequent experiments were then carried out with GC/FID in 
the  hope  that  the  structures  of  some  of  the  predicted  compounds  could  be 
correctly identified.  
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Fig. 7.11a i) Mass spectrum of XD1   compound 1 (TOF MS EI +) Page | 158  
 
    
           
    Fig. 7.11a ii)  Mass spectrum of XD1 compound 2 Page | 159  
 
  
    
   Fig.7.11b i)  Mass spectrum of XD2   compound 1 
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 Fig. 7.11b ii) Mass spectrum of XD2 compound 2   Page | 161  
 
 
 
Fig. 7.11b iii) Mass spectrum of  XD2 compound 3 Page | 162  
 
 
 
   
Fig.7.11b iv)  Mass spectrum of XD2 compound 4 Page | 163  
 
        
 
 
 
Fig.7.11b v) Mass spectrum of XD2 compound 5 Page | 164  
 
 
       
             
  Fig.7.11c i) Mass spectrum of XD3   compound 1 Page | 165  
 
      
   
Fig. 7.11c ii)  Mass spectrum of XD3 compound 2 Page | 166  
 
 
      
         
            
        Fig.7. 11d i) Proton NMR spectrum (300 MHz) of TLC spot 1 – XD1
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Fig.7.11 d ii) 
13C NMR (75 MHz) spectrum of TLC spot 1 (XD 1) Page | 168  
 
 
  
    
 
  Fig. 7.11d iii)  
13C DEPT NMR (75 MHz) spectrum of XD1 Page | 169  
 
 
 
 
Fig. 7.11d iv)  Proton NMR spectrum (300 MHz) of TLC spot 2 – XD2 Page | 170  
 
   
 
Fig. 7.11d v)  Proton NMR (300 MHz) spectrum of TLC spot 3 (XD 3)Page | 171  
 
 7.4.5.4 Gas chromatographic analysis of crude hexane, dichloromethane 
and column fractions of X.  americana 
GC analysis was considered as an alternative method since resolution of the 
active  fractions  by  LC was  difficult.  Acetylenic fatty  acids  and  oleanolic  acid 
saponin have been reported in the chloroform extract of X. americana root by 
other investigators (Fatope et al., 2000; D’Agostino et al., 1994). Crude samples 
were analysed by GC and the retention times of available standard compounds, 
stigmasterol,  β-sitosterol,  cholesterol  and  stearic  acid  were  compared  to  the 
retention times of the plant extracts. Crude hexane and DCM extracts (500 mg 
each) were individually subjected to dry column flash chromatography using  n-
hexane/ethylacetate  (90/10v/v)  and  hexane/DCM/ethanol  (25/25/50  v/v/v)  to 
obtain two fractions which would  be enriched in fatty acids and phytosterols 
respectively (Verleyen et al., 2002).  
The results show the individual retention times of the standards and extracts 
(Figure 7.12, Appendix F). The standard compounds were tested individually 
and as a mixture. Following the experiment, extracts were also tested alone and 
spiked with 10 µL volumes of the reference compounds.  The initial temperature 
programme  was  for  51  minutes  (initial  temperature,  100  ˚C  (hold  1  min.), 
ramped at 5 °C/min to 300 °C (hold for 10 min) which was shortened to 31 
minutes in the final experiments (Figure 7.12a).  The retention times of stearic 
acid, cholesterol, stigmasterol and sitosterol are as shown in Figure 7.12a.  The 
crude  extract  fractions  showed  intense  peaks  (retention  time,  1.546  -7.371) 
which eluted within the temperature range 100 – 140 °C and could be attributed 
to  the  fatty  acid  and  low  molecular  weight  components.  The  standard 
compounds  (stearic  acid,  cholesterol,  stigmasterol  and  sitosterol)  eluted  at 
4.568, 15.960, 17.732 and 18.434 minutes while crude XH and XD showed less 
intense peaks at 17.753 (XH) and 17.074, 17.788, 19.445 for XD (Figure 7.12bi 
and ii). The retention time of the most intense peaks at 17.184, 17.753 (XH) and 
17.299, 17.788 (XD) were close to the retention time for an unknown peak and 
stigmasterol  (17.227,  17.732  min)  in  standard  mixture  as  shown  in  Figure 
7.12aii. 
The  intensity  of  the  peaks  observed  with  10  mg/mL  solutions  of  the  crude 
extracts  show  that  the  phytosterol  content  is  small  compared  to  the  low Page | 172  
 
molecular weight components while the enriched fractions show intense peaks 
at 17.922 and 18.055 for 10 mg/mL XH2 and XD2 respectively (Figure 7.12b.v 
and vi). The enriched fractions were each spiked with a 10 µL volume of the 
standard  mixture  and  an  increase  in  the  intensity  of  peak  at  17.1  min  was 
observed however the intensity of the low molecular weight enriched fractions 
decreased when compared to the crude fractions (Figure 7.12bi- iv). The order 
of elution of the phytosterol standards followed a similar pattern to that obtained 
by  INA  using  Rtx-5  column  (The  Institute  for  Nutraceutical  Advancement; 
http://www.restekcorp.com).  The  hyphenated  GC/MS  was  unavailable  to 
continue further work so subsequent arrangements were made to analyse the 
samples by SFC-UV-ELSD in collaboration with Waters Corporation. While this 
would not give such high efficiency, volatility would not be an issue, as with FID 
all  eluting  compounds  would  be  detected  with  ELSD  and  there  would  be  a 
possibility of subsequently transferring methods to SFC-MS. 
 
a)   
Fig.  7.12.a  GC  analysis  of  a  mix  of  1  -  stearic  acid,  2  -  cholesterol,  3  -  
stigmasterol, 4 – sitosterol.  Temperature programme: Initial 200 °C (hold for 
1min), rate 5 °C/min to 300  °C final temperature (hold for 10 mins). 
2 
3 
4 
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 i.   
 
 
ii.  
 
Fig.7.12bi  and  ii)  GC  chromatographic  profiles  for  crude  XH  (i),  XD  (ii)Page | 174  
 
 
 
 iii.   
 
 
 
   iv.   
 
 
Fig.7.12b.iii and iv) GC chromatographic profiles for enriched fractions XH1 
(iii), XD1(iv) Page | 175  
 
v.   
 
 
vi.   
 
Fig.7.12b. v and iv) GC chromatographic profiles for  fractions XH2 (v) and  
XD2 (vi)  
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vii.   
 
 
viii.   
 
Fig.7.12b. vii and  viii) GC chromatographic profiles for spiked fractions XH1 
(vii), XD1 (viii), 
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ix.   
 
 
 x.   
 
 
Fig.7.12b ix, x) GC chromatographic profiles for spiked fractions XH2 (ix), XD2 
(x) 
While the GC work revealed that the crude extract contained some quite volatile 
components it was not possible to identify these because of the non-availability Page | 178  
 
of GC-MS at the time. There was clearly very little in the way of phytosterols 
present. While it might have been possible to study some of the more polar 
constituents in the materials by using more polar columns, there was insufficient 
time to carry out the method development needed or to wait for the repair of the 
GC-MS. 
 
 
7.4.5.5 LC analysis of XAH, XAD, XAT, XD3 and XD4 (active sub-fractions) 
using refractive index detector and photodiode array detector. 
Following the series of analytical approaches described in earlier sections, it 
seemed that the fractions of the non-polar extracts of X. americana responsible 
for  anti-TB  activity  contained  mixtures  of  hydrophobic  compounds,  probably 
diacylglycerols,  dehydrated  sterols,  phytosterol  conjugates  or  pentacyclic 
triterpenoids which were not readily resolvable into single compounds by TLC 
using UV detection.  
On further exploration of the literature on analysis of phytosterols, it was then 
necessary to consider NPLC of dichloromethane and XD3/4 extracts (TB active 
fractions) as well as RP LC of the total water extract which was used in the 
initial testing TB with RI or ELSD detection. Discussions with industry experts 
led to suggestions that   NPLC-ELSD or SFC- FID-MS would give much better 
sensitivity  compared  to  LC-UV  methods  previously  used  (Personal 
communication with G. Cox, August, 2011). The chromatographic profiles of the 
TB-active fractions and standard phytosterols were carried out using a universal 
detector prior to analysis by SFC-FID-MS.  
The  extracts  showed  the  presence  of  compounds  with  poor  UV  absorbing 
properties and this was corroborated by the presence of NMR signals within the 
aliphatic regions from earlier experiments.  The first experiment was conducted 
using silica column (ACE 5 SILICA, 250 x 7.75 mm) on Agilent 1290 Infinity 
series  with  refractive  index  andvariable  wavelength  detectors  (G1362A  and 
G1314E respectively). The chromatographic profiles and conditions are shown 
in Figure 7.13a. A major peak at 8.295 minutes was observed with RID for the 
crude samples (XAH, XAD). IPA-hexane (2:98, v/v) mobile system was used to 
analyse samples XAT, XAH and XAD on ACE 5 CN column, 150 x 4.6 mm on 
the same system in order to compare the profiles.  Page | 179  
 
The results for XAT are presented in Figure 7.13a iv and v. The peaks observed 
with  UV  eluted  close  to  the  solvent  peak  while  an  additional  peak  at  18.5 
minutes  was  observed  with  RID  suggesting  the  presence  of  a  carbohydrate 
molecule in the total water extract. Further experiments using NP on hypercarb 
showed that XAT contained some peaks with the same retention time as XAD 
suggesting that the total water extract contained peaks that were observed in 
the TB-active dichloromethane fraction (Figure 7.13 v and vi).   
 
 
   
 
 
Fig.7.13a  i)  Chromatographic  profiles  of  samples  analysed  on  Agilent  1290 
Infinity  system  with  RID  detector  and  on  ACE  5  SILICA  column  at  230  nm. 
Sample: XH (1 mg/mL), Conditions: column length - ACE 5 SILICA, 250 x 7.75 
mm i.d; Mobile phase - methanol: DCM (2:98, v/v); Flow rate - 1mL/min; column 
temperature - 21.06 °C; VWD -  230 nm;  RID - 40 °C; Run-time: 60 min 
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ii.   
 
 
iii.   
 
Fig.7.13a ii and iii) Sample containing 1 mg/mL XD (ii) sample containing 1 
mg/mL sitosterol (iii) conditions: same as Fig.7.13a i. 
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iv   .  
 
 
Fig.7.13a iv) Chromatographic profiles of XAT (1 mg/mL) on ACE 5 SILICA 
column at 210 nm.  Conditions: same as above 
 
 
 
 
 
Fig.  7.13a  v)  Chromatographic  profile  of  XAT  (1  mg/mL)  on  HYPERCARB 
column run with DCM at 210 nm. Page | 182  
 
 v   
 
 
Fig. 7.13a vi) XAD 10 mg/mL run on HYPERCARB column with DCM at 254 
nm. 
 
 
Attempts  were  made  to  conduct  some  RPLC  separations  on  the  methanol 
soluble  fraction  of  X.  americana  active  fraction  (XD3)  obtained  from  TLC  of 
XAD. 
The methanol-soluble fractions of the dichloromethane extract (XAD) were also 
analysed by isocratic and gradient RPLC on HP 1090 LC with PDA detector to 
get an overview of the number of compounds present in the fractions. Mass 
spectral  analysis  of  TLC  spot  3  (XD3)  had  given  signals  for  two  distinct 
compounds with an error margin > 5 ppm. The anti-TB activity was shown to 
reside in this fraction by autobiography so efforts were aimed at finding out the 
active  constituents  by  a  more  sophisticated  and  unambiguous  method  than 
those previously used.  
LC  analysis  of  XD3  by  methanol-water  (70:30,  v/v)  mobile  phase  showed  a 
single peak at 210 and 230 nm while three peaks were observed at 254 nm 
(Figure 7.13b). Further experiments on the fraction were conducted by SFC in 
collaboration with Waters Corporation. Page | 183  
 
 
 
 
Fig. 7.13b.  Chromatographic profile of XD3 on ACE 5   C18 column, 250 x 4.6 
mm i.d. 
 
The  methanol  -  soluble  fraction  of  XAD  may  be  amenable  to  structure 
determination  by  LC-MS  upon  further  optimisation  of  LC  in  conjunction  with 
detectors other than UV-visible.  
 
 
7.5    Supercritical fluid chromatography 
SFC-MS provides an efficient and alternative route to analysing components of 
non-polar complex mixtures due to incompatibility issues arising from coupling 
NPLC to MS because of the solvents utilised in normal phase. It has also been 
reported to have the advantage of reducing work-up time for samples before 
analysis,  faster  run-times  and  equilibration,  simultaneous  chiral  and  achiral 
separation, decreased solvent consumption and combined detection capabilities 
of MS (www.waters.com).  The mobile phase properties of carbon dioxide (e.g. 
diffusivity, density, viscosity, etc.) are intermediate between those of gases and Page | 184  
 
liquids  and  can  be  varied  and  controlled  by  small  changes  in  pressure  or 
temperature. These features allow for high mass transfer of lipid compounds 
with little consumption of solvents unlike NPLC (Wright and DePhillipo, 2010).  
SFC can be carried out with open tubular and packed columns, with differences 
in selectivity, detection and need of modifier addition to the carbon dioxide. Both 
types  have  been  employed  in  the  separation  of  sterols  in  a  wide  variety  of 
samples.  Supercritical  carbon  dioxide  has  an  adequate  solvating  power  for 
sterol separation with both column types without the need of modifier addition. It 
is  therefore  possible  to  separate  sterols  in  complex  samples  at  lower 
temperatures  than  gas  chromatography  and  in  shorter  times  than  liquid 
chromatography (Senorans and Markides, 2000). The equipment used in the 
analysis is shown in Figure 7.14. 
 
 
7.6  Experimental conditions 
Flow: 5 mL/min 
column: 2 ethylpyridine, 15 cm x 4.6 mm 
co-solvent: EtOH 
Pressure: 125 bar 
Temperature: 40 ° C 
Injection volume: 5 µL (1 mg/mL of drug- lanosterol, stigmasterol and sitosterol) 
Gradient: 
 
Time (min)  % co-solvent  % CO2  Flow(ml/min) 
0  5  95  5 
1  5  95  5 
8  40  60  5 
10  40  60  5 
 
UV detector: 220 nm 
ELSD detection 
Make-up MS: 0.6 mL/min, MeOH Page | 185  
 
7.7 Results and Discussion 
The standard samples of lanosterol, stigmasterol and sitosterol were analysed 
initially by SFC-UV-ELSD in order to establish detectability and to explore likely 
mobile phase conditions that might be needed for subsequent extract samples 
(TLC having shown the important TLC 3 and TLC 4 fractions to have been more 
polar than phytosterols. They showed good separation but ELSD gave sharper 
peaks with the retention time falling within three minutes. The separation of a 
mixture  of  the  three  compounds  on  fluorophenyl  column  gave  better 
detectability  when  compared  to  2-ethyl  pyridine  and  silica  columns  (Figure 
7.14b). 
The  main  properties  of  supercritical  fluid  chromatography  which  affect  sterol 
separations are related to the high solvating power of supercritical fluids and a 
low  viscosity,  which  yields  a  high  resolving  power  and  rapid  throughput.  In 
addition to its other advantages, the ability of SFC to resolve complex mixtures 
of low volatility compounds allows the direct injection of samples that contain 
sterols with no or little pre-treatment. Some sterols can be degraded or lost 
during exposure to light, heat or extreme values of pH. In the SFC of sterols, all 
these factors can be avoided, providing a separation under mild conditions that 
preserves the integrity of the sample (Senorans and Markides, 2000). 
 
i.  
 
 
Fid delivery 
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Fig.7.14a.  i) Waters  Analytical  SFC  system,  Method  Station  II  equipment.  ii)  schematic  overview  of  the  components  of  SFC 
coupled to PDA detector and mass spectrometer (Waters Corporation, 2011). Page | 187  
 
 
i.    
 
 
ii.   
 
Fig. 7.14b i and ii)  SFC profiles of standards;  lanosterol, stigmasterol and 
sitosterol on 2-ethylpyridine  column with ELSD and UV detection. 
ELSD detection 
UV detection 
lanosterol 
stigmasterol 
  sitosterol Page | 188  
 
iii.   
 
Fig.7.14b iii) Chromatographic profiles of a mixture of standard compounds, 
lanosterol, stigmasterol and sitosterol on different columns using UV  detection. 
 
 
The  standard  compounds  were  separated  by  SFC  and  detection  with  ELSD 
gave better detectability compared to UV. Further experiments on the TB active 
fraction,  XAD  showed  that  detectability  improved  with  ELSD  under  gradient 
conditions compared to isocratic analysis using UV detection (Figures 7.14e i-
iii).    The  separation  was  not  enhanced  with  pressure  or  temperature 
modification (Figure 7.14c iv). SFC analysis of XD3 showed similar profiles for 
the extract with the use of methanol and ethanol as co-solvent (Figures 7.14d i- 
iii).    Column  screening  of  XD4  (TB  active  fraction  of  XAD)  showed  weak 
retention of the compounds (Figures 7.14e 1-iv).  
The  presence  of  poor  UV  absorbing  constituents  might  provide  a  possible 
explanation  for  the  inability  to  separate  the  constituents  by  earlier  methods 
involving LC/UV. 
 
 
 
 
Fluorophenyl 150 x 4.6 mm 
 
2EP  150 x 4.6 mm 
 
 Silica 150 x 4.6 mm 
 Page | 189  
 
 
 
 
Fig. 7.14c i) SFC profile of a mixture of lanosterol, stigmasterol and sitosterol 
on 2-ehylpyridine column. Conditions are described in Section 7.6 
 
 
 
Fig. 7.14c ii) SFC profile of XAD using the same gradient conditions as the 
standards. Page | 190  
 
 
 
Fig. 7.14c iii) SFC profile of XAD with modified gradient condition as described 
above. 
 
 
 
Fig. 7.14c iv) SFC profile of XAD on 2- ethylpyridine column using isocratic 
conditions as described above. 
UV 
ELSD 
 
UV 
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Fig. 7.14c  v) SFC profile of XAD on 2- ethylpyridine column with pressure 
modification. 
 
 
 
Fig.  7.14d  i)  SFC  profile  of  XD3  on  2-ethylpyridine  column  using  gradient 
conditions with EtOH as co-solvent. 
 
UV 
ELSD 
UV 
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Fig. 7.14d ii) SFC profile of XD3 on 2-ethylpyridine column using a modified 
gradient condition with MeOH as co-solvent. 
 
 
 
Fig. 7.14d iii) SFC profile of XD3 on 2-ethylpyridine column using a modified 
flow rate  with MeOH as co-solvent. 
ELSD 
UV 
UV 
ELSD Page | 193  
 
 
 
 
Fig.  7.14e  i)  SFC  profile  of  XD4  on  2-ethylpyridine  column  using  gradient 
conditions with EtOH as co-solvent 
 
 
 
 
 
Fig.  7.14e  ii)  SFC  profile  of  XD4  on  2-ethylpyridine  column  using  isocratic 
conditions with EtOH as co-solvent. 
UV 
ELSD Page | 194  
 
 
 
 
 
Fig. 7.14e iii) SFC profile of XD4 screened with different columns using UV 
detection and gradient conditions with EtOH as co-solvent.  
 
 
 
Fig. 7.14e iv) SFC profile of XD4 screened with different columns using ELSD 
detection and gradient conditions with EtOH as co-solvent.  
 
UV 
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7.8 Identification of compounds from P. crassipes leaf. 
 
Initial screening  studies with the methanol extract of P. crassipes showed some 
inhibitory  activity  against  M.  aurum  so  attempts  were  made  to  separate  and  
identify the constituents  of the extract using LC, MS and NMR. 
 Reversed phase LC analysis of the methanol fraction resulted in eight fractions, 
two of which were found to be of high enough purity for analysis by NMR and 
mass spectrometry measurements. The crude methanol extract tested positive 
with  FeCl3  solution  and  NaOH  suggesting  that  tannins  and  flavonoids  were 
present (Evans, 2009). The compounds, 5-caffeoyl quinic acid methyl ester and 
quercetin-3-rutinoside were  identified by  accurate mass measurements and 
confirmed  by  NMR  data  and  literature.  The  results  obtained  by  mass 
spectrometry are presented in Figures 7.15d and e while assignments of the 
signals are presented in Tables 7.5b and c respectively. Compounds 5 and 7 
were  identified  by  accurate  mass  measurements  as  5-O-caffeoyl  quinic  acid 
methyl ester and rutin respectively after separation and isolation by reversed 
phase semi-preparative LC (Figure 7.15a).  
The structures were confirmed by comparison of 1H and 
13C NMR data of the 
isolated compound to a standard sample of  rutin (Sigma-Aldrich, S2424, Lot # 
129K2568V) and with literature values for 5-O-caffeoyl quinic acid methy ester 
(Chan et al., 2009; Clifford et al., 2003).   
 
i)    
                                                Retention time (minutes) 
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Fig.7.15a.  Semi-preparative  LC  profiles  of  P.  crassipes  (methanol)  extract 
(10mg/mL) on ACE 5 C18 column, 250 x 10 mm with gradient elution using 
methanol: water (B – methanol). 
 
Compound 5 (Me 5-CQA) has a molecular formula C17H19O9 established by HR-
ESI-MS (m/z: 367.10339 [M-H] 
- , calculated as 367.10346, ʴ - 0.18 ppm (Figure 
7.15d). Compound 7 (rutin) was compared to NMR data of an authentic sample 
and  both  compounds  showed  similar  signals  (Table  7.5c).  The  molecular 
formula was established by HR-ESI-MS as C27H29O16 (m/z: 609.14603 [M-H] 
- , 
calculated as 609.14611, ʴ – 0.13 ppm (Table 1).    
 
 
Table 7.5a. Preparative LC data of P. crassipes methanol extract 
 
Fraction  compound 
5  5-caffeoyl-quinic acid methyl ester 
7  Quercetin-3-rutinoside (rutin) 
1  unknown 
2  unknown 
3  unknown 
4  unknown 
6  unknown 
8  unknown 
 
 
 
Table 7.5b.  
1H and 
13C NMR spectral assignment of compound  5  from P. 
crassipes leaf dissolved in CD3OD   
 
Atom  5 - Me 5-CQA     
 
13C                       
1H 
13C HSQC 
13C HMBC 
1  72.14                      -          Page | 197  
 
2            2.04 - 2.05 (m)  ~36.9   
3  4.16 (m)       ~69   
4  3.72 (m)  ~71.7   
5  5.29 (m)       ~71   
6  2.22 (m)       ~37   
COO-  175.43     
OCH3  52.96                3.76 (s)                           
1'  122.98               6.96 (dd, 2.06 Hz,  
                          8.25 Hz) 
   
2'  116.54                6.79 (d, 8.25 Hz)     
3'  146.91                       -              
4'                                    -           ~149 
5'  115.09                 7.06 (d, 2.06 Hz)     
6'  127.61                       -     
7'  147.22                7.53 (d, 15.81 Hz)     
8'  115.01                6.22 (d, 15.81 Hz)     
9'  168.27                                  -     
~ estimated chemical shift values in ppm from HSQC and HMBC spectra 
 
Table 7.5c. 
1H and 
13C NMR spectral assignment of compound 7 from P. 
crassipes leaf dissolved in CD3OD 
Atom   7- Rutin  Rutin reference standard 
 
13C                             
1H 
13C                         
1H 
1  179.38                          -  179.41                      - Page | 198  
 
2  135.6                            -  135.64                      - 
3  159.29                          -  159.33                      - 
4  158.56                          -  158.50                      - 
5  94.95           6.39 (d, 1.83 Hz)      94.87         6.42 (d, 2.07 Hz)          
6  166.48                          -  165.98                      - 
7  100.09         6.20 (d, 1.83 Hz)  99.95          6.24 (d, 2.07 Hz) 
8  162.98                         -      162.96                      - 
9  105.51                         -  105.65                      - 
10  123.54                         -  123.57                      - 
11  123.12          7.62 (dd, 1.83 Hz, 
8.25 Hz)                
123.15        7.64 (dd, 2.17,      
                    8.48 Hz)   
12  116.06          6.87 (d, 8.48 Hz)     116.07        6.92 (d, 8.48 Hz) 
13  145.86                         -  145.82                       - 
14  149.84                         -  149.78                       - 
15  117.66         7.66 (d, 1.83 Hz)  117.71        7.69 (d, 2.17 Hz) 
1'  104.75         5.10 (d, 7.56 Hz)  104.74        5.15 (d, 7.44 Hz) 
2'  78.20           3.40 (m)                              78.20          3.40 (m) 
3'  75.73           3.46 (m)               75.73          3.47 (m) 
4'  69.71           3.44 (m)  69.70          3.45 (m) 
5'  73.93           3.27 (m)    73.95          3.27 (m) 
6'  68.55          3.36 (m), 3.81 (dd, 
1.15,11 Hz) 
68.57          3.35, 3.82 (d, 
10.27 Hz) 
7'  102.43         4.51 (s)  102.41        4.55 (d, 1.41 Hz) 
8'  77.23           3.32 (m)  77.23          3.32 (m) Page | 199  
 
9'  72.24           3.52 (dd, 3.44, 9.39 
Hz) 
72.26          3.53 (dd, 3.49, 
9.42 Hz) 
10'  71.4             3.25 (m)    71.41          3.26 (m) 
11'  72.11           3.62 (m)  72.10          3.66 (dd, 1.60  
                   Hz)        
12'  17.88           1.12 (d, 6.19 Hz)  17.87          1.16 (d, 6.22 Hz) 
Values of 
1H and 
13C chemical shifts are in ppm (ʴ), and those of coupling 
constants, J in Hz 
a)    b)   
    
Fig.7.15b   Structures of 5-O-caffeoyl quinic acid methyl ester (a) and 
quercetin-3-rutinoside (rutin) (b).Page | 200  
 
 
 
      
 
Fig. 7.15c i. LC-MS UV trace of P. crassipes methanol extract obtained on Esquire 3000+ mass spectrometer at 225 nm (top 
trace). Bottom trace: Extract ion chromatogram for 369 ion - PCM 5 (trace A) extract ion chromatogram for 611 ion - PCM 7 (trace 
B) acquired in positive ion mode. 
1 
A 
B Page | 201  
 
         
 
      
 Fig. 7.15 c ii. Mass spectrum of P. crassipes methanol extract in positive ion mode  (Esquire 3000 + spectrometer). Page | 202  
 
 
 Fig.7.15 c iii. Mass spectrum of P. crassipes methanol extract in positive ion mode (Esquire 3000 + spectrometer). Page | 203  
 
 
 
 
   Fig.7.15 c iv.  Mass spectrum of P. crassipes methanol extract in positive ion mode  (Esquire 3000 + spectrometer). Page | 204  
 
 
 
 
Fig.7.15 d i. Accurate mass spectrum of PCM 5 from P. crassipes leaf by ESI-MS (negative ion mode) Page | 205  
 
 
 
Fig.7.15 d ii.  Proton NMR spectrum (500 MHz) of PCM 5 from P. crassipes leaf. 
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 Fig.7.15d iii. Carbon 13 NMR (125 MHz) spectrum  for PCM 5 from P. crassipes leaf. 
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Fig.7.15e i. Accurate mass measurement for PCM 7 from P. crassipes leaf by ESI- MS (negative ion mode) 
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Fig.7.15e ii. Proton NMR spectrum  (500 MHz) of PCM 7 from P. crassipes leaf 
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Fig.7.15e iii. Carbon 13 NMR (125 MHz) spectrum of PCM 7 from P. crassipes leaf 
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     Fig.7.16.i. Proton NMR  spectrum of PCM 2 from P. crassipes leaf Page | 211  
 
 
        Fig.7.16.ii. HSQC spectrum of PCM 2 from P. crassipes leaf Page | 212  
 
 
     Fig.7.17.i.   Proton NMR spectrum (300MHz) of PCM 3 from P. crassipes leaf  Page | 213  
 
 
           
Fig.7.17.ii. Proton NMR spectrum (300 MHz) of PCM 3 from P. crassipes leaf Page | 214  
 
 
  
 Fig.7.17.iii. HSQC  spectrum of PCM 3 from P. crassipes leaf Page | 215  
 
 
 
Fig.7.18.i.  Proton NMR (300 MHz) spectrum of PCM 4 from P. crassipes leaf Page | 216  
 
     
 
Fig.7.18.ii.  HSQC spectrum of PCM 4 from P. crassipes leaf 
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Fig.7.19.i.  Proton NMR (300 MHz) spectrum of PCM 6 from P. crassipes leaf Page | 218  
 
 
 
 
           Fig.7.19.ii. HSQC spectrum of PCM 6 from P. crassipes leaf Page | 219  
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Fig.7.20  Chromatographic  profile  of  P.  crassipes  hexane  extract  on  ACE  5 
SILICA column, 250 x 4.6 mm using hexane:DCM (30:70,  v/v) mobile phase. 
 
 
 
 
Fig. 7.21 SFC profile of P. crassipes total water extract solvent screening on 
fluorophenyl column, 150 x 4.6 mm i.d. using methanol-water (98:2). 
 
LC/UV and SFC profiles of P. crassipes hexane and total water extracts are 
shown  in  Figures  7.20  and  7.21  respectively.  The  Preparative  RPLC  of  P. 
crassipes methanol extract was successfully used to identify two compounds in 
conjunction  with  accurate  mass  measurement  and  NMR  analyses  without 
rigorous isolation or purification processes. Further work is required in order to 
identify compounds in the other fractions. Page | 220  
 
 
 
 
 
 
 
 
Chapter 8   Conclusions and Suggestions for Further Work 
 
 
The plants selected for the study were the basis for one of several recipes used 
in North Central Nigeria for the traditional treatment of coughs and respiratory 
infections  of  bacterial  origin  (Harira  Adamu,  2006;  Personal  communication). 
This particular remedy had been used by the indigenous people of North Central 
Nigeria for many years but there was no documented evidence for the bioactive 
constituents in relation to the use in traditional medicine.  
The  main  objective  of  the  study  had  been  to  evaluate  the  anti-tubercular 
activities of the plant extracts with a view to isolating the active constituents. The 
process  of  structural identification proved  very  challenging  due  to  the  lack  of 
resources at the initial stage of the research and testing of extracts against M. 
tuberculosis virulent strain was performed off-site. However, the results obtained 
from this study show that the plants had potential anti-TB activities but the most 
active  TB  fraction  was  found  to  be  complex  in  nature  and  not  amenable  to 
structure  determination  by  the  methods  used.    To  help  clarify  the  extensive 
analytical processes followed in attempting to evaluate the plant materials, these 
are shown in Figures 8.1 and 8.2.   
From  systematic  classification,  families  such  as  Olacaceae,  Santalaceae  and 
Loranthaceae  which  belong  to  the  order  Santales  are  characterised  by 
acetylenic  acids,  mono-  and  sesquiterpene  alcohols,  glycoproteins,  lignans, 
flavonoids etc (Evans, 2009).  Compounds such as oleanolic acid saponin, C18 
acetylenic fatty acids and ximonicane (sesquiterpene) have been reported to be 
present in X. americana, Family Olacaceae (D’Agostino et al., 1994; Fatope et Page | 221  
 
al., 2000; Araujo  et al., 2009). The extracts exhibited anti-bacterial, anti-acne 
and anti-TB activities at MIC levels of 31.25 µg/mL, 62.5 µg/mL and 30.5 µg/mL. 
Anti-TB  activities  of  natural  products  have  been  attributed  to  terpenes  in  a 
majority of cases while oleanolic acid derivatives have been used in cosmetic 
products (Copp, 2003; Gordien, 2009). Steroidal constituents have also been 
demonstrated  to  have  anti-TB  activities  (Saludes,  2002).  There  were 
suggestions  that  stigmast-3,  5  -diene,  stigmasterol  oleate  and  β-sitosterol 
derivatives were possible constituents of the TB - active fraction. The anti -TB 
activities of the plant extracts may therefore be attributed to the presence of a 
mixture of fatty acids, triterpenoid and phytosterol- related compounds.   
Comparatively, P. crassipes which belongs to family Rubiaceae is characterised 
by a wide variety of classes of natural products e.g. alkaloids of indole, oxindole, 
quinolone and purine types, anthocyanins, iridoids as well as anthraquinones 
(Heinrich  et  al.,  2004).  In  this  study,  P.  crassipes  extracts  exhibited  less 
inhibition  against  most  of  the  gram  positive  bacteria  tested  but  the  activity 
against gram negative bacteria was better compared to X. americana extracts.  
Caffeoylquinic acid methyl ester and rutin were isolated and characterised from 
P.  crassipes.  Rutin  has  been  reported  to  have  anti-inflammatory  actions  and 
anti-oxidant properties by other investigators (Guardia et al., 2001; Amos et al., 
1998).  Based on the philosophy of synergy in alternative medicine, it may thus 
be acting in concert with X. americana in an anti-inflammatory or anti-oxidant 
capacity to enhance the overall pharmacological effect.  
SFC results showed that ELSD was better adapted for detection of constituents 
from  the  TB  active  fractions  than  UV  detection.  Pressure  and  temperature 
modifications in the operating conditions did not result in better separations while 
gradient  analysis  gave  better  separations  compared  to  isocratic  conditions. 
Importantly,  there  was  clear  evidence  that  complexity  of  the  TLC  and  LC 
fractions  had  been  the  reason  for  the  difficulties  in  identifying  individual 
constituents. In future work, preparative SFC or SFC-MS with the aid of the NIST 
database would clearly be useful in further studies to identify constituents. LC-
NMR with CDCl3 as mobile phase would be another option. 
Overall  though,  the  results  obtained  from  this  study  contributed  to  current 
knowledge  about  the  plants  and  provide  a  platform  for  prioritizing  further Page | 222  
 
studies. The information could also be of great benefit in the quality control and 
toxicity testing of the herbal remedy which would ultimately aid the provision of  
safer ethnomedicines for the indigenous users. Page | 223  
 
         
 
  
Fig. 8.1. Flow chart showing the analytical steps taken with X. americana extract. 
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Fig. 8.2. Flow chart showing analytical steps taken with P. crassipes Page | 225  
 
 
8.1 Further Work 
The  full  elucidation  of  the  ambiguous  structures  from  X.  americana  and  P. 
crassipes could be continued by using SFC-UV/ELSD-MS as a tool of green 
technology. LC-NMR is another useful technique which could aid the elucidation 
of  structures  from  the  extracts  after  further  purification  of  the  fractions.    In 
particular, the use of deuterochloroform and/or deuteromethanol on a microbore 
LC set-up with mobile phase delivered by a large volume loop set up between 
the  pump  and  the  LC  column  which  might  contain  hypercarb  to  give  more 
suitable retentivity and better selectivity than ACE CN or ACE silica.  
Also SFC separations obtained would be transferrable to USFC-MS (Capillary 
SFC not being readily available commercially nowadays), for identification (EI; 
NIST)  or  prep  SFC  to  isolate  individual  compounds.  Characterised  pure 
compounds could be subjected to further TB and cytotoxic testing, potentially 
leading to a lead optimisation semi-synthetic programme. 
Furthermore, enzyme inhibition studies on the active drug molecule could be 
initiated  to  determine  whether  the  extracts  are  enzyme  inducers  and  could 
affect  anti-TB  activity  in  the  probability  of  co-administration  with  HIV  drugs. 
Current  TB  drug  regimens  have  shown  some  incompatibility  with  HIV/AIDS 
drugs  due  to  cytochrome  P3A4  enzyme  induction  (CYP3A4)  by  rifampicin 
(Lilienkampf et al., 2009).  The ability of drugs to act as inducers, inhibitors, or 
substrates  for  CYP3A  is  predictive  of  whether  concurrent  administration  of 
these compounds with a known CYP3A substrate might lead to altered drug 
disposition,  efficacy  or  toxicity  (Zhou,  2008).  Several  herbal  and  dietary 
components have been implicated as  CYP3A4 inhibitors suggesting that this 
may be a productive line of investigation. 
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  Appendix A: Tables showing methods used to prepare antibiotics and to determine MIC values. 
 
1). Preparation and storage of antibiotic solutions (≥ 1000 mg/L) 
      Antibiotic  solvent  diluent  4°C        -20°C      -70°C 
a.  Ampicillin(trihydrate) 
         (prepare fresh) 
sat.NaHCO3 solution  water  7days   unstable  30 days 
b.  Gentamicin SO4  water  water  6 mths       NR           NR 
c.   Strept. SO4  water  water       -               -               - 
d.  Sulphamethoxazole 
     (free acid) 
Water+0.1M  
NaOH to dissolve 
water  1 mth       6 mths    2 yrs 
e.  Trimethoprim base  1 mL water+ 10 µL 
Acetic acid 
water  1 mth       6 mths    2 yrs 
f.  Tetracycline HCl 
       (prepare fresh) 
water  Water  -        NR
i             NR
i 
  NR- Not recommended, NR
i – precipitates on freezing Page | 246  
 
 
2). MIC determination (µg / mL) by macrodilution method (BSAC). 
 
  S. aureus  E. coli  P. aeruginosa 
Ampicillin (etest strips)  8  >256  >256  
Streptomycin  0.5  0.25  2 
Gentamicin  0.03  0.25  0.13 
Tetracycline  0.03  0.06  2 
Sulphamethoxazole  >128  <2  >128 
Trimethoprim  0.13  <0.03  32 
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3). Data for synergy testing by checkerboard analysis 
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Appendix B: Efflux data obtained from Rotor-Gene 3000 instrument. 
 
1) EtBr controls assay data 
 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-09-21 (2) 
Run Start  21/09/2010 14:28:06 
Run Finish  21/09/2010 15:46:08 
Operator  Patricia 
Notes    
Run On Software Version  Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  5. 
Gain JOE  5. 
Profile 
Cycle  Cycle Point 
Cycling (240 repeats)  Step 1 @ 37°c, hold 20 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
   
Concentration data for Cycling A.FAM 
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No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    1 EtBr +glu +EC  0.78  [0.73 , 0.83] 
2    1 EtBr +glu +EC     
3    1 EtBr +glu +EC     
4    1 EtBr +glu +EC     
5    1 EtBr +glu +EC     
6    1 EtBr + PBS+EC  0.32  [0.27 , 0.37] 
7    1 EtBr + PBS+EC     
8    1 EtBr + PBS+EC     
9    1 EtBr + PBS+EC     
10    1 EtBr + PBS+EC     
11    1 EtBr +PBS+Glu  0.10   
12    1 EtBr +PBS+Glu     
 
 
Appendix B2: Controls used in EtBr assay 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-10-05 controls and EB assay 
(0.6GC) 
Run Start  05/10/2010 16:49:31 
Run Finish  05/10/2010 17:49:11 
Operator  Patricia 
Notes    
Run On Software 
Version 
Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  10. 
Gain JOE  5. Page | 264  
 
Profile 
Cycle  Cycle Point 
Cycling (30 repeats)  Step 1 @ 37°c, hold 60 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
Concentration data for Cycling A.FAM 
 
 
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    PBS  2.14   
2    EC  3.14  [2.69 , 3.60] 
3    EC     
4    EC     
5    EB 2.0  1.82  [0.97 , 2.67] 
6    EB 2.0     
7    EB 2.0     
8    EB 2.0 + EC  2.86  [2.35 , 3.36] 
9    EB 2.0 + EC     
10    EB 2.0 + EC     
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Appendix  B3: Chlorpromazine concentration assay and controls 
 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-10-06 CPZ assay OVN B-C 
Run Start  06/10/2010 14:47:48 
Run Finish  06/10/2010 15:33:43 
Operator  Patricia 
Notes    
Run On Software Version Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  10. 
Gain JOE  10. 
Profile 
Cycle  Cycle Point 
Cycling (30 repeats)  Step 1 @ 37°c, hold 60 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
Concentration data for Cycling A.FAM 
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No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    EC  4.39   
2    EC +EB 2  3.86   
3    EB 2  2.17   
4    CPZ 8  1.40   
5    EB 2.0 + CPZ 8  1.73   
6    EC + EB 2.0 + CPZ 1 in PBS  4.02   
7    EC + EB 2.0 + CPZ 2 in PBS  4.08   
8    EC + EB 2.0 + CPZ 3 in PBS  3.42   
9    EC + EB 2.0 + CPZ 5 in PBS  3.76   
10    EC + EB 2.0 + CPZ 4 in PBS  3.62   
11    EC + EB 2.0 + CPZ 6 in PBS  3.89   
12    EC + EB 2.0 + CPZ 8 in PBS  3.65   
13    EC + EB 2.0 + CPZ 1 in Glu  5.56   
14    EC + EB 2.0 + CPZ 2 in Glu  5.30   
15    EC + EB 2.0 + CPZ 3 in Glu  6.12   
16    EC + EB 2.0 + CPZ 4 in Glu  4.96   
17    EC + EB 2.0 + CPZ 5 in Glu  5.43   
18    EC + EB 2.0 + CPZ 6 in Glu  4.99   
19    EC + EB 2.0 + CPZ 8 in Glu  4.62   
20    EtBr + glu + EC  18.65   
 
 
Appendix   B4: EtBr accumulation assay data in the presence of glucose and 
chlorpromazine 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-09-23 (2) 
Run Start  23/09/2010 16:58:53 
Run Finish  23/09/2010 18:20:25 
Operator  Patricia 
Notes    
Run On Software Version  Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. Page | 267  
 
Gain FAM  5. 
Gain JOE  5. 
   
 
Profile 
Cycle  Cycle Point 
Cycling (240 repeats)  Step 1 @ 37°c, hold 20 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
Concentration data for Cycling A.FAM 
 
 
 
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    1 EtBr + Ec in glu (CPZ)  0.49   
2    EtBr + Ec in glu (CPZ)  0.35  [0.28 , 0.41] 
3    EtBr + Ec in glu (CPZ)     
4    EtBr + Ec in glu (CPZ)     
5    EtBr + Ec in glu (CPZ)     
6    1 EtBr + Ec in PBS ((CPZ)  0.54   
7    EtBr + Ec in PBS ((CPZ)  0.38  [0.27 , 0.50] 
8    EtBr + Ec in PBS ((CPZ)     
9    EtBr + Ec in PBS ((CPZ)     
10    EtBr + Ec in PBS ((CPZ)     
11    1 EtBr + EC in Glu (CPZ)  0.26  [0.22 , 0.30] Page | 268  
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
12    1 EtBr + EC in Glu (CPZ)     
13    1 EtBr + EC in Glu (CPZ)     
14    1 EtBr + EC in Glu (CPZ)     
15    1 EtBr + EC in Glu (CPZ)     
16    1 EtBr + Glu + CPZ  0.13   
17    1 EtBr + Glu + CPZ     
18    1 EtBr + PBS + CPZ  0.08   
19    1 EtBr + PBS + CPZ     
20    EtBr + glu + EC  0.49   
 
 
Appendix   B5: E. coli efflux assay data 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-10-11 EC efflux assay 
Run Start  11/10/2010 17:15:26 
Run Finish  11/10/2010 18:13:52 
Operator  Patricia 
Notes    
Run On Software Version Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  10. 
Gain JOE  10. 
Profile 
Cycle  Cycle Point 
Cycling (30 repeats)  Step 1 @ 37°c, hold 60 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
Concentration data for Cycling A.FAM Page | 269  
 
 
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    EC in PBS  9.33   
2    EC in PBS     
3    EC +EB 2.0 + CPZ 8.0  8.05   
4    EC +EB 2.0 + CPZ 8.0     
5    EB 2.0 + CPZ 8  1.91   
6    EB 2.0 + CPZ 8     
7    washed EC + CPZ 8.0- no glu  6.50   
8    washed EC + CPZ 8.0- no glu     
9    washed EC + CPZ 1.0 glu  6.56   
10    washed EC + CPZ 1.0 glu     
11    washed EC + CPZ 2.0 glu  6.50   
12    washed EC + CPZ 2.0 glu     
13    washed EC + CPZ 4.0 glu  5.64   
14    washed EC + CPZ 4.0 glu     
15    washed EC + CPZ 8.0 glu  5.60   
16    washed EC + CPZ 8.0 glu     
 
Appendix   B6:  EtBr and M. aurum initial concentration assay  
 
 
 
Concentration Measurement Report Page | 270  
 
Experiment Information 
Run Name  Run 2010-10-11 M.  aurum EB initial assay 
Run Start  11/10/2010 15:02:39 
Run Finish  11/10/2010 16:01:07 
Operator  Patricia 
Notes    
Run On Software Version Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  10. 
Gain JOE  10. 
Profile 
Cycle  Cycle Point 
Cycling (30 repeats)  Step 1 @ 37°c, hold 60 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
Concentration data for Cycling A.FAM 
 
 
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    M0  2.75   
2    M + EB 1 pbs  2.91   
3    M + EB 2 pbs  2.93   
4    M + EB 3 pbs  2.28   
5    M + EB 4 pbs  2.50   
6    M + EB 5 pbs  2.10   
7    M + EB 6 pbs  1.89   Page | 271  
 
No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
8    M0 glu  3.79   
9    M + EB 1 glu  2.78   
10    M + EB 2 glu  2.15   
11    M + EB 3 glu  1.93   
12    M + EB 4 glu  2.03   
13    M + EB 5 glu  1.52   
14    M + EB 6 glu  1.56   
 
 
 
 
Appendix   B7: EtBr assay with M. aurum  in the presence of CPZ 
 
Concentration Measurement Report 
Experiment Information 
Run Name  Run 2010-10-11 M aurum EB3, cpz 8 assay 
Run Start  11/10/2010 16:22:57 
Run Finish  11/10/2010 17:08:07 
Operator  Patricia 
Notes    
Run On Software Version Rotor-Gene 6.1.93 
Run Signature  The Run Signature is valid. 
Gain FAM  10. 
Gain JOE  10. 
 
 
Profile 
Cycle  Cycle Point 
Cycling (30 repeats)  Step 1 @ 37°c, hold 60 secs, acquiring to Cycling A(FAM,JOE) 
   Step 2 @ 37°c, hold 20 secs 
   Step 3 @ 37°c, hold 20 secs, acquiring to Cycling B(JOE) 
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No.  Colour  Name  Rep. Fl.  Rep. Fl. (95% CI) 
1    MA + EB 0 glu  3.39   
2    MA + EB 0 glu     
3    MA +EB3  2.41   
4    MA +EB3     
5    MA +EB3 + CPZ 8 pbs  2.21   
6    MA +EB3 + CPZ 8 pbs     
7    MA +EB3 + CPZ 8 glu  2.17   
8    MA +EB3 + CPZ 8 glu     
 
 
This report generated by Rotor-Gene Real-Time Analysis Software 6.1 (Build 93) 
Corbett Research 2005  
All Rights Reserved  
ISO 9001:2000 (Reg. No. QEC21313)  
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Appendix C : LC chromatograms for crude fractions and LC fractions. 
a.  LC chromatograms showing details of analytical and semi-preparative LC  of X. americana methanol  fraction. 
i.   Page | 274  
 
ii.   Page | 275  
 
b.  Reversed phase LC chromatograms of XD3 and XD4 active TB fractions on LC-DAD using (isocratic and gradient) methanol 
water (30:70) mobile phase on Ace 5 C18 column, 250 x 4.6 mm. 
i.   Page | 276  
 
ii.   
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c.  X. americana  dichloromethane extract on Ace 5 silica , 250 x 7.7 mm column  
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 Appendix D: NMR spectra for fractions and reference compounds. 
1.  XAH  (peak1 ) 
1H and 
13C , HMBC, HMQC  spectra (expanded ) 
 
i.   
 
ii.    
XAH1 
1H 
XAH1 
1H Page | 280  
 
 
iii.   
 
iv.   
XAH1 
13 C 
XAH1 
13C Page | 281  
 
v.   
 
vi.   
XAH1 COSY 
XAH 
13C 
dept Page | 282  
 
 
vii.   
 
viii.   
XAH1 HMQC 
 XAH1 HMBC 
XAH1 HSQC Page | 283  
 
 ix.    
 
 
 
1.  XAD 
i.   
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ii.   
 
iii.    Page | 285  
 
iv.   
 
v.    
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vi.   
 
vii.   
 
  XAD  TOCSY 
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3. XD 
 
i.   
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iii.   
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 iv. 
 
 
v.   
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 vi.   
 
vii.   Page | 291  
 
4.  XD2 
 
i.  
5. XD3 
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6. β-sitosterol  
i.  
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iii.  
iv.   
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 v.    
vi.   
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vii.   
 
7.  Stigmasterol. 
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ii.   
iii.   
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iv.    
 
v.   
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vi.   
vii.   
 
8. PCM 5 Page | 299  
 
i.   
 
ii.   
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iii.   
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v.   
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9. PCM 7 
i.   
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iii.   
 
iv.   
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v.   
vi.   
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vii.   
 
viii.   
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   ix.   
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10. Rutin reference standard  
   i.   
 
ii.   
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 iii.   
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 v.   
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11. PCM2 
 i.   
 
 
ii.   
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1.  PCM                            
i..  
ii.  
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 iii.   
 
12. PCM4 
 i.   
 Page | 313  
 
 ii.   
iii.   
 
13.PCM6 
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i.   
 
ii.   
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iii.   
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        Appendix E : Mass spectral data. (TOF MS EI+) 
1.  XD1  
i.  Page | 317  
 
ii.   
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2.  XD2. 
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g.   Page | 320  
 
h.   Page | 321  
 
i.   Page | 322  
 
j.   Page | 323  
 
k.   Page | 324  
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3. XD3 
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4. XAD fractions analysed by EI MS + 
 i.   
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iii.   
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iv.   
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v. .  
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vi.   
XD3 Page | 333  
 
   vii.   
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viii.     
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5) MS data for LC fractions obtained by TOF MS  ASAP + 
i.   
XAD Page | 336  
 
  ii.      
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 iii.   
 
XD2 Page | 338  
 
iv.   
XD3 Page | 339  
 
v.    
XH1 Page | 340  
 
vi.   
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6.  TOF MS AP + data (Acquity LCT Premier XE) 
  i.   
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  ii.  
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 iii.  
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 iv.  
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 vi.   
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    Appendix F : GC data 
 
1.   
2.   Page | 349  
 
3.   
 
4.   
1-  Stearic acid, 2- cholesterol, 3- stigmasterol, 4- sitosterol 
1 
2 
3 
4 Page | 350  
 
5.   
 
 
6.    
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7.   
 
8.   
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    9.   
 
 
. 
 